

NATIONAL QUALITY FORUM

Resource Use Measure Evaluation 1.0 January 2011

This form contains the measure information submitted by stewards. Blank fields indicate no information was provided. Attachments also may have been submitted and are provided to reviewers. The subcriteria and most of the footnotes from the evaluation criteria are provided in Word comments within the form and will appear if your cursor is over the highlighted area. Hyperlinks to the evaluation criteria and ratings are provided in each section.

Resource Use Definition:

- Resource use measures are broadly applicable and comparable measures of input counts—(in terms of units or dollars)-- applied to a population or population sample
- Resource use measures count the frequency of specific resources; these resource units may be monetized, as appropriate.
- The approach to monetizing resource use varies and often depends on the perspective of the measurer and those being measured. Monetizing resource use allows for the aggregation across resources.

NQF Staff: NQF staff will complete a preliminary review of the measure to ensure conditions are met and the form has been completed according to the developer's intent. Staff comments have been highlighted in green.

TAP/Workgroup (if utilized): Complete all yellow highlighted areas of the form. Evaluate the extent to which each subcriterion is met. Based on your evaluation, summarize the strengths and weaknesses in each section.

Note: If there is no TAP or workgroup, the SC also evaluates the subcriteria (yellow highlighted areas).

Steering Committee: Complete all pink highlighted areas of the form. Review the workgroup/TAP assessment of the subcriteria, noting any areas of disagreement; then evaluate the extent to which each major criterion is met; and finally, indicate your recommendation for the endorsement. Provide the rationale for your ratings.

Evaluation ratings of the extent to which the subcriteria are met (TAP or Steering Committee)

High (H) - based on the information submitted, there is high confidence (or certainty) that the criterion is met

Moderate (M) - based on the information submitted, there is moderate confidence (or certainty) that the criterion is met

Low (L) - based on the information submitted, there is low confidence (or certainty) that the criterion is met

Insufficient (I) - there is insufficient information submitted to evaluate whether the criterion is met, e.g., blank, incomplete, or information is not relevant, responsive, or specific to the particular question (unacceptable)

Not Applicable (NA) - Not applicable (only an option for a few subcriteria as indicated)

Evaluation ratings of whether the measure met the overall criterion (Steering Committee)

Yes (Y)- The overall criteria has been met

No (N)-The overall criterion has NOT been met

High (H) - There is high confidence (or certainty) that the criterion is met

Moderate (M) - There is moderate confidence (or certainty) that the criterion is met

Low (L) - There is low confidence (or certainty) that the criterion is met

Recommendations for endorsement (Steering Committee)

Yes (Y) - The measure should be recommended for endorsement

No (N)-The measure should NOT be recommended for endorsement

Abstain (A)- Abstain from voting to recommend the measure

TAP/Workgroup Reviewer Name:
Steering Committee Reviewer Name:
Staff Reviewer Name(s):
NQF Review #: 1560 NQF Project: Endorsing Resource Use Standards- Phase II

BRIEF MEASURE INFORMATION
Measure Title: Relative Resource Use for People with Asthma
Measure Steward (IP Owner): National Committee for Quality Assurance (NCQA), 1100 13th Street NW, STE 1000, Washington, District Of Columbia, 20005
Brief description of measure: The risk-adjusted relative resource use by health plan members with asthma during the measurement year.
Resource use service categories: Inpatient services: Inpatient facility services Inpatient services: Evaluation and management Inpatient services: Procedures and surgeries Inpatient services: Imaging and diagnostic Inpatient services: Lab services Inpatient services: Admissions/discharges Ambulatory services: Outpatient facility services Ambulatory services: Emergency Department Ambulatory services: Pharmacy Ambulatory services: Evaluation and management Ambulatory services: Procedures and surgeries Ambulatory services: Imaging and diagnostic Ambulatory services: Lab services
Brief description of measure clinical logic: This measure addresses the resource use of members identified as having asthma. Both encounter and pharmacy data are used to identify members for inclusion in the eligible population, and the results are adjusted to account for age, gender, and HCC-RRU risk classifications that predict cost variability (Refer to Attachment S8_Clinical Logic for additional information).
<i>If included in a composite or paired with another measure, please identify composite or paired measure:</i>
Subject/ Topic Areas: Pulmonary/Critical Care Pulmonary/Critical Care : Asthma
Type of resource use measure: Cost/Resource Use
Data Type: Administrative claims Electronic Clinical Data Electronic Clinical Data : Electronic Health Record Electronic Clinical Data : Imaging/Diagnostic Study Electronic Clinical Data : Laboratory Electronic Clinical Data : Pharmacy Paper Records

CONDITIONS FOR CONSIDERATION BY NQF	
Four conditions must be met before proposed measures may be considered and evaluated for suitability as voluntary consensus standards:	NQF Staff
A. Measure Steward Agreement. <i>The measure is in the public domain or an intellectual property (measure steward agreement) is signed. Public domain only applies to governmental organizations. All non-government organizations must sign a measure steward agreement even if measures are made publicly and freely available.</i>	A Y <input type="checkbox"/> N <input type="checkbox"/>

<p>A.1. Do you attest that the measure steward holds intellectual property rights to the measure? (If no, do not submit)</p> <p>Yes</p> <p>A.2. Please check if either of the following apply:</p> <p>Proprietary measure</p> <p>A.3. Measure Steward Agreement.</p> <p>Agreement signed and submitted</p> <p>A.4. Measure Steward Agreement attached:</p>	
<p>B. Maintenance.</p> <p><i>The measure owner/steward verifies there is an identified responsible entity and process to maintain and update the measure on a schedule that is commensurate with the rate of clinical innovation, but at least every 3 years. (If no, do not submit)</i></p> <p>Yes, information provided in contact section</p>	<p>B</p> <p>Y <input type="checkbox"/></p> <p>N <input type="checkbox"/></p>
<p>C. Purpose/ Use (All the purposes and/or uses for which the measure is specified and tested:</p> <p>Professional Certification or Recognition Program</p> <p>Public Reporting</p> <p>Quality Improvement with Benchmarking (external benchmarking to multiple organizations)</p> <p>Regulatory and Accreditation Programs</p>	<p>C</p> <p>Y <input type="checkbox"/></p> <p>N <input type="checkbox"/></p>
<p>D. Testing.</p> <p><i>The measure is fully specified and tested for reliability <u>and</u> validity (See guidance on measure testing).</i></p> <p>Yes, reliability and validity testing completed</p>	<p>D</p> <p>Y <input type="checkbox"/></p> <p>N <input type="checkbox"/></p>
<p>E. Harmonization and Competing Measures.</p> <p><i>Have NQF-endorsed measures been reviewed to identify if there are related or competing measures? (List the NQF # and title in the section on related and competing measures)</i></p> <p>Yes</p> <p>E.1. Do you attest that measure harmonization issues with related measure (either the same measure focus or the same target population) have been considered and addresses as appropriate? (List the NQF # and title in the section on related and competing measures)</p> <p>No related measures</p> <p>E.2. Do you attest that competing measures (both the same measure focus and the same target population) have been considered and addressed where appropriate? No competing measures</p>	<p>E</p> <p>Y <input type="checkbox"/></p> <p>N <input type="checkbox"/></p>
<p>F. Submission Complete.</p> <p><i>The requested measure submission information is complete and responsive to the questions so that all the information needed to evaluate all criteria is provided.</i></p>	<p>F</p> <p>Y <input type="checkbox"/></p> <p>N <input type="checkbox"/></p>
<p>Have all conditions for consideration been met?</p> <p>Staff Notes to Steward (if submission returned):</p>	<p>Y <input type="checkbox"/></p> <p>N <input type="checkbox"/></p>

Staff Notes to Reviewers (issues or questions regarding any criteria):**File Attachments Related to Measure/Criteria:**

Attachment:
Attachment:
Attachment:
Attachment:
Attachment:
Attachment: S8_Clinical Logic_RAS.pdf
Attachment:
Attachment:
Attachment:
S12_Sample Score Report_RAS.pdf
Attachment: SA_Reliability_Veracity Testing-634364798866745084.pdf

IMPORTANCE TO MEASURE AND REPORT

Extent to which the specific measure focus is important to making significant gains in health care quality (safety, timeliness, effectiveness, efficiency, equity, patient-centeredness) and improving health outcomes for a specific high impact aspect of healthcare where there is variation in performance.

Importance to Measure and Report is a threshold criterion that must be met in order to recommend a measure for endorsement. All subcriteria must be met to pass this criterion.

High Impact**IM1. Demonstrated high impact aspect of healthcare:**

Affects large numbers
A leading cause of morbidity/mortality
High resource use
Patient/societal consequences of poor quality
Severity of illness

IM1.1. Summary of evidence of high impact:**Clinical Importance**

Asthma is one of the most prevalent chronic diseases; becoming increasingly more commonplace over the past twenty years. Approximately 23.3 million Americans have asthma and it is responsible for over 3,000 deaths in the U.S. annually (American Lung Association, 2010). In 2006, 13.3 million clinical visits (hospital, outpatient, emergency department, and physician offices) were attributed to asthma (CDC, 2008). The incidence rate, and subsequently the number of asthma-related health visits, is expected to increase by an additional 100 million globally by 2025 (World Health Organization, 2007).

Financial Importance

Asthma accounts for over \$20 billion spent on health care in the United States. Direct costs, including prescriptions, make up \$15.6 billion of that total, and indirect costs, such as lost productivity, add an additional \$5.1 billion (CDC, 2008). Inpatient hospitalization accounts for over 50 percent of overall asthma-related costs (Bahadori, 2009). In addition to the direct financial burden, asthma is also a leading cause of absenteeism and productivity, accounting for an estimated 14.2 million missed workdays for adults and over 14 million missed school days for children (Akinbami, 2009). Studies have shown that the indirect costs of asthma are becoming a growing financial burden on patients, and resulting in significant additional costs (Bahadori, 2009).

Appropriate medication management could potentially prevent a significant proportion of asthma-related costs (hospitalizations, emergency room visits and missed work and school days) (Akinbami, 2009). The Asthma Regional Council supported this inference, stating that proper management could potentially save at least 25 percent of total asthma costs, or \$5 billion, nationally by reducing health care costs (American Lung Association, 2009). Another initiative, the Children's Health Fund's Childhood Asthma Initiative, examined patients enrolled in an asthma intervention program. Results illustrated that treatment that aligned with clinical guidelines reduced the severity of experienced symptoms experienced, as well as asthma-related events (e.g., hospitalizations, emergency room visits, etc.)

**Eval
Rating****1a**

H ☐
M ☐
L ☐
I ☐

Rating: H=High, M=Moderate, L=Low, I=Insufficient, NA=Not Applicable
Updated 3/1/11

(Columbia University, 2010). Additionally, subsequent savings attributed to improved clinical outcomes totaled to nearly \$4.2 million or \$4,525 per patient. This translated to a significant reduction in federally subsidized and private insurance-based costs for this population.

IM1.2. Citations for evidence of high impact cited in IM1.1.:

Akinbami, LJ. The State of Childhood Asthma, United States, 1980–2007. Advance Data from Vital and Health Statistics. Revised February 16, 2009. Pediatrics 123 (Supplement); S131-45. Hyattsville, MD: National Center for Health Statistics. Available from: http://pediatrics.aappublications.org/cgi/content/full/123/Supplement_3/S131. (March 2010)

American Lung Association. Trends in Asthma Morbidity and Mortality. 2009.

Bahadori et al. Economic burden of asthma: a systematic review. BMJ 9(24): 1-16, 2009.

British Thoracic Society. British Guideline on the management of asthma. A national clinical guideline. Scotland: British Thoracic Society (BTS); 2009 June.

Centers for Disease Control and Prevention. Asthma: A Presentation of Asthma Management and Prevention. 2009. Available from: <http://www.cdc.gov/asthma/speakit/default.htm>. (September 2010)

Columbia University. Best Practice Asthma Program Saves the US Healthcare System More than \$4500 a Year per Child. 2010. Available from: <http://www.mailman.columbia.edu/news/best-practice-asthma-program-saves-us-healthcare-system-more-4500-year-child>. (December 2010)

NHLBI/NAEPP (National Heart Lung and Blood Institute/National Asthma Education and Prevention Program). Measures of asthma assessment and monitoring: Expert panel report 3: guidelines for the diagnosis and management of asthma. Washington (DC): National Heart Lung and Blood Institute (NHLBI); 2007 Aug.

World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. 2007.

IM2. Opportunity for Improvement

IM2.1. Briefly explain the benefits envisioned by use of this measure:

Clinical practice guidelines and research stipulate that both appropriate distribution of medication and patient adherence to medication regimens are associated with improved health outcomes for individuals. Several studies have been undertaken to define measures of asthma quality of care based upon the continuing gaps in care and the guideline recommendations and supporting evidence cited above, including the current Use of Appropriate Medications for People with Asthma measure as defined for the Healthcare Effectiveness Data and Information Set (HEDIS) (NCQA 2010). As stated within the financial and clinical importance regarding asthma control, outstanding gaps and disparities in asthma care lie in the following areas:

- Continued elevation of morbidity and mortality rates
- Lack of control over asthma symptoms
- Implications of financial and disease burden (e.g., direct and indirect costs, absenteeism, number of episode-free days, rate of exacerbations, number of emergency department visits and inpatient stays with a diagnosis of asthma)
- Adherence to medication regimens
- Insurance coverage for asthma education and prevention programs and initiatives (i.e. smoking cessation, home visits by certified asthma educators)

IM2.2. Summary of data demonstrating variation across providers or entities:

Annual analysis of RRU data collected by NCQA over the last four years demonstrates substantial variation in health plan resource use from an overall perspective and with respect to specific service areas (e.g., procedure and surgery services or pharmacy services) and regions. Moreover, a substantial number of health plans can be identified as statistically significantly better or worse than average along RRU and quality dimensions. A number of recent studies have been undertaken to define measures more directly related with outcomes such as risk of subsequent ED visits, and increasing use of reliever medications, which serves as a surrogate outcome for severe and acute symptoms and exacerbations (Schatz 2010, Broder 2010, Fuhlbrigge 2004). The intent of this research is based in part on verifying some of the findings from previous research on the positive associations between the outcomes of interest and appropriate asthma-specific medication management in people with persistent asthma.

IM2.3. Citations for data on variation:

Broder MS, Guiterrez B, Chang E, et al. Ratio of controller to total asthma medications: determinants of the measure.

1b

H ☐
M ☐
L ☐
I ☐

Formatted: Spanish (Dominican Republic)

Am J Managed Care. 2010;16(3):170-178.

Fuhlbrigge A, Carey VJ, Adams RJ. Evaluation of asthma prescription measures and health system performance based on emergency department utilization. Med Care. 2004;42(5):1-7.

National Committee for Quality Assurance (NCQA) HEDIS® 2010 Relative Resource Use (RRU) Annual Analytic Report.

Schatz M, Zeiger RS, Yang ST, et al. Relationship of asthma control to asthma exacerbations using surrogate markers within a managed care database. Am J Managed Care. 2010;16(5):327-333.

IM2.4. Summary of data on disparities by population group:

The National Health Interview Survey (NHIS) data examined asthma prevalence among a range of subgroups from the late 1980s to 2006 (CDC, 2009). Results showed that asthma affects more children than adults, who consistently demonstrate lower prevalence and hospitalization rates (CDC, 2009). Over 7 million children under the age of 18 have asthma, placing it among the leading causes of hospitalization for children (American Lung Association, 2010). Asthma disproportionately affects a higher percentage of boys than girls (CDC, 2009). In addition, children of low-income families experience higher frequencies of urgent care visits, hospitalizations and mortality due to asthma when compared to the general public (CDC, 2009). In terms of racial/ethnic disparities, rates were highest for non-Hispanic African-American children (14.2 percent) and lowest for Asian children (7.1 percent), with the greatest amount of variability among Hispanic subgroups (CDC, 2009).

These findings are strengthened by a study highlighting disparities in the delivery of care when considering socioeconomic status and race/ethnicity. Data was collected using the Medical Expenditure Panel Survey (MEPS) (1996-2000), surveying 982 children with asthma younger than 18 years of age. The primary control variables associated with asthma-related service utilization were race/ethnicity, socioeconomic status, and health insurance status (Kim, 2009). Race/ethnicity subcategories included Hispanic, non-Hispanic black, non-Hispanic white and other racial groups; socioeconomic status subcategories included annual family income and mother's education; and insurance coverage subcategories included uninsured, public (both years of study), and private/public (both years of study). Private and public insurance subcategories were separated and analyzed in parallel, producing results similar to the original groupings.

The MEPS results showed that non-Hispanic African-American children utilized urgent care services more frequently than preventive care services (Kim, 2009). Additionally, children from low-income families were less likely to have prescriptions filled and/or receive annual primary health examinations (Kim, 2009). The study also examined insurance coverage, showing that children with insurance coverage utilized primary health care services for asthma more often (Kim, 2009).

In terms of the adult subgroup and race/ethnicity-based disparities, the NHIS data displayed that from the late 1980s to 2006, African-Americans have had a higher prevalence of asthma in comparison to Caucasians. In addition, non-Hispanic African-Americans have reported higher rates since 1997 when compared to both Hispanics and non-Hispanic Caucasians, who reported the lowest rates (CDC, 2009). African Americans are also more likely to be hospitalized or die as a result of asthma-based complications (CDC, 2009).

In comparing women versus men, the NHIS survey demonstrated that women have consistently outranked men in terms of the prevalence of asthma (CDC, 2009). This is corroborated by the hospital discharge rates per 10,000 population from 1980 to 2006, as well as mortality rates due to asthma, which have both been historically elevated for women versus men (CDC, 2009). Overall, mortality due to asthma has declined since 1999 for both men and women (CDC, 2009).

IM2.5. Citations for data on disparities cited in IM2.4:

American Lung Association. Epidemiology & Statistics Unit, Research and Program Services. Asthma. 2010. Available from: <http://www.lungusa.org/lung-disease/asthma/>. (September 2010)

Centers for Disease Control and Prevention. Asthma: A Presentation of Asthma Management and Prevention. 2009. Available from: <http://www.cdc.gov/asthma/speakit/default.htm>. (September 2010)

Kim H, Kieckhefer GM, Greek AA, Joesch JM, Baydar N. Health care utilization by children with asthma. Prev Chronic Dis 2009;6(1). http://www.cdc.gov/pcd/issues/2009/jan/07_0199.htm. (October 2010)

IM3. Measure Intent

IM3.1. Describe intent of the measure and its components/ Rationale (including any citations) for analyzing variation in resource use in this way

When health plans select providers, negotiate price, design benefits or implement incentives, they use interventions to

1c

H ☐
M ☐
L ☐
I ☐

Rating: H=High, M=Moderate, L=Low, I=Insufficient, NA=Not Applicable
Updated 3/1/11

influence quality and moderate cost. When plans and other stakeholders can compare results with other health plans using the RRU measurement set based on national and regional benchmarks, they have a growing body of information with which to gauge their performance in categories such as clinical quality, patient experience and resource use-cost. Purchasers and plans can independently and collectively review and select appropriate, targeted interventions. RRU measures indicate how a plan uses a set of key resources (e.g., physician visits, hospital stays) to care for its members with specific diseases, compared with the average for plans in the same region and adjusted for the set of diseases and case mix of plan members. RRU results make it possible to simultaneously evaluate both the quality of services and key elements that drive costs and premiums. In the interest of transparency, NCQA has issued quality reports on individual measures and in aggregate ratings of quality—for example, in the State of Health Care Report and America's Best Health Plans—that make it possible to compare plan performance with market averages. NCQA created additional disease-specific composites for use with the RRU measures. By reviewing a health plan's RRU and quality ratios together, purchasers and plans can engage in a balanced, data-driven dialogue about benefit design or the effectiveness of a wellness program or disease management program. Plan performance information can be supplemented with a detailed analysis of internal data by self-insured employers or by plans studying expenditures. These individual plan or purchaser data can provide a detailed look at specific criteria (e.g., age and disease, procedure-specific admissions).	
IM4. Resource use service categories are consistent with measure construct <i>Refer to IM3.1. & all S9 items to evaluate this criteria.</i>	1d H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/>
TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for <i>Importance to Measure and Report</i> ?	
Steering Committee: Was the threshold criterion, <i>Importance to Measure and Report</i> , met? Rationale:	Y <input type="checkbox"/> N <input type="checkbox"/>

SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES	
Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of care when implemented.	
MEASURE SPECIFICATIONS	
<p>S1. Measure Web Page: <i>Do you have a web page where current detailed measure specifications can be obtained?</i></p> <p>No</p> <p>S2. General Approach <i>If applicable, summarize the general approach or methodology to the measure specification. This is most relevant to measures that are part of or rely on the execution of a measure system or applies to multiple measures.</i></p> <p>Relative Resource Use (RRU) measures are a standardized way to measure relative resource use as related to different types of health care services. When evaluated in conjunction with corresponding quality of care measures, they provide important information related to the efficiency or value of health care services. RRU measures have the following features:</p> <ul style="list-style-type: none"> • Focus on high-cost conditions for which there are corresponding HEDIS Effectiveness of Care measures • Segment the effect of unit price and utilization variation • Rely on an indirect standardization approach to risk adjustment originally developed from regression analysis 	<p>Eval Rating 2a1/2b1</p>

RRU measures report the organization's total resource use for defined diseases, by service category and by use of standardized price to relate service units for each eligible member, during each measure's treatment period. The organization does not report prices based on its contracts and fee schedules; rather it applies a standard price to each service, multiplies it by the number of units of service, and reports the resulting standard cost. For RRU measures that relate to chronic conditions (e.g., Relative Resource Use for People With Asthma), the treatment period is the 12-month measurement year. As contrasted with episode grouper based measures, Relative Resource Use is calculated for included services regardless of their relation (direct or indirect as defined by some algorithm or episode grouper) to the specific chronic condition.

Attachment:

S3. Type of resource use measure:

Per capita (population- or patient-based)

S4. Target Population:

Populations at Risk

S4.1. Subject/Topic Areas:

Pulmonary/Critical Care

Pulmonary/Critical Care : Asthma

S4.2. Cross Cutting Areas (HHS or NPP National health goal/priority)

Population Health

S5. Data dictionary or code table

Please provide a web page URL or attachment if exceeds 2 pages. NQF strongly prefers URLs. Attach documents only if they are not available on a web page and keep attached file to 5MB or less.

Data Dictionary:

URL:

Please supply the username and password:

Attachment:

Code Table:

URL: <http://www.ncqa.org/downloads/rru/9C9848A9-59EE-4E8D-B092-2350FA74EA35>

Please supply the username and password:

Attachment:

S6. Data Protocol (Resource Use Measure Module 1)

The measure developer must determine which of the following data protocol steps: data preparation, data inclusion criteria, data exclusion criteria, and missing data, are submitted as measure specifications or as guidelines. Specifications limit user options and flexibility and must be strictly adhered to; whereas guidelines are well thought out guidance to users while allowing for user flexibility. If the measure developer determines that the requested specification approach is better suited as guidelines, please select and submit guidelines, otherwise specifications must be provided.

Data Protocol Supplemental Attachment or URL:

If needed, attach document that supplements information provided for data protocol for analysis, data inclusion criteria, data exclusion criteria, and missing data (Save file as: S6_Data Protocol). All fields of the submission form that are supplemented within the attachment must include a summary of important information included in the attachment and its intended purpose, including any references to page numbers, tables, text, etc.

URL:

<p>Please supply the username and password: Attachment:</p>	
<p>S6.1. Data preparation for analysis <i>Detail (specify) the data preparation steps and provide rationale for this methodology.</i></p> <p>Specifications : Organizations must identify the eligible population from transactional or other administrative databases. The organization reports results based on all members who meet the eligible population criteria and who have received the services required for the measure through administrative data. The following types of data must be available in these databases in order to include members in the RAS measure: -Demographic enrollment data (i.e. age, gender) -Complete data on any clinical diagnoses and encounters for the two year period of interest -Required medical benefit information for the entire timeframe</p> <p>S6.2.Data inclusion criteria <i>Detail initial data inclusion criteria and rationale(related to claim-line or other data quality, data validation, e.g. truncation or removal of low or high dollar claim)</i></p> <p>Specifications : To identify the eligible population, include all services whether or not the organization paid for (or expects to pay for) the services (i.e., include denied claims). For cost and frequency reporting, report all services the organization paid for or expects to pay for (i.e., claims incurred but not paid yet). Do not include any denied service or day. If a member is enrolled retroactively, count all services for which the organization paid or expects to pay. Organizations and providers that use proprietary codes, Level II or state-specific Level III HCPCS codes must map to the industry standard code and remove codes that are not included in the NCQA Standard Pricing Tables. The reporting organization has several options when determining payment for claims: a) Cover the full amount; b) Pay only a portion of the fee (e.g., 80 percent); c) Not pay anything because the member must cover the entire amount to meet a deductible; d) Not pay anything because the service is covered as part of a PMPM payment; or e) Deny the service.</p> <p>Count the service if: 1) The organization pays the full amount or a portion of the amount (e.g., 80 percent) 2) The member paid for the cost of a service that is part of their benefit offering (e.g., to meet a deductible), or 3) The service was covered under a PMPM payment. Do not count the service if: 1) The organization denied the service for any reason unless the member paid for the cost of a service that is part of the benefit offering (e.g., to meet a deductible) 2) The claim for the service was rejected because it was missing information or was invalid for some other reason.</p> <p>S6.3. Data exclusion criteria <i>Detail initial data exclusion criteria and rationale (related to claim-line or other data quality, data validation, e.g. truncation or removal of low or high dollar claim)</i></p> <p>Specifications : Denied services or days are not included in either the cost or frequency categories of the RRU measurement calculations. Reporting organizations are not to count services if: • The organization denied the service for any reason, unless the member paid for the cost of a service that is part of the benefit offering (e.g. to meet a deductible) • The claim for the service was rejected because it was missing information or was invalid for another reason</p> <p>S6.4. Missing Data <i>Detail steps associated with missing data and rationale(e.g., any statistical techniques used)</i></p> <p>We do not provide measure specifications or guidelines for missing data : NCQA requires reportable observed data in order to calculate RRU results. All measures must have a final, audited result submitted to NCQA. All plans that do not have any blanked-out utilization numbers are included in the calculation of the raw observed-to-expected ratio. When normalizing the ratios to develop an index, if any raw ratio = 0 (zero), or a plan has submitted a \$0.00 cost for its given member months, that ratio is discarded.</p>	

S7. Data Type: Administrative claims

Electronic Clinical Data

Electronic Clinical Data : Electronic Health Record

Electronic Clinical Data : Imaging/Diagnostic Study

Electronic Clinical Data : Laboratory

Electronic Clinical Data : Pharmacy

~~Paper Records~~**S7.1. Data Source or Collection Instrument**

Identify the specific data source/data collection instrument (e.g. name of database, clinical registry, collection instrument, etc.)

NCQA collects HEDIS RRU data directly from Health Plan Organizations and Preferred Provider Organizations via a data submission portal - the Interactive Data Submission System (IDSS).). RRU measures use NCQA's standardized prices and NCQA collects data with only the standardized prices applied. The list below summarizes the standard pricing tables (and table names) which organizations use to apply to each service captured for reporting RRU. Consistent standard prices protect the organization's proprietary fee schedules and contracts and support measure comparison across organizations and across regions without requiring adjustment for levels of service payment

HEDIS 2011 STANDARD PRICING TABLES: Volume 2: Technical Specifications

1. Description of codes and services included in the standard price and supporting tables (RRU Reference Table)
2. Cost Cap Amounts (SPT-CAP Amounts)

Inpatient Facility Tables

1. Length of Stay Group (LOS Group)
2. Standard price for inpatient facility services using DRGs (SPT-INP-DRG)
3. Standard price for inpatient facility services using ADSC (SPT-INP-ADSC)
4. Inpatient ICD-9-CM Diagnosis mapping to ADSC (ADSC-Table)
5. Codes indicating major surgery (Maj-Surg-Table)

E&M Table

1. Standard price for evaluation and management (SPT-EM Inpatient and Outpatient)

Surgery and Procedure Table

1. Standard price for surgery and procedures (SPT-Surg-Proc Inpatient and Outpatient)

Diagnostic Lab and Imaging Table

1. Standard price for diagnostic laboratory services (SPT-LAB)
2. Standard price for diagnostic imaging services (SPT-IMG)

Pharmacy Tables

1. Standard price for pharmacy services (SPT-Pharm)
2. Standard price for RLB measure-specific pharmacy services (SPT-Pharm for RLB)

Risk Adjustment Tables

1. CC comorbid category assignments (Table CC-Comorbid)
2. CC ranking assignments (Table HCC-Rank)
3. CC combination assignments (Table HCC-Comb)
4. Age/gender HCC weighting (Table RRU-age/gender HCC)
5. Predefined risk weight (Table RRU-Weight)

S7.2. Data Source or Collection Instrument Reference

(Please provide a web page URL or attachment). NQF strongly prefers URLs. Attach documents only if they are not available on a web page and keep attached file to 5MB or less)

URL: <http://www.ncqa.org/tabid/370/default.aspx>

Please supply the username and password:

Attachment:

<p>S8.Measure Clinical Logic (Resource Use Measure Module 2) <i>The measure's clinical logic includes the steps that identify the condition or event of interest and any clustering of diagnoses or procedures. For example, the diagnoses and procedures that qualifies for a cardiac heart failure episode, including any disease interaction, comorbid conditions, or hierarchical structure to the clinical logic of the model. (Some of the steps listed separately below may be embedded in the risk adjustment description, if so, please indicate NA and in the rationale space list 'see risk adjustment details.')</i></p>	
<p>Clinical Logic Supplemental Attachment or URL: <i>If needed, provide a URL or document that supplements information provided for the clinical framework, co-morbid interactions, clinical hierarchies, clinical severity levels, and concurrency of clinical events</i></p> <p>URL: Please supply the username and password: Attachment: S8_Clinical Logic_RAS.pdf</p>	
<p>S8.1. Brief Description of Clinical Framework <i>Briefly describe your clinical logic approach including clinical topic area, whether or not you account for comorbid and interactions, clinical hierarchies, clinical severity levels and concurrency of clinical events.</i></p> <p>This measure addresses the resource use of members identified as having asthma. Both encounter and pharmacy data are used to identify members for inclusion in the eligible population, and the results are adjusted to account for age, gender, and HCC-RRU risk classifications that predict cost variability (Refer to Attachment S8_Clinical Logic for additional information).</p> <p>S8.2. Clinical framework <i>Detail any clustering and the assignment of codes, including the grouping methodology, the assignment algorithm, and relevant codes and rationale for these methodologies.</i></p> <p>Members are identified for the eligible population of the measure in two ways: by an encounter with a diagnosis; or by multiple asthma medication events. An organization must use both methods to identify the eligible population, but a member only needs to be identified by one to be included in the measure. The following steps are employed in order to identify the eligible population for measurement</p> <p>Step 1: Health Plan members are identified as having persistent asthma by meeting at least one of the following criteria during both the measurement year and the year prior to the measurement year. Criteria need not be the same across years.</p> <ul style="list-style-type: none"> • At least one ED visit (Tables ASM-A and ASM-B) with asthma as the principal diagnosis, or • At least one acute inpatient claim/encounter (Tables ASM-B) with asthma as the principal diagnosis (Table ASM-A), or • At least four outpatient asthma visits (Table ASM-B) with asthma as one of the listed diagnoses (Table ASM-A) and at least two asthma medication dispensing events (Table ASM-C), or • At least four asthma medication dispensing events (Table ASM-C) <p>Table ASM-A: Codes to Identify Asthma ICD-9 Diagnosis: 493</p> <p>Table ASM-B: Codes to Identify Visit Type Outpatient CPT: 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99382-99386, 99392-99396, 99401-99404, 99411, 99412, 99420, 99429 UB Revenue: 051x, 0520-0523, 0526-0529, 057x- 059x, 0982, 0983 Acute inpatient CPT: 99221-99223, 99231-99233, 99238, 99239, 99251-99255, 99291</p>	<p>Eval Rating 2a1</p> <p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/></p> <p>Eval Rating 2b1</p> <p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/></p>

UB Revenue: 010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x, 021x, 072x, 0987
 ED: 99281-99285
 UB Revenue: 045x, 0981
 Table ASM-C: Asthma Medications
 Antiasthmatic combinations: dyphylline-guaifenesin, guaifenesin-theophylline, potassium iodide-theophylline
 Antibody inhibitor: omalizumab
 Inhaled steroid combinations: budesonide-formoterol, fluticasone-salmeterol,
 Inhaled corticosteroids: beclomethasone, budesonide, ciclesonide, flunisolide, fluticasone CFC free, mometasone, triamcinolone
 Leukotriene modifiers: montelukast, zafirlukast, zileuton
 Long-acting, inhaled beta-2 agonists: aformoterol, formoterol, salmeterol
 Mast cell stabilizers: cromolyn, nedocromil
 Methylxanthines: aminophylline, dyphylline, oxtriphylline, theophylline
 Short-acting, inhaled beta-2 agonists: albuterol, levalbuterol, metaproterenol, pirbuterol

Step 2: Since a member can be identified as having persistent asthma using only leukotriene modifiers as the sole asthma medication dispensed in that year, these members must also have at least one diagnosis of asthma (Table ASM-A), in any setting, in the same year as the leukotriene modifier prescription (e.g. measurement year or year prior to the measurement year).

Members with one or more of the following dominant clinical conditions during the measurement year are excluded from the RAS data set.

1) Active cancer. Exclude members who had at least one face-to-face encounter, in any setting, with any diagnosis of cancer in conjunction with any treatment code (Table RRU-A), during the measurement year.

Table RRU-A: Codes to Identify Active Cancer Treatment

ICD-9 diagnosis for cancer: 140-209, 230-239

WITH treatment

CPT: 38230, 38240-38242, 77261-77799, 79005-79999, 96401-96549

ICD-9 Procedure: 00.10, 00.15, 41.0, 41.91, 92.2, 99.25, 99.28, 99.85

UB Revenue: 028x, 033x, 0342, 0344, 0973

2) ESRD. Exclude members who had at least one face-to-face encounter with any code to identify ESRD (Table RRU-B), during the measurement year.

Table RRU-B: Codes to Identify ESRD

CPT: 36145, 36147, 36800-36821, 36831-36833, 90935, 90937, 90940, 90945, 90947, 90957-90962, 90965, 90966,

90969, 90970, 90989, 90993, 90997, 90999, 99512

HCPCS: G0257, G0392, G0393, S9339

ICD-9 Diagnosis: 585.5, 585.6, V42.0, V45.1

ICD-9 PCD: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93, 39.94, 39.95, 54.98

UB Revenue: 080x, 082x-085x, 088x

UB Type of Bill: 72x

POS: 65

3) Organ transplant. Exclude members who had at least one face-to-face encounter, in any setting, with any code to identify organ transplant (Table RRU-C), during the measurement year.

Table RRU-C: Codes to Identify Organ Transplant

CPT: 32850-32856, 33930-33945, 44132-44137, 44715-44721, 47133-47147, 48160, 48550-48556, 50300-50380

HCPCS: S2152, S2053-S2055, S2060, S2061, S2065

ICD-9 PCD: 33.5, 33.6, 37.5, 41.94, 46.97, 50.5, 52.8, 55.6

UB Revenue: 0362, 0367, 0810-0813, 0819

4) HIV/AIDS. Exclude members who had at least two face-to-face encounters in an outpatient or nonacute inpatient setting, or at least one face-to-face encounter in an acute inpatient or ED setting, with any diagnosis of HIV (Table RRU-D), with different dates of service during the measurement year. Refer to Table RRU-E for codes to identify visit type.

Table RRU-D: Codes to Identify HIV

ICD-9 Diagnosis: 042

Table RRU-E: Codes to Identify Visit Type

Formatted: Spanish (Dominican Republic)

Outpatient

CPT: 92002, 92004, 92012, 92014, 98925-98929, 98940-98942, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99420, 99429, 99455, 99456

UB Revenue: 051x, 0520 -0523, 0526-0529, 057x-059x, 082x-085x, 088x, 0982, 0983

Nonacute inpatient

CPT: 99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337

UB Revenue: 0118, 0128, 0138, 0148, 0158, 019x, 0524, 0525, 055x, 066x

Acute inpatient:

CPT: 99221-99223, 99231-99233, 99238, 99239, 99251-99255, 99291

UB Revenue: 010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x, 021x, 072x, 080x, 0987

ED:

CPT: 99281-99285

UB Revenue: 045x, 0981

5) Members diagnosed with emphysema, COPD, cystic fibrosis or acute respiratory failure (Table ASM-E) on or prior to December 31 of the measurement year.

Table ASM-E: Codes to Identify Other Clinical Exclusions

Emphysema (ICD-9): 492, 506.4, 518.1, 518.2

COPD (ICD-9): 491.2, 493.2, 496, 506.4

Cystic fibrosis (ICD-9): 277.0

Acute respiratory failure (ICD-9): 518.81

S8.3. Comorbid and interactions

Detail the treatment of co-morbidities & disease interactions and provide rationale for this methodology.

NCQA utilizes a risk adjustment model based on components of the CMS-HCC risk adjustment methodology that accounts for variable risk classifications due to comorbidities and other disease interactions. For each condition, members are assigned to a clinical cohort category that provides a more specific classification of the condition and has been shown to be a predictor of healthcare costs. A member/patient's age, gender, and HCC-RRU category all determine their risk score (cohort). Refer to section S10.1 for a more complete description of the steps for risk adjustment that account for comorbidities and other disease interactions.

S8.4. Clinical hierarchies

Detail the hierarchy for codes or condition groups used and provide rationale for this methodology.

The RRU-HCC risk adjustment divides qualified service diagnoses into 184 condition categories which are subject to hierarchy logic, assigning each a ranking group and an HCC group using tables provided by NCQA. The approach captures the combined effect of multiple unrelated conditions; however some diseases (e.g. diabetes, vascular disease) have multiple HCCs to differentiate disease severity and identify rankings (hierarchy) so that a member/patient's highest ranked HCC for a given disease will cancel out lower ranked HCCs for the same disease. See Section S10.1 for the specific steps required to assign HCCs and rankings. Members/patients are assigned to a demographic cohort, each of which is defined by a range of severity as estimated by HCC-RRU. A weight is calculated for each identified HCC for the member/patient and summed to provide a summarized total risk score, which is then assigned to a predetermined risk cohort for reporting.

S8.5. Clinical severity levels

Detail the method used for assigning severity level and provide rationale for this methodology.

The methodology for calculating risk via HCC and the mapping of that estimated risk to HCC-RRU risk categories accounts for clinical severity as well as other interactions that have been shown to be significant predictors of health care costs. Refer to section S10.1 for a more complete description of the steps for risk adjustment that account for comorbidities and other disease interactions.

S8.6. Concurrency of clinical events (that may lead to a distinct measure)
Detail the method used for identifying concurrent clinical events, how to manage them, and provide the rationale for this methodology.

We do not provide specifications for concurrency of clinical events.
 The NCQA RRU measures account for all health plan members who meet the disease specific criteria. All events or encounters for the predefined population that occur during the measurement year are captured by the measure cost or frequency of service categories.

S9. Measure Construction Logic (Resource Use Measure Module 3)
The measure's construction logic includes steps used to cluster, group or assign claims beyond those associated with the measure's clinical logic. For example, any temporal or spatial (i.e., setting of care) parameters used to determine if a particular diagnosis or event qualifies for the measure of interest.

Construction Logic Supplemental Attachment or URL:
If needed, attach supplemental documentation (Save file as: S9_Construction Logic). All fields of the submission form that are supplemented within the attachment must include a summary of important information included in the attachment and its intended purpose, including any references to page numbers, tables, text, etc.)

URL:
 Please supply the username and password:
 Attachment:

S9.1. Brief Description of Construction Logic
Briefly describe the measure's construction logic.

The measure reports total standard costs for all included services for which the organization has paid or expects to pay for the eligible population during a pre-specified measurement year. The eligible population for RAS includes all health plan members with persistent asthma that were continuously enrolled for a two year period (the measurement year and the year prior). Total standard costs are assigned to each service the member received during the measurement year by matching codes for services rendered to codes listed in the NCQA Standardized Price Tables (SPTs)

<http://www.ncqa.org/downloads/rru/9C9848A9-59EE-4E8D-B092-2350FA74EA35>

. Standard costs are calculated and reported for the following service categories:

- Inpatient Facility
- E&M (inpatient and outpatient service categories)
- Laboratory Services
- Surgery and Procedure (inpatient and outpatient service categories)
- Imaging Services
- Pharmacy

S9.2. Construction Logic
Detail logic steps used to cluster, group or assign claims beyond those associated with the measure's clinical logic.

An organization counts all services listed in the SPTs rendered to members in the eligible population during the measurement year. The unit prices are calculated to represent data derived from a single source, using a single approach for classifying and pricing services. Pricing algorithms represent average service pricing levels for organizations for the most recent period. Standard prices support consistent comparisons of "weighted utilization" across all members, organizations and geographic areas and protect individual proprietary pricing and fee schedules.

First the eligible population is defined using the clinical and eligibility criteria outlined in Section S8.2 and below:

Step 1: Identify members or patients eligible within the specified clinical condition. Members must meet the following eligibility criteria to be included in the data set for reporting RRU measures:

- 5-64 years of age as of December 31 of the measurement year
- They must be continuously enrolled throughout the measurement year and the year prior to the measurement year.
- They may not have more than one gap in enrollment (of up to 45 days) anytime during the measurement year. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may

not have more than a 1-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).

-They must have medical and pharmacy benefits for the measurement year

Exclusion criteria are then applied to the eligible population as detailed in Section S8.2. Member months are then calculated for each measure's eligible population after all exclusion criteria has been applied to the eligible population data set using the following steps:

Step 1: Determine member months using a prespecified day (e.g., the 15th or the last day of the month), determined according to the organization's administrative processes. The day selected must be consistent from month to month and year to year. For example, if the organization tallies membership on the 15th of the month and Ms. X is enrolled in the organization on January 15, Ms. X contributes one member month in January. Organizations may count any month in which members were enrolled retrospectively and the organization received a retroactive capitation payment.

Step 2: Use the member's age on the last day of the treatment period to determine the age group where member months will be counted.

Step 3: Attribute all member months to the product line in which the member is enrolled on the last day of the treatment period.

Note: Pharmacy member months are the number of months during the treatment period when the member is covered by a pharmacy benefit. Calculate pharmacy member months with the same method described in steps 1–3.

In order to calculate outpatient procedures and services, organizations count the number of specified services the organization paid for, or expects to pay for, during the treatment period. The organization is responsible for reporting all services under the member's age and product on the last day of the treatment period.

In order to calculate inpatient services, organizations categorize member services into services for pricing and services for frequency: 1) in services for standard pricing, each organization identifies all inpatient stays that occurred during the treatment period, even if the inpatient admission was prior to the treatment period or the inpatient discharge was after the end of the treatment period. Include all services billed for any inpatient facility, E&M; surgery and procedure, and pharmacy service. Include multiple billings that have the same date of service in the member/patient record. 2) To determine frequency of services, each organization identifies all inpatient utilization and reports by discharge date (rather than admission date) using the member's age and product on the last day of the treatment period. Include all discharges that occurred during the treatment period. For inpatient discharges, ED visits and condition-specific frequencies, count discharges, not the frequency of procedure codes billed. Transfers between institutions are treated as separate admissions especially when the transfer is between acute and nonacute levels of service or between mental health/chemical dependency services and non-mental health/chemical dependency services. Only one admission is counted when the transfer takes place within the same service category but to a different level of care.

When calculating inpatient services length of stay, organizations should use the following formula to report length of stay (LOS).

$LOS = \text{discharge date} - \text{admit date} - \text{denied days}$

LOS includes all paid days from admission up to discharge except the last day of the stay unless the admission and discharge date are the same. For inpatient stays that start before the treatment period and end during the treatment period, or that start during the treatment period and end after the treatment period, count all paid days during the inpatient stay, even if they occur outside of the treatment period. When an inpatient revenue code (i.e., UB Revenue code or equivalent) is associated with a stay, the LOS must equal at least one day. If the discharge date and the admission date are the same, the discharge date minus admission date equals 1 day, not 0 days. If the inpatient stay falls completely within the treatment period, the total number of paid days is used as the per diem multiplier. If the inpatient stay does not fall completely inside the treatment period, or all days are not paid for or expected to be paid for, only the days within the treatment period (including the last day in the treatment period) that are paid for or expected to be paid for, are counted to compute the per diem multiplier.

Step 4-Calculate total cost: Sum the total standard cost for each eligible member. Within each service category, if a member's standard cost exceeds the service category cap amount, report the total standard cost specified in the NCQA Cost Cap Amounts table (released with the SPTs).

Sum and report the total standard cost for the eligible population in each service category by member cohort.

Service frequency counts are reported for all services for which the organization has paid or expects to pay for the eligible population during the treatment period. Organizations capture each eligible member's services rendered during the treatment period for the following utilization categories.

- Total Inpatient Facility: Discharges, Days and ALOS
- Acute Inpatient: Discharges, Days, ALOS
- Acute Medicine: Discharges, Days, ALOS
- Acute Surgery: Discharges, Days, ALOS
- Nonacute: Discharges, Days, ALOS
- ED Discharges
- Pharmacy Utilization:

Step 5: For each of the RRU reporting services categories, if a member's standard cost exceeds the set cap amount (<http://www.ncqa.org/tabid/1275/Default.aspx>), only the total standard cost, including the truncated amount taken from the NCQA Member Cost Cap Amounts table, is reported. Members are not excluded from the data set when the capped amount is reached.

Service Category Cap Amount

Inpatient Facility	\$75,000
E&M – Outpatient	\$2,500
E&M – Inpatient	\$2,500
Surgery – Outpatient	\$7,500
Surgery – Inpatient	\$15,000
Pharmacy	\$15,000

S9.3. Measure Trigger and End mechanisms

Detail the measure's trigger and end mechanisms and provide rationale for this methodology.

The measure captures total annual resource use measured from January 1st to December 31st of the measurement year.

S9.4. Measure redundancy or overlap

Detail how redundancy and overlap of measures can be addressed and provide rationale for this methodology.

We do not provide specifications for measure redundancy or overlap.

The NCQA RRU measurement approach accounts for all health plan members who meet the disease specific criteria. All events or encounters for the predefined population that occur during the measurement year are captured by the measure cost or frequency of service categories.

S9.5. Complementary services

Detail how complementary services have been linked to the measure and provide rationale for this methodology.

We do not provide specifications for linking complementary services.

The NCQA RRU measurement approach accounts for all health plan members who meet the disease specific criteria. All events or encounters for the predefined population that occur during the measurement year are collected separately across all service categories, and standard costs and service frequencies are aggregated across services and members to compute the overall resource use for that member for that year. Including all events for a member, whether or not it can be attributed to a specific chronic condition captures a true snapshot of the resources required to treat a health plan member with a chronic condition..

S9.6. Resource Use Service Categories

Inpatient services: Inpatient facility services
 Inpatient services: Evaluation and management
 Inpatient services: Procedures and surgeries
 Inpatient services: Imaging and diagnostic
 Inpatient services: Lab services
 Inpatient services: Admissions/discharges
 Ambulatory services: Outpatient facility services
 Ambulatory services: Emergency Department
 Ambulatory services: Pharmacy
 Ambulatory services: Evaluation and management
 Ambulatory services: Procedures and surgeries

Ambulatory services: Imaging and diagnostic
Ambulatory services: Lab services

S9.7. Identification of Resource Use Service Categories

For each of the resource use service categories selected above, provide the rationale for their selection and detail the method or algorithms to identify resource units, including codes, logic and definitions.

Standard Costs are reported for the following categories:

Inpatient facility: this category reports standard prices for inpatient facility services assigned to each stay and based on the standard per diem price. Organizations use the length of stay and ICD-9-CM Diagnosis codes to assign the appropriate standard price.

E&M: Standard prices for E&M services use a resource-based, relative value scale (RBRVS) that establishes consistent prices across a wide range of professional services, including those performed by different specialists and other professionals. Additionally, inpatient E&M services are summarized and collected separately from outpatient services.

Surgery and Procedures: Standard prices for surgery and procedure services (professional component) use a resource-based, relative value scale (RBRVS) that establishes consistent prices across a wide range of professional services, including those performed by different specialists and other professionals. Additionally, inpatient surgery and procedure services are summarized and collected separately from outpatient services.

Diagnostic Lab and Imaging: Standard prices for imaging and laboratory services (professional and technical components) use an approach that establishes consistent prices across a wide range of services, including those performed by facilities, specialists and other professionals. An RBRVS is the primary source of data for these prices.

Pharmacy: Standard prices for ambulatory prescriptions are based on an index of average wholesale prices for drugs of interest. The standard price is listed per metric quantity for each NDC code. Organizations that do not capture the metric quantity for a prescription can use the standard price per days supply for an NDC. Both the standard price per metric quantity and the standard price per days supply are included in the SPT provided on the NCQA Web site (www.ncqa.org).

Service Frequency is reported for the following categories:

Inpatient Facility: This category measures the number of acute and nonacute inpatient facility discharges, days and ALOS regardless of diagnosis. Count each discharge once. Include data from any institution that provides acute or long-term/specialty nonacute care.

If days from the stay are counted in the cost calculation, the stay should also be counted in the inpatient frequency calculation. For nonacute discharges, days and ALOS, include care from any institution that provides nonacute care in hospice, nursing homes, rehabilitation, SNFs, transitional care and respite.

ED Visits: This category measures use of ED services. Count each visit to an ED during the treatment period that does not result in an inpatient stay, regardless of the intensity of care required during the stay or the length of stay. Count only one ED visit per date of service. Do not count visits to urgent care centers.

Refer to Table AMB-B for codes to identify ED visits. Services for members admitted to the hospital from an ED visit are included in the Inpatient Facility category only.

Table AMB-B: Codes to Identify ED Visits

CPT: 99281-99285

UB Revenue: 045x, 0981

Or

CPT: 10040-69979 WITH POS: 23

Pharmacy Utilization: Use Table SPT-Pharm (<http://www.ncqa.org/tabid/1277/Default.aspx>) to identify the prescription categories for each drug dispensed in the treatment period. Sum and report the number of prescriptions in each of the four categories in the Pharmacy—Total Service Frequency by Prescription Category table.

If needed, provide specifications URL (preferred) or as an attachment:

URL:

Please supply the username and password:

Attachment:

S9.8. Care Setting; provides information on which care settings the measure encompasses.

Ambulatory Care : Ambulatory Surgery Center (ASC)
 Ambulatory Care : Clinic/Urgent Care
 Ambulatory Care : Clinician Office
 Dialysis Facility
 Emergency Medical Services/Ambulance
 Hospital/Acute Care Facility
 Imaging Facility
 Laboratory
 Pharmacy
 Post Acute/Long Term Care Facility : Nursing Home/Skilled Nursing Facility
 Post Acute/Long Term Care Facility : Rehabilitation

S10.Adjustments for Comparability (Resource Use Measure Module 4)

External factors can mingle and affect or confound a measure's result. Confounding occurs if an extraneous factor causes or influences the outcome (e.g., higher resource use) and is associated with the exposure of interest (e.g., episode of diabetes with multiple co-morbidities). Measure developers often include steps to adjust the measure to increase comparability of results among providers, employers, and health plans.

S10.1. Risk adjustment method

Define risk adjustment variables and describe the conceptual, statistical, or other relevant aspects of the model and provide rationale for this methodology.

The current risk model utilized by NCQA is based on components of the CMS-HCC risk adjustment methodology and accounts for age, gender, and HCC-RRU risk classifications that predict cost variability. For each condition, members are assigned to a clinical cohort category that provides a more specific classification of the condition. For example, a member with Type 1 or Type 2 diabetes is assigned to one of 64 HCC-RRU risk categories based on diagnosis codes that are identified in claims for each member in the prior year. A member's age, gender, and HCC category determines their risk score (cohort). NCQA then calculates the average per-member per-month (PMPM) cost for each cohort then weights that cost by the total member months within each cohort. Each plan will have its own weight for each cohort since case-mix varies across plans. These weighted cohort PMPMs are then summed across all cohorts to estimate total resource use that would be expected if the "average" plan had the same case-mix as the plan in question. The ratio of the observed to expected PMPM utilization indicates the degree to which a plan deviates from expected performance. This is known as indirect standardization.

Health plans submit the member month and summarized standardized cost separately for each member cohort, and NCQA calculates expected per member per month (PMPM) results. Thus, each health plan's RRU results are adjusted based on its mix of members.

The following steps assign each member a risk score and HCC-RRU risk reporting category for RRU measurement. Steps are implemented after the eligible population is identified:

Step 1: Identify the qualified service diagnosis.

Identify all diagnosis for face-to-face encounters during the treatment period.

- Outpatient, acute and nonacute inpatient, and ED services. Services with a CPT procedure code or UB Revenue code in Table PCR-B.

- Surgery and procedure services. Services with a CPT Procedure code in Table HCC-Surg.

Use all diagnosis codes for all services that meet the criteria listed above to complete the steps below.

Table PCR-B: Codes to Identify Visit Type

Outpatient

CPT: 92002, 92004, 92012, 92014, 98925-98929, 98940-98942, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99420, 99429, 99455, 99456

UB Revenue: 051x, 0520 -0523, 0526-0529, 057x-059x, 082x-085x, 088x, 0982, 0983

Nonacute inpatient

CPT: 99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337

UB Revenue: 0118, 0128, 0138, 0148, 0158, 019x, 0524, 0525, 055x, 066x

Acute inpatient

CPT: 99221-99223, 99231-99233, 99238, 99239, 99251-99255, 99291

UB Revenue: 010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x, 021x, 072x, 080x, 0987

ED

CPT: 99281-99285

UB Revenue: 045x, 0981

Step 2: Assign each diagnosis code to one of the 184 Clinical Condition (CC) categories using Table CC-Comorbid. Exclude all diagnoses that cannot be assigned to a CC category. For members with no qualifying diagnoses from face-to-face encounters, skip to step 6. All digits must match exactly when mapping diagnoses codes to the CCs.

Step 3: Determine HCCs for each CC identified. Refer to Table HCC-Rank.

For member's CC list, match the CC code to the CC code in the Table HCC-Rank, and assign:

- The ranking group
- The rank
- The HCC

For CCs that do not match to Table HCC—Rank, use the CC as the HCC and assign a rank of 1.

Note: One CC can map to multiple HCCs; each HCC can have one or more CCs.

Step 4: Select only the highest ranked HCC-RRU in each ranking group . using the Rank column (1 is the highest rank possible).

Drop all other HCCs in each ranking group and if necessary, de-duplicate the HCC list.

For example, for member 1, the following HCCs would be listed:

- HCC-RRU-5
- HCC-RRU-15

Note: One CC-RRU can map to multiple HCC-RRUs; each HCC-RRU can have one or more CC-RRUs.

Step 5: Identify combination HCCs listed in Table HCC-Comb

Some combinations suggest a greater amount of risk when observed together. For example, when diabetes and CHF are present, an increased amount of risk is evident. Additional HCCs are selected to recognize these relationships.

Compare each stay's list of unique HCCs to those listed in the HCC column in Table HCC-Comb

(<http://www.ncqa.org/tabid/1252/Default.aspx>) and assign any additional HCC conditions.

For fully nested combinations (e.g., the diabetes/CHF combinations is nested in the diabetes/ CHF/renal combination), use only the more comprehensive pattern. In this example, only the diabetes/CHF/renal combination is counted.

For overlapping combinations (e.g., the CHF, COPD combination overlaps with the CHF/ renal/diabetes combination), use both sets of combinations. In this example, both CHF/ COPD and CHF/renal/diabetes combinations are counted.

Based on the combinations, a member can have none, one or more of these additional HCCs.

Step 6: Identify Demographic HCCs for RRU.

Categorize members by age and gender using the age ranges described in Table RRU-Age/Gender-HCC. Based on gender and the member's age on the last day of the treatment period, assign a demographic HCC.

At the end of step 6, each member will have a final list of HCCs that includes at least one demographic HCC and 0, 1 or more HCCs based on Steps 1 – 5.

Note: Each RRU measure has its own demographic criteria.

Step 7: Calculate the weight for all the HCC's on each member's list using Table RRU-Weight.

(<http://www.ncqa.org/tabid/1252/Default.aspx>) Each HCC for RRU carries a predefined risk weight.

Step 8: Sum each member's risk weights based on the final list of HCCs. A member's risk score is the sum of the risk weights for all HCCs on that member's list. Sum the weights based on the member's HCC lists.

Step 9: Assign the member to a HCC-RRU risk cohort for reporting.

Assign members to a reporting risk category based on their risk score.

Category Lower Score Range Upper Score Range

1	0.000-0.249
2	0.250-0.499
3	0.500-0.749
4	0.750-0.999
5	1.000-1.249
6	1.250-1.499
7	1.500-1.999
8	2.000-2.499
9	2.500-2.999
10	3.000-3.999
11	4.000-4.999
12	5.000-5.999
13	6.000-6.999 over

If needed, provide supplemental information via a web URL (preferred) or attachment with the risk adjustment specifications.

If needed, provide supplemental information via a web URL (preferred) or attachment with the risk adjustment specifications.

URL:





Please supply the username and password:

Attachment:

S10.2. Stratification Method

Detail the stratification method including all variables, codes, logic or definitions required to stratify the measure and rationale for this methodology

NCQA collects resource measures at the plan level and summarizes across reporting cohorts along the following dimensions:

-  Product line (3 levels): commercial, Medicaid, and Medicare;
-  Reporting type (2 levels): HMO and PPO;
-  Area level (2 levels): national and region;
-  Resource use or utilization (11 levels): inpatient facility, procedure and surgery (inpatient and outpatient), evaluation and management (inpatient and outpatient), laboratory services, imaging services, ambulatory pharmacy, inpatient discharges, emergency department discharges.

Stratification of RRU results to control for individual confounding variables is not performed since age, gender and risk variables (comorbidity and disease interactions) that affect healthcare costs are accounted for in the RRU-HCC risk adjustment process. These include age and gender along with one of the 13 assigned HCC-RRU risk categories (e.g. male 18-44 HCC-RRU 1; male 18-44 HCC-RRU 2; male 18-44 HCC-RRU 3; etc...). However, in order to assist organizations in identifying opportunities for improvement, NCQA reports RRU results using the HCC-RRU cohorts as reporting strata. Reporting the measure results by these strata increases the ability of the reporting organizations to target areas for improvement without having to reverse engineer their measure results.

S10.3. Costing Method

Detail the costing method including the source of cost information, steps to capture, apply or estimate cost information, and provide rationale for this methodology.

Formatted: Indent: Left: 0.25", Hanging: 0.1", Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5"

RRU measures use NCQA's standardized prices. The organization does not report prices based on its contracts and fee schedules, rather it applies a standard price to each service, multiplies it by the number of units of service and reports the resulting standard cost. Using this approach protects proprietary fee schedules and contracts while supporting equitable measure comparison across organizations and across regions without requiring adjustment for levels of service payment. Each year, NCQA updates RRU SPTs that catalog a unit price for each type of health service necessary to report the measure. The SPTs allow health plans to match resource use in various service categories to a standardized cost structure, thus translating utilization to relative resource use. The standard pricing approach is based on the following sources of data:

- Relative values from the Medicare Fee Schedule (Resource-Based Relative Value Scale, or RBRVS)
- Pharmacy prices published by First Bank Data
- Inpatient prices based on a model that uses a broad set of averages, representing different local, regional and national health plans across the country.

A plan maps a standard price to each service, multiplies it by the number of units of service and reports the resulting standard cost. It then calculates total standard costs for eligible members across different areas of clinical care and aggregates standard costs across services and members to compute the overall relative resource use.

All RRU measures report the standard cost for the following categories.

- o Inpatient Facility
- o Surgery and Procedure
- o Inpatient Services
- o Outpatient Services
- o Evaluation and Management (E&M)
- o Inpatient Services
- o Outpatient Services
- o Diagnostic Laboratory Services
- o Diagnostic Imaging Services
- o Pharmacy, Ambulatory

Calculating Standard Cost

The organization applies the SPTs to all services in each service category using the following steps.

Step 1: Identify eligible members for each major clinical condition and assign them into the appropriate HCC-RRU risk category (See Section S10.1).

Step 2: Identify all services rendered during the treatment period for each service category.

- Inpatient Facility (services provided by a facility during an inpatient stay, standard price includes room and board and ancillary services)
- E&M (inpatient visits, and outpatient visits including office visits, consultations and other services)
- Surgery and Procedure (inpatient and outpatient procedures)
- Pharmacy (ambulatory prescriptions included in a member's pharmacy benefit)

Step 3: Multiply the standard price by the units of service to compute a standard cost for the service. Refer to each service category's instructions below to calculate standard cost.

Step 4: For each major clinical condition, aggregate or sum each eligible member's total standard cost for each service category.

Step 5: Aggregate and report the total standard cost at the member cohort level.

Step 6: In each service category, if a member's standard cost exceeds the cap amount, report the total standard cost including only the cap amount from Table SPT-CAP (<http://www.ncqa.org/tabid/1277/Default.aspx>). Do not exclude members who exceed the capped amount. Methods used to identify the unit of service and assign standard unit prices vary by service category. The steps required for calculating each category are described below.

Calculating Total Standard Cost: Inpatient Facility

Step 1: Identify all inpatient stays that occurred during the treatment period. Include stays that may have started before the treatment period or ended after the close of the treatment period. Define a single, unique record describing the member's inpatient stay.

Step 2: Determine the LOS for frequency reporting. Compute the LOS in days, using paid for or expected-to-be-paid-for days only. Include all paid days in the calculation, whether or not they fall inside the treatment period. Use this LOS

when reporting the frequency counts for each inpatient stay.

Step 3: Determine the LOS category for standard cost reporting. Assign the appropriate LOS group using Table C.

Table C: Length of Stay Group

LOS (Days) LOS GRP

1	A
2	B
3-4	C
5-6	D
7-8	E
9-15	F
16 +	G

Formatted: Spanish (Dominican Republic)

Step 4: Determine the LOS per diem multiplier. If the inpatient stay falls within the treatment period, use the total number of paid for or expected-to-be-paid-for days as the per diem multiplier. If the inpatient stay does not fall inside the treatment period, or if all days are not paid for or expected to be paid for, count only the days within the treatment period (including the last day of the treatment period) that are paid for or expected to be paid for, as the per diem multiplier.

Step 5: Determine if the inpatient stay is acute or nonacute. Nonacute stays include nursing home, skilled nursing facility, rehabilitation, hospice, hospital transitional care, swing bed and respite; all other inpatient stays are acute. For frequency reporting of inpatient stays, acute and nonacute stays will be reported separately. Note: SPT-INP tables assign the Acute field a value of "1" if the discharge was from an acute inpatient stay and a value of "0" if the discharge is from a nonacute stay.

Step 6: Assign an Aggregate Diagnostic Service Category (ADSC) for the inpatient stay using the principal discharge diagnosis. To assign ADSC, download the ADSC Table from the NCQA Web site (www.ncqa.org) and match the principal ICD-9-CM Diagnosis code from the discharge claim to an ADSC. If the principal ICD-9-CM Diagnosis code is invalid or missing or cannot be determined, map the inpatient stay to the ADSC Table's MISA category.

Step 7: Determine if the member underwent major surgery during the inpatient stay. Identify major surgeries by using the list of codes from the Maj-Surg Table. Flag eligible members if one procedure code in the Maj-Surg-Table is present from any provider during the stay. If the inpatient stay is acute and it has a major surgery, include it in the acute surgery category for frequency reporting. If the stay is acute but does not have a major surgery, include it in the Acute Medicine category. Nonacute stays are not categorized as surgical or non-surgical for frequency reporting. Note: SPT-INP-ADSC assigns the field MAJSURG a value of "1" to indicate the standard price when a major surgery is identified and a value of "0" if no major surgery is identified during the member's inpatient stay.

Step 8: Match each ADSC, LOS group, major surgery flag and acute or nonacute assignment for the stay to the NCQA-provided SPT to obtain the assigned standard price. Multiply the per diem multiplier by the per diem standard price to compute the total standard cost for the stay. For frequency reporting, report the stay in the appropriate category based on the acute or nonacute assignment and surgery or medicine assignment.

Calculating Total Standard Cost: E&M

Step 1: Identify all E&M services that occurred during the treatment period. The valid E&M codes used to select these services are listed in Table SPT-EM. (<http://www.ncqa.org/tabid/1277/Default.aspx>)

Step 2: Match each E&M service to the CPT codes in Table SPT-EM and assign the standard price to the E&M service.

Step 3: Multiply the standard price by the number of units associated with the E&M service. Most services have one unit.

Step 4: Sum the standard prices across the E&M services to calculate the total cost. Include all units of service on a claim line. Sum E&M services labeled as inpatient separate from those labeled as outpatient services.

Calculating Total Standard Cost: Surgery and Procedure

Step 1: Identify all surgery and procedure services provided by physicians and other professional providers during the treatment period. The valid procedure codes for these services are listed in Table SPT-Surg-Proc.

Step 2: Identify modifier codes. Procedure modifiers are sometimes used to define a service in more detail. The standard price for procedure modifiers varies, so these modifiers are combined with the procedure code to match to the appropriate row in the SPT table. Use only the applicable modifiers below to combine with procedure codes.

- 26 = Professional Component
- 50 = Bilateral Service
- 51 = Multiple Surgery
- 52 = Reduced Service
- 54 = Surgical Care Only
- 55 = Post-Surgical Care Only
- 56 = Pre-Op Surgical Care Only
- 62 = Two Surgeons
- 78 = Return to Operating Room
- 80–82 = Assistant at Surgery
- TC = Technical Component

If a procedure code is billed with a nonapplicable modifier, set the modifier to blank. If the procedure code has no modifiers or if all modifiers for a specific procedure code are not applicable, price the procedure code with a blank modifier. Surgery and Procedure CPT codes that have a proprietary modifier indicating an anesthesiology bill are not priced.

Step 3: Identify surgeries or procedures provided during an acute or nonacute inpatient stay. In the SPT, services provided in an inpatient setting are under the Excel workbook tab labeled “Std Price—IP Surgery” and services provided in an outpatient setting are under the Excel workbook tab labeled “Std Price—OP Surgery.” Organizations can distinguish between services provided in an inpatient or outpatient setting in several ways.

- Treat a surgery or procedure as outpatient unless it has a POS code of 21, 31, 39, 51 or 61.
- If the POS code is not available, determine if the member was admitted overnight for the surgery or procedure. If so, treat the surgery or procedure as inpatient; if not, treat it as outpatient.
- Treat a surgery as inpatient if it falls between the dates of an inpatient stay. If a surgery was used to classify an inpatient stay as surgical, price the surgery as inpatient.

Step 4: Download Table SPT-Surg-Proc for surgery and procedure services from the NCQA Web site (<http://www.ncqa.org/tabid/1276/Default.aspx>).

Step 5: Match each procedure code, applicable modifier and POS to obtain the assigned standard price for the service.

Step 6: Multiply the standard price by the number of units associated with the service. Most services have one unit.

Step 7: Sum the standard prices across the surgery and procedure services to calculate the total cost. Sum inpatient and outpatient costs separately. Note: • Surgeries must be correctly classified as inpatient or outpatient because the overhead charges for inpatient surgeries are included in the Inpatient Facility Cost category. The overhead for outpatient surgeries are included in the total cost of the surgery. If the health care facility bills the plan for overhead charges using codes in the SPT-Surg-Proc table, those costs should not be counted in this category.

- Do not include services provided by anesthesiologists. If an anesthesiologist submits a claim or encounter with codes included in Table SPT-Surg-Proc, the claim or encounter for these services should not be included in the total cost.

Calculating Total Standard Cost: Laboratory Services

Step 1: Identify all lab services that occurred during the treatment period. The valid lab codes used to select these services are listed in Table SPT-LAB.

Step 2: Match each lab service to the codes in Table SPT-LAB and assign the standard price to the service.

Step 3: Multiply the standard price by the number of units associated with the lab service. Most services have one unit.

Step 4: Sum the standard prices across the lab services to calculate the total cost. Include all units of service on a claim line.

Calculating Total Standard Cost: Imaging Services

Step 1: Identify all Imaging services that occurred during the treatment period. The valid imaging codes used to select these services are listed in Table SPT-IMG.

Step 2: Match each imaging service to the codes in Table SPT-IMG and assign the standard price to the imaging service.

Step 3: Multiply the standard price by the number of units associated with the imaging service. Most services have one unit.

Step 4 Sum the standard prices across the imaging services to calculate the total cost. Include all units of service on a claim line.

Calculating Total Standard Cost and Frequency: Pharmacy Services

Step 1: Identify all ambulatory prescriptions dispensed (pharmacy services) during the treatment period.

Step 2: Identify the NDC code and the metric quantity for each prescription. If metric quantity is available, the organization must use it to determine standard price. If the metric quantity is not available, the organization should use the standard unit price per day in the NCQA table.

An organization that uses proprietary or regional codes should map them to standard NDC codes.

Step 3: Download Table SPT-Pharm from the NCQA Web site (<http://www.ncqa.org/tabid/1277/Default.aspx>). The table contains:

- The NDC code
- A standard unit price per metric quantity
- A standard unit price per day.
- Prescription category

Name brand only (N1) Generic only (G1)

Name brand—Generic exists (N2) Generic name—Name brand exists (G2)

Step 4: Match each NDC code to the appropriate row in Table SPT-Pharm.

Step 5: Aggregate and report service frequencies within each prescription category at the total level by organization for pharmacy prescription utilization.

Step 6: If the metric quantity is available, multiply the metric quantity dispensed by the standard price per metric quantity for each prescription.

Step 7: If the metric quantity is unavailable, multiply the days supply dispensed by the standard unit price per day for each prescription.

Step 8: Sum the unit prices for all unique prescription dispensing events.

S11. Measure Reporting (Resource Use Measure Module 5)

The measure developer must determine which of the following Measure Reporting functions: attribution approach, peer group, outliers and thresholds, sample size, and benchmarking and comparative estimates, are submitted as measure specifications or as guidelines. Specifications limit user options and flexibility and must be strictly adhered to; whereas guidelines are well thought out guidance to users while allowing for user flexibility. If the measure developer determines that the requested specification approach is better suited as guidelines, please select and submit guidelines, otherwise specifications must be provided.

S11.1. Detail attribution approach

Detail the attribution rule(s) used for attributing costs to providers and rationale for this methodology (e.g., a proportion of total measure cost or frequency of visits during the measure's measurement period) and provide rationale for this methodology.

Using administrative claims data submitted by all organizations, NCQA estimates the expected RRU amounts for each clinical condition for each organization. RRU index amounts are based on the ratio of observed to expected amounts. Results can be assessed at an overall basis, across all members and major clinical conditions, by

service category or for a member cohort within a condition. Relative resource use is calculated at the plan-level and no attribution of resource use is made below this level. Attribution of resource use to a particular NCQA submission is based on the product line and reporting type of the plan that the member was enrolled in as of the end of the measure year.

S11.2. Identify and define peer group

Identify the peer group and detail how peer group is identified and provide rationale for this methodology

Specifications : There are multiple concepts of a “peer group” for the RRU measures. NCQA collects resource measures at the plan level and summarizes across reporting cohorts along the following dimensions:

- ? Product line (3 levels): commercial, Medicaid, and Medicare;
- ? Reporting type (2 levels): HMO and PPO;
- ? Area level (2 levels): national and region;
- ? Resource use or utilization (11 levels): inpatient facility, procedure and surgery (inpatient and outpatient), evaluation and management (inpatient and outpatient), laboratory services, imaging services, ambulatory pharmacy, inpatient discharges, emergency department discharges.

In the context of calculation of RRU ratios for risk adjustment purposes, NCQA uses indirect standardization to define a “case-mix peer group” for each plan relative to a hypothetical plan (with the same case-mix). The national average of PMPM resource use for each cohort is used to calculate this “case-mix peer-group.” Conceptually speaking, the “case-mix peer group” represents what we might expect resource use to look like from the “average” plan if it had the same case-mix as the observed plan. Mathematically, this expected resource use is the national mean PMPM resource use for each cohort (weighted by the cohort’s member months in an individual plan) summed up over all of the cohorts in the plan for each service category (e.g. Inpatient facility, Inpatient E&M, etc.). Resource use can be summed across service categories to get grand totals such as “Total Medical.” At this point, there are estimates of both observed and expected resource use.

In order to determine how different a plan is from its own hypothetical “case-mix peer-group” (i.e. how different observed resource use is from expected resource use) the observed and expected total costs are expressed as an observed to expected (O/E) ratio. If a plan used 10% fewer resources than expected, it would have an O/E ratio of 0.9.

Conversely, a plan that used 10% more resources than expected, the O/E ratio would be 1.1.

These O/E ratios are subsequently indexed to facilitate comparisons of efficiency by region and by reporting type (e.g. HMO/PPO), with the “indexed peer group” defined by the average O/E ratio for all plans in the same region and of the same reporting type. The difference between the “case-mix peer group” and the “indexed peer group” is that the former is an intermediate step of risk-adjustment and the latter is a means for making comparisons within a plan type and within a region more straightforward.

After calculating the indexed O/E ratios, NCQA provides organizations with their relative resource index score at the service category and major clinical condition level.

- ▲ A score of 1.00 indicates that the observed amounts for standard costs or utilization are equal to the expected amounts for a given region and plan type.
- ▲ A score >1.00 indicates that the observed amounts for standard costs or utilization are greater than the expected amounts for a given region and plan type.
- ▲ A score <1.00 indicates that the observed amounts for standard costs or utilization are lower than the expected amounts for a given region and plan type.

For example, an organization whose indexed observed-to-expected ratio is 1.10 for pharmacy services in its Relative Resource Use for People With Asthma measure has a total standard cost for pharmacy services for RAS that is 10 percent higher than the expected total pharmacy services cost for other plans in the same region and of the same plan type.

S11.3. Level of Analysis:

Clinician : Group/Practice
Health Plan
Integrated Delivery System
Population : National
Population : Regional

S11.4. Detail measure outliers or thresholds

Detail any threshold or outlier rules and decisions based on measure resource use and provide

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5"

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5"

rationale for this methodology

Specifications : NCQA does not exclude any plan submission from the RRU calculations; however we do not publicly report any plan's result if the O/E ratio for the specific service category (or overall service category) is less than 0.33 or greater than 3.0, or whose eligible population (n) is <400.

S11.5.Detail sample size requirements

Detail the sample size requirement including rules associated with the type of measure

Specifications : Organizations submit all patients who meet the eligible population criteria for asthma to NCQA; however we do not publicly report any organization whose eligible population (n) is <400. The sample size of 400 is based on a bootstrap sampling approach in which the standard errors of each plan's O/E ratios for Total Medical and Total Pharmacy were calculated from 100 simulations. In these simulations, plans were drawn from 44 market areas with pre-specified eligible populations of 30, 50, 100, 200, 400, 1000, and 2500. This analysis was conducted for the Diabetes, Asthma, and Acute Low Back Pain RRU measures. Across all three chronic diseases, the decrease in the average standard error (estimated over the 100 simulations) with increasing sample size begins to flatten out at a sample of size close to 400, indicating reliable estimates of the O/E ratios can be obtained for plans with as few as 400 cases of the chronic disease.

S11.6.Define benchmarking or comparative estimates

Detail steps to produce benchmarking and comparative estimates and provide rationale for this methodology

Specifications : A ratio of observed-to-expected resource use is calculated for each clinical condition for each plan. The observed value is the actual summarized use data that health plans submit to NCQA for each measure's eligible population. NCQA calculates the expected value, or the resources the plan would be expected to use if it performed at the average level of use for all other plans that submitted data with consideration of case mix differences between plans (See Section S11.2). Upon obtaining these values, NCQA calculates an observed-to-expected ratio and reports it for each plan's national and regional peer group. If a plan reported that its level of resource use for all patients with asthma was identical to the average of all plans and the plan had a case mix of patients that was identical to the average for all plans, the observed and expected values would be the same and the O/E ratio would be 1.0. If the plan used more resources for members/patients with asthma than the average of all plans but had the same (average) case mix, the actual reported RRU (observed) would be higher than expected and the O/E ratio would be >1.0. Generally, NCQA calculates the index ratio, which compares a plan's resource use to the average performance of all health plans in a specific product line. NCQA does not set benchmarks or thresholds for the O/E or indexed ratios (other than the outlier exclusion for O/E ratios > 3 and < 0.33).

~~We do not provide specifications or guidelines for defining benchmarking and comparative estimates~~

S12.Type of Score:

Frequency Distribution
Rate/Proportion
Ratio
Weighted score/composite scale

If available, please provide a sample report:

[S12_Sample Score Report_RAS.pdf](#)

S12.1. Interpretation of Score.

(Classifies interpretation of score (s) according to whether higher or lower resource use amounts is associated with a higher or lower score, a score falling within a defined interval, or a passing score, etc)

RRU measures indicate how a plan uses a set of key resources (e.g., physician visits, hospital stays) to care for its members with specified diseases, compared with the average for plans in the same region and adjusted for the set of

diseases and case mix of plan members. When used in tandem with quality measures, RRU results make it possible to simultaneously evaluate the quality of services and key elements that drive costs and premiums. As described in detail in Sections S11.2 and S11.6, a ratio of observed-to-expected resource use is calculated for each clinical condition for each plan which is then indexed to a mean of 1.0 to allow for equitable comparisons between plan peer groups. When considering RRUs for members/patients with asthma, an RRU index ratio result of 1.00 indicates that a health plan used the same level of resources to treat its population of patients with asthma as the average of all plans for a similar (case mix-adjusted) group of members/patients with asthma. An index ratio of 1.12 indicates that a health plan used 12 percent more resources than their national or regional (depending on which benchmark is being used) peer average. An index ratio of 0.73 indicates that a plan used 27 percent fewer resources than the average of all plans for a similar (case mix-adjusted) group of members/patients.

S12.2. Detail Score Estimation

Detail steps to estimate measure score.

A ratio of observed-to-expected resource use is calculated for each clinical condition for each plan. The observed value is the actual summarized use data that health plans submit to NCQA for each measure's eligible population. NCQA calculates the expected value for each plan—the resources the plan would be expected to use if it performed at the average level of use for all other plans that submitted data, considering case mix differences between plans. NCQA then calculates an observed to expected ratio and reports it for each plan's national and regional peer group.

The definitions below provide the rationale behind the type of score and how each are reported:

Observed (O): A plan's resource use, calculated using units of resources used (inpatient days) converted to dollar terms using the SPT and reported to NCQA. Summarized data are displayed as PMPM dollars for the four RRU service categories and as per 1,000 member years for the service frequency categories.

Expected (E): A plan's resource use assuming that the plan performed like an "average" plan with the same case-mix. NCQA provides these values to the plans.

O/E ratio: A plan's observed (reported) RRU values divided by its expected RRU values.

Indexed O/E ratio: The O/E ratio adjusted such that the mean of the O/E ratios for all plans equals 1.0

NCQA estimates and reports both the national peer group O/E results and the indexed plan type/regional peer group O/E results. An indexed ratio result of 1.00 indicates that one plan's level of resource use is the same as the average of all plans' level of resource use. This calculation creates a method for purchasers to examine the differences in plan resource use for a specific condition.

S12.3. Describe discriminating results approach

Detail methods for discriminating differences (reporting with descriptive statistics--e.g., distribution, confidence intervals)

IDSS report information gives health plans an opportunity to identify areas where resource use is too high (O/E >1.0) or offers a benchmark of best performance. NCQA concurrently publishes an organization's RRU ratio, indexed ratio, and quality index ratios for both the national and regional peer groups.

The O/E ratio for each plan can indicate if that plan's O/E is different from 1 or not. These include confidence interval (CI) calculations for the national Total Medical and Total Pharmacy service categories. The O/E ratio for each plan can indicate if that plan's O/E is different from 1 or not. Unfortunately, statistical tests have not been developed to determine the statistical significance of differences between one plan's O/E ratio and another's.

Service category-specific confidence intervals for a given plan are calculated using the following.

$$95\% \text{ Confidence Limit} = \text{O/E ratio} \pm 1.96 \times \text{SE}$$

where:

"SE" is the standard error

1.96 is the standard normal deviate that corresponds to a 95% confidence limit

The standard error (SE) that NCQA uses in the calculation of the plan confidence limits is derived through a bootstrap approach resulting in 100 simulations drawing from plans covering 44 market areas (Ingenix Impact Benchmark Database). These simulations result in plans with pre-specified eligible populations (30, 50, 100, 200, 400, 1000, and

Formatted: Spanish (Dominican Republic)

2500). The standard error across simulations of O/E ratios for each eligible population size is the estimated standard error for the O/E ratio. For a given plan, the standard error chosen for the calculation of its confidence limit is the estimate corresponding to the nearest match on eligible population size (highest bootstrap sample size that an observed eligible population exceeds).

TESTING/ANALYSIS	
Measure testing must demonstrate adequate reliability and validity in order to be recommended for endorsement. Testing may be conducted for data elements and/or the computed measure score. See guidance on measure testing.	Eval Rating
<p>TESTING ATTACHMENT (5MB or less) or URL:</p> <p><i>If needed, attach <u>supplemental</u> documentation (Save file as: SA_Reliability_VValidity Testing) All fields of the submission form that are supplemented within the attachment must include a summary of important information included in the attachment and its intended purpose, including any references to page numbers, tables, text, etc.</i></p> <p>URL:</p> <p>Please supply the username and password:</p> <p>Attachment: SA_Reliability_VValidity Testing-634364798866745084.pdf</p>	
<p>SA1. Reliability Testing <i>For each module tested or for the overall measure score:</i></p> <p>SA1.1. Data/sample <i>(Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included)</i></p> <p>For the asthma RRU measure (RAS), health plans report resource use for all members who meet the HEDIS case definition for asthma and also meet the measure eligibility criteria for age and who are not excluded for dominant conditions. NCQA then calculates observed and expected cost and expresses risk-adjusted resource use as the ratio of observed to expected per-member per-month utilization. Outlier ratios in excess of 3 or less than 0.33 are not publicly reported, nor are plans whose eligible populations are less than 400 members publically reported.</p> <p>For the Relative Resource Use measurement set, NCQA annually conducts an analysis on the data submitted for the HEDIS RRU measures, including an examination of the reliability and validity of the current year data compared to all previous years data. The intent of this annual report is to ensure the continued reliability and consistency of the data used to calculate the RRU results. The primary data for these analyses are derived from the HEDIS 2010 reports of relative resource use (RRU) by commercial, Medicaid, and Medicare plans. These results are reviewed by the Efficiency Measurement Advisory Panel (EMAP) and results are approved by the Committee on Performance Measurement. A standard set of questions are asked to ensure the validity and repeatability of the RRU results that are publically reported. The most recent annual RRU analytic report (2010) produced a number of key findings related to the continued reliability of resource measurement at the health plan level:</p> <ul style="list-style-type: none"> • There were a sufficient number of plans reporting across all the RRU measures. • Among the commercial health plans that submitted HEDIS data, approximately 86 percent submitted RRU data for asthma. Although in 2010, 45% of 348 Commercial plans that reported RAS results could not publicly report results; for Medicaid (n = 90) this number was approximately 34%, due almost exclusively to eligible populations below 400 members. • Among Medicaid plans (HMO only) 53 percent submitted RRU data for asthma. <p>SA1.2. Analytic Methods <i>(Describe method of reliability testing and rationale)</i></p> <p>To help improve our understanding of the measures' performance, we have structured the annual analyses to provide comprehensive univariate information and selective correlational and multivariate analyses of the RRU data submitted to NCQA. By answering the following research questions, NCQA was able to set specific objectives for the 2010 RRU</p>	<p>2a2</p> <p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/></p>

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5"

analysis to examine the continued reliability and validity of the RRU HEDIS data supporting the measures:

- Are a sufficient number of plans reporting RRU data?
- Did notice of public reporting of RRU results in 2010 result in a change in the number of makeups of plans that reported RRU in 2010?
- Has the range in RRU results remained stable over time?
- Did the number of plans identified as “outliers” change in 2010?
- Are plans’ observed-to-expected results for the RRU measures stable over time? Across all product lines, approximately nearly 90% of all plans shifted at most one quartile and within that group, over half did not change quartiles at all. Stability over time indicates that spurious observations and results are not common and that estimates of resource use are stable over time. Resource use for individual plans should not change appreciably.
- Is there a relationship between plans’ O/E results and quality results? There are few significant correlations between risk-adjusted resource use and the quality composite, all of which are weak at best.

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5", Position: Horizontal: -0.02", Relative to: Margin, Vertical: 0.02", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

SA1.3. Testing Results

(reliability statistics, assessment of adequacy in the context of norms for the test conducted)

The 2010 annual Analytic Report provided a number of conclusive results supporting previous validity and reliability testing of the RRU measures. RAS continues to perform strongly for the commercial product line and exhibits stability among the cohort of plans that are reporting the measure.

Between 2009 and 2010 health plan O/E results were stable. From 2009 to 2010, based on their RRU results (O/E) results, 97% of HMO plans placed in the same quartile or moved only to the neighboring quartile while 94% of PPOs moved less than 1 quartile. Around 1% of HMOs and 1.7% of PPOs moved from the highest to lowest quartile. Total Medical and Pharmacy RRU values were positively correlated between 2009 and 2010 among HMO plans while being somewhat condition-dependant for the commercial and Medicare PPO plans. Additionally, the range and variation in both the submitted data and final plan results were not found to be excessive nor was there a significant relationship noticed between health plan Total Medical O/E results and plan quality results.

SA1.4. Finding statement(s)—(i.e., is the measure deemed reliable, limitations identified)

The Efficiency Measurement Advisory Panel (EMAP), NCQA’s external expert panel, reviewed submitted data and results and determined that all five of the RRU measures demonstrated reliability and validity. These determinations were supported by NCQA’s Committee on Performance Measurement (CPM).

SA2. Validity Testing

For each module tested or for the overall measure score:

SA2.1. Data/Sample

(Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included)

To guide the development of the RRU measures (2004-2010), NCQA convened an expert advisory panel, the Efficiency Measurement Advisory Panel (EMAP), to discuss different methodological issues related to RRU measurement and develop an approach to measure relative resource use. Using a large managed care database and Integrated Healthcare Information Services, Inc (IHGIS), NCQA performed research focusing on different methodological issues proposed by the EMAP. The approach to measurement used for the investigation focused on creating and testing a meaningful and “manageable” approach as seen below.

- Select relevant clinical conditions for study – conditions that are both financially and clinically important, but also conditions that can support generalization to a broader group of diseases. These conditions were further selected because relevant quality metrics are currently available for the same conditions allowing for subsequent linking of quality and resource use for the same conditions.
- Employ measures of resource utilization that can be obtained in a reliable and practical way – using methods that can be replicated across health plans and also present a reasonable burden in measurement.
- Explore those components of resource costs that can be measured reliably – if a subset of services can be found that can be measured reliably, that subset can serve as a good proxy for all services.

The IHGIS Managed Care Benchmark Database served as the source of data for the analysis. The Benchmark Database includes medical and pharmacy claims and enrollment for more than 25 million unique individuals, 30 health plans and

2b2

H
M
L
I

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5", Position: Horizontal: -0.02", Relative to: Margin, Vertical: 0.02", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

other contributors. The database population was comprised of primarily non-elderly, commercially enrolled individuals. All data were standardized and evaluated for completeness and consistency. Costs were based on a standard pricing methodology applied across all contributors and time periods (using Relative Value Units (RVUs) and other methodologies). For the analysis described here, a subset of the Benchmark Database population was selected. In particular, the study population met the following criteria:

- at least 6 months of enrollment in the year (2003) used to identify patients and measure costs and utilization.
- selected from a number of different populations (health plans) that met sufficient product and geographic variation (given available data).

In the end 1 Medicare Risk, 1 Medicaid and 12 commercial populations were selected for the study meeting the above selection criteria. The total population meeting the above criteria exceeded 7.5 million individuals. The population included a mix of HMO, PPO and POS products and included Blue Cross Blue Shield and regional plans of different sizes from across the U.S. The population was disproportionately from the northeast, with only limited enrollment from the Pacific region.

SA2.2. Analytic Method

(Describe method of validity testing and rationale; if face validity, describe systematic assessment)

For the developmental phase of the RRU measures, cost and utilization experience were measured for the same 12 months used to identify patients. All inpatient facility, outpatient facility, professional, ancillary and pharmacy claims for the disease-identified members were selected. Measures of cost and utilization were produced for all services and some selected service categories that may serve as a proxy for all services. The selected service categories included inpatient facility, pharmacy, evaluation and management (including consults), procedures (including outpatient facility and ambulatory surgical center services), laboratory, and imaging services. The cost measure used in the analysis was based on a standard costing methodology and priced at calendar year (CY) 2003 levels. Early on in the process it was determined by the EMAP that collecting true unit price would not be possible due to the proprietary nature of prices and discounts negotiated between health plans and providers. For the purposes of the developmental field test, pricing levels reflect total allowed payments, inclusive of health plan liability and patient cost-sharing. Costs were reported by a cost per patient per month (PMPM) measure. Since a standard costing methodology was employed for the field test study data, the costs reported can be considered "weighted utilization," i.e., they were computed using service counts and RVUs per service and a dollar factor to convert RVUs to dollars. These RVUs represent units of standard priced dollars, in relative terms.

Early in measure development (2004-2005), two different approaches were tested to identify disease-related costs. The first approach employed a widely-used tool, ETGs, which uses an episode of care approach to assign medical and pharmacy services to conditions and diseases. More specifically, ETGs use a basic illness classification methodology that combines related services into a medically relevant unit describing a complete episode of care. Episodes are created based on a series of rules and the diagnoses and procedures found on medical claims, including drug treatments listed on 14 pharmacy claims. Examples of ETGs are: insulin-dependent diabetes, with co-morbidity; coronary disease, with AMI, with coronary artery bypass graft; and asthma, without comorbidity, age less than 18. For this field study the ETG grouper software was applied to 12-months of medical and pharmacy claims used for each patient. The result was an output file that includes the ETG assigned to each service, along with other information, which were then mapped to each of the major clinical groupings. Where patients were identified for a clinical grouping within a larger major clinical category (e.g., cardiovascular or asthma/COPD), all of the disease-related costs within that category were assigned as disease-related for that clinical grouping for that patient. For example, for a member assigned ultimately to a CHF clinical category, any disease-related costs for all ETGs assigned to CAD, angina, and AMI were also included. The same approach was used for asthma/COPD, where a patient identified ultimately as a COPD patient received the disease-related costs for both asthma and COPD. Since ETGs assign each service uniquely to a single episode of care, services could not be disease-related to multiple major clinical categories.

The second approach to assigning disease-related costs employed the same diagnosis and procedure-based methodology as was used to identify patients for the study. This approach was called the Disease Identification (DID) approach. A medical service was determined to be disease-related if any of the diagnosis (using the first 3 diagnostic positions) or procedure codes on the service corresponded to one or more of the diagnosis or procedure codes used to identify the clinical categories. Disease-related pharmacy services were identified based on the NDC code on the pharmacy claim and mapped to the highest-level therapeutic categorization developed for each major clinical category. For example, Cardiovascular System Agents, Blood Agents, Agents that Affect Blood Lipids/Sugar/Amino Acids, and Drugs Given to Alter Blood Coagulation were included as disease-related to cardiovascular conditions. Since a single service could have multiple diagnosis codes (some of which could be assigned to a different clinical category), using the DID approach allows a service to be used as disease-related for multiple conditions. For example, an inpatient stay with

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5", Position: Horizontal: -0.02", Relative to: Margin, Vertical: 0.02", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

diagnoses listed for both CHF and diabetes type I would be assigned as disease-related for both conditions.

The disease-related methodologies were used to assign services and costs to each clinical category. An important objective of the study was to measure total service costs for patients in each clinical category, including those related to the disease and other services. This measurement required a population-based risk assessment approach that could capture the overall patient morbidity, including conditions related to the clinical category being studied as well as all conditions observed for the patient. Morbidity categories include groups of patients with similar levels of health risk. Two different approaches were used to assign patients to morbidity categories for the analysis. The first method employed a widely used diagnosis-based tool, Episode Risk Groups (ERGs). ERGs are an episode-based approach to health risk assessment and compute an overall level of risk for an individual based on their observed mix of episodes of care. A patient's relative risk score is a number such as 0.50, 1.00, or 1.50. A risk score of 0.50 indicates a health risk approximately half of that of the average member in an index population, a score of 1.00 means the patient's relative risk is equal to the average member, and 1.50 indicates a fifty percent greater risk. The index population for ERGs is a large, non-elderly managed care population. Retrospective (concurrent) values of health risk were used for the analysis. Eight ERG morbidity categories were created for use in the study:

1. 1-risk score less than 1.00 5. risk score 8.00 to less than 12.00
2. 2-risk score 1.00 to less than 2.00 6. risk score 12.00 to less than 15.00
3. 3-risk score 2.00 to less than 4.00 7. risk score 15.00 to less than 20.00
4. 4-risk score 4.00 to less than 8.00 8. risk score 20.00 or higher

Using their risk score a patient was assigned to the appropriate ERG morbidity category. The ranges used for these categories were based on the observed distribution of risk for study patients and the desire to create a limited number of categories to support sufficient sample size within each grouping and also to limit reporting burden. The second approach to morbidity adjustment for measuring the relative resource utilization for total service employed an age-sex model. Based on an analysis of the distribution of study patients and their costs, the following age-sex categories were employed, where "All" indicates both genders for the same age range:

- All, 00-17 years
- Females, 18-44 years
- Males, 18-44 years
- All, 45-54 years
- All, 55-64 years
- All, 65-74 years
- All, 75+ years

In summary, ERGs and the age-sex model were used as the basis for creating morbidity categories to support total service measurement. Further, given the stratification of patients into the 18 clinical categories previously described, the final population-based risk assessment methodology was an ERG-based Morbidity Adjustment – using ERGs within clinical categories, including with and without co-morbidity alongside an "Age-Sex" and Clinical Category-based Morbidity Adjustment – using age-sex groupings, within clinical categories, including with and without co-morbidity.

SA2.3. Testing Results

(statistical results, assessment of adequacy in the context of norms for the test conducted; if face validity, describe results of systematic assessment)

The investigations described in attachment SA_Reliability_Veracity Testing provided insights into the conceptual and methodological issues in measuring relative utilization at a health plan level. Using a large research database, the study addressed a number of questions related to assessing resource utilization at the health plan and population levels. The following questions were assessed during the initial validity testing of the RRU approach:

Question 1: What is the typical total expenditures for patients with different conditions? Do patients with the same condition and co-morbidity have different costs? How do the estimates vary across populations?

Interpretation (See Table 5, page 35 of attached file "SA_Reliability_Veracity Testing"):

- Patient costs were highest for AMI and CHF and lowest, on average, for asthma patients.
- As expected, costs for members with a condition and a qualified co-morbidity were higher than for patients with the same condition without co-morbidity.
- In general (with a few exceptions), the average costs for a clinical grouping were similar across plans.

Question 2: What is the typical total expenditures for patients with different conditions, by service category? What is the most important service category financially?

How do the estimates vary across clinical categories?

Formatted: Numbered + Level: 1 +
Numbering Style: 1, 2, 3, ... + Start at: 1 +
Alignment: Left + Aligned at: 0.25" + Indent
at: 0.5", Position: Horizontal: -0.02", Relative
to: Margin, Vertical: 0.02", Relative to:
Paragraph, Horizontal: 0.13", Wrap
Around

Formatted: Bulleted + Level: 1 + Aligned at:
0.25" + Indent at: 0.5", Position: Horizontal:
-0.02", Relative to: Margin, Vertical: 0.02",
Relative to: Paragraph, Horizontal: 0.13", Wrap
Around

Formatted: Bulleted + Level: 1 + Aligned at:
0.25" + Indent at: 0.5", Position: Horizontal:
-0.02", Relative to: Margin, Vertical: 0.02",
Relative to: Paragraph, Horizontal: 0.13", Wrap
Around

Interpretation (See Table 6, page 36 of attached file “SA_Reliability_VValidity Testing”):

- As expected, variation in patient costs across clinical categories was observed. Further, differences in the relative importance of categories by clinical grouping were also evident.
- Inpatient and pharmacy services comprise the largest individual service category percentages. Inpatient services were most important for cardiovascular conditions.
- The “Other” category (denoting services that may be more difficult to quantify and measure) comprises 10-15 percent of total service costs – a consistent percentage across clinical groupings.

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5", Position: Horizontal: -0.02", Relative to: Margin, Vertical: 0.02", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

Question 3: What is the magnitude of disease-related costs for each clinical grouping? How do these amounts vary by service category?

Interpretation (See Tables 7&8, pp. 38-40 of attached file “SA_Reliability_VValidity Testing”):

- Disease-related costs represent a significant portion of total service costs for some conditions – in particular the cardiovascular conditions (approx 50-80 percent). These percentages vary by service category.
- Disease-related costs represent a lesser portion of total service costs for some conditions, e.g., asthma, COPD, arthritis and LBP.
- For many conditions, the magnitude of the disease-related costs was comparable whether using the ETG or DID approach – the exceptions were asthma, COPD and diabetes, with comorbidity, where the DID amounts were higher (for total services and other service categories). In general, findings were comparable between the two approaches.

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5", Position: Horizontal: -0.02", Relative to: Margin, Vertical: 0.02", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

Formatted: Bulleted + Level: 2 + Aligned at: 0.25" + Indent at: 1", Position: Horizontal: -0.02", Relative to: Margin, Vertical: 0.02", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

Findings on Relative Resource Utilization – Variation by Type of Service:

- For a given health plan and clinical category, measures of relative resource utilization were generally similar across different types of service, with only some modest variations. The consistency was greatest for those services comprising a larger portion of overall costs measured (e.g., inpatient and pharmacy).
- In addition to showing the variation in findings across type of service categories, for a given health plan and clinical category, measures of relative resource utilization were generally similar using the “selected” group of services (inpatient, pharmacy, E&M and procedures) versus all types of service. In general, where differences were observed, relative resource utilization for diagnostic services (radiology, laboratory, and other diagnostic testing) were the primary factor. The study explored the potential for the use of a subset of services as a proxy for measuring resource use for all services (see Table 7 pp. 38 of attached file “SA_Reliability_VValidity Testing”). In this way, services that can be reliably measured could be the focus of initial measurement and also present a reasonable burden on health plans in collecting this information. The study found measures of relative resource utilization were generally similar using “selected” services (inpatient, pharmacy, evaluation and management, and procedures, including ASC costs) versus measurement using all services.

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5", Position: Horizontal: -0.02", Relative to: Margin, Vertical: 0.02", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5", Position: Horizontal: -0.02", Relative to: Margin, Vertical: 0.02", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5", Position: Horizontal: -0.02", Relative to: Margin, Vertical: 0.02", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

Findings on Relative Resource Utilization – Variation across Clinical Category:

- For a given population, measures of relative resource utilization were generally similar across the major clinical categories, i.e., similar findings were observed for the same population for cardiovascular disease, diabetes, depression, asthma/COPD, and arthritis/LBP. This was particularly true for total service costs. For disease-related costs somewhat greater variation was observed across conditions for the same population.

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5", Position: Horizontal: -0.02", Relative to: Margin, Vertical: 0.02", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5", Position: Horizontal: -0.02", Relative to: Margin, Vertical: 0.02", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

Findings on Relative Resource Utilization – Variation Across the Four Methods

- For a given population and clinical category, measures of resource utilization were generally similar across the four different approaches to measurement described above, with only some modest variations.

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5", Position: Horizontal: -0.02", Relative to: Margin, Vertical: 0.02", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

Summary Interpretation:

- A typical standard error for measuring total service relative resource utilization was observed to be approximately 0.025 at samples of 2,000 patients or more. For example, for a condition with a typical prevalence of 1 percent of enrolled members, a health plan of 250,000 members would yield a patient sample of 2,500. Based on the above standard error, the expected 95 percent confidence interval around the estimated resource utilization index would be approximately +/- 0.05, where 0.05 equals twice 0.025 (a 95 percent confidence interval is approximately 2 standard errors).
- In general, the standard errors were relatively higher for measures of disease-related services versus total services.

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5", Position: Horizontal: -0.02", Relative to: Margin, Vertical: 0.02", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

SA2.4. Finding statement(s)—(i.e., is the measure deemed reliable, limitations identified)

The Measuring Health Plan Relative Resource Utilization study (2005) produced a number of key findings related to resource measurement; however, we are still challenged by the value of these metrics and their meaning to purchasers. The study conclusively determined that:

- Health plans can be meaningfully measured and compared with respect to the relative resource consumption of their networks for select resource categories.
- Methodologically defensible non-proprietary methods can be identified for severity and case adjustment. These methods can serve as the basis for the development of practical algorithms to support measurement of resource utilization at the health plan level – involving a reasonable burden on health plans in measurement and also avoiding the need for requiring their use of a proprietary tool.
- A significant obstacle in sharing cost information at the health plan level is the proprietary nature of the fee schedules and contracts that describe their pricing of services. This study employed standard pricing methods that removed unit price variation as a factor in resource measurement.
- Relative resource consumption seems to vary meaningfully between health plans. More specific findings related to these measures provided insights related to the services, conditions and methods used for study:
- Services – for a given health plan and clinical category, measures of relative resource utilization were generally similar across different types of service, with only some modest variations. The consistency was greatest for those services comprising a larger portion of overall costs measured (e.g., inpatient and pharmacy).
- Study Conditions – for a given health plan, measures of relative resource utilization were generally similar across the study conditions – i.e., similar findings were observed for the same population for cardiovascular disease, diabetes, depression, asthma/COPD, arthritis and LBP.
- Methods – four different approaches were used by the study to measure relative resource use – varying by the risk adjustment methodology employed and the focus on total service versus disease-related costs. For a given population and clinical category, measures of resource utilization were generally similar across the four different approaches to measurement described above, with only some modest variations.
- The study explored the potential for the use of a subset of services as a proxy for measuring resource use for all services. In this way, services that can be reliably measured could be the focus of initial measurement and also present a reasonable burden on health plans in collecting this information. The study found measures of relative resource utilization were generally similar using “selected” services costs) versus measurement using all services.
- The relationship between population size and variation in measures of relative resource utilization – i.e., what is a sufficient sample size to produce consistently valid numerators and denominators and how large of a health plan is required to achieve these thresholds – was explored.

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5", Position: Horizontal: -0.02", Relative to: Margin, Vertical: 0.02", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

Formatted: Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5", Position: Horizontal: -0.02", Relative to: Margin, Vertical: 0.02", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

SA3. Testing for Measure Exclusions

SA3.1. Describe how the impact of exclusions (if specified) is transparent as required in the criteria

Measure specifications require that members of plans in all three product lines who had evidence of other dominant medical conditions, such as active cancer, organ transplants, end stage renal disease (ESRD) or HIV/AIDS, are required to be excluded from RRU measurement. Member/patient age criteria are also used to exclude individuals, specifically: patients less than 5 years of age or greater than 64 years of age are excluded from asthma.

Additionally, members with specifically identified comorbidities are also excluded from the measure. Anyone diagnosed with emphysema, COPD, cystic fibrosis or acute respiratory failure on or prior to December 31 of the measurement year is excluded from the eligible population.

SA3.2. Data/sample for analysis of exclusions

(Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included)

NCQA has not conducted testing of exclusions for active cancer, organ transplants, end stage renal disease (ESRD) or HIV/AIDS to determine the effect on the eligible population for this measure; however field testing of new asthma measures for HEDIS, conducted in fall 2010, examined the effect of exclusions for emphysema, COPD, cystic fibrosis and acute respiratory failure on the eligible population. Nine health plans provided member-level administrative data to NCQA. Plans' enrollment included both commercial and Medicaid product lines, with representative membership ranging in size from 2,000 to 700,288. The service areas of the participating plans were also fairly extensive, providing comprehensive coverage to select states or regions from a variety of geographic areas within the United States.

2b3

H ☐
M ☐
L ☐
I ☐

<p>SA3.3. Analytic Method <i>(Describe type of analysis and rationale for examining exclusions, including exclusion related to patient preference)</i></p> <p>For the field test population, the presence of diagnostic exclusions was studied to determine the level of noise experienced as a result of applying optional exclusions. Members identified as having persistent asthma were excluded based on the following ICD-9 codes and corresponding diagnoses: COPD (496), chronic bronchitis (491), emphysema (492, 506.4, 518.1, 518.2), cystic fibrosis (277.0), and acute respiratory failure (518.81). This information was particularly important in examining the 51-64 age cohort, as this group is most likely to experience concomitant diagnoses of asthma and COPD or chronic bronchitis.</p> <p>SA3.4. Results <i>(statistical results for analysis of exclusions, e.g., frequency, variability, sensitivity analyses)</i></p> <p>The field test results indicated that exclusions for cystic fibrosis and acute respiratory syndrome were rare (< 3% of members) in the Commercial and Medicaid plans included in the field test. Exclusions for chronic bronchitis and emphysema were also rare for members between the ages of 5 and 50. COPD was a rare exclusion for 5 to 11 year olds but became more prevalent with increasing age (~40% for 51 to 64 year olds).</p> <p>SA3.5. Finding statement(s)-- <i>(i.e., is the measure deemed reliable, limitations identified)</i></p> <p>While these exclusions for comorbidities do have a significant effect on the eligible population size, they do appear to reliably exclude patients who might be confounding the clinical criteria for eligibility due to the presence of comorbid conditions.</p> <p>SA4. Testing Population <i>Which populations were included in the testing data? (Check all that apply)</i></p> <p>Commercial Medicaid</p>	
<p>SA5. Risk adjustment strategy <i>Refer to items S10.1 and S10.2 to rate this criterion.</i></p>	<p>2b4</p> <p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/></p>
<p>SA6. Data analysis and scoring methods <i>Refer to items S12-S12.3 to rate this criterion.</i></p>	<p>2b5</p> <p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/></p>
<p>SA7. Multiple data sources <i>Refer to S7 & all SA1 items to evaluate this criterion.</i></p>	<p>2b6</p> <p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/> NA <input type="checkbox"/></p>
<p>SA6. Stratification of Disparities (if applicable) <i>Refer to item S10.2 to rate this criterion.</i></p>	<p>2c</p> <p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/></p>

	I <input type="checkbox"/>
TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for <i>Scientific Acceptability of Measure Properties</i>?	
Steering Committee: Overall, was the criterion, <i>Scientific Acceptability of Measure Properties</i> , met? Rationale:	Y <input type="checkbox"/> N <input type="checkbox"/>
USABILITY	
Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making.	Eval Rating
<p>Meaningful, Understandable, and Useful Information</p> <p>U1. Current Use:</p> <p>Internal quality improvement Public reporting (disclosure to performance results to the public at large) Quality improvement with external benchmarking</p> <p>U1.1. Use in Public Reporting Initiative Use in Public Reporting. <i>Disclosure of performance results to the public at large (If used in a public reporting program, provide name of program(s), locations, Web page URL(s). If not publicly reported in a national or community program, state the plans to achieve public reporting, potential reporting programs or commitments, and timeline, e.g., within 3 years of endorsement)</i></p> <p>Relative Resource Use results are reported through NCQA's Quality CompassTM: Relative Resource Use module on an annual basis. http://www.ncqa.org/tabid/177/Default.aspx National RRU aggregate results are also published in the annual State of Health Care Quality report. http://www.ncqa.org/tabid/836/Default.aspx</p> <p>U1.2. Use in QI <i>(If used in improvement programs, provide name of program(s), locations, Web page URL(s)).</i></p> <p>U1.3. Use for other Accountability Functions (payment, certification, accreditation) <i>(If used in a public accountability program, provide name of program(s), locations, Web page URL(s)).</i></p> <p>RRU measures are not currently used for accreditation scoring</p>	<p>3a</p> <p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/></p>
<p>U2. Testing of Interpretability <i>(Provide a rationale for why the measure performance results are meaningful, understandable, and useful to the intended audience(s) for both public reporting and quality improvement).</i></p> <p>U2.1. If understanding or usefulness was demonstrated <i>(e.g., through systematic feedback from users, focus group, cognitive testing, analysis of quality improvement initiatives) describe the data, methods, and results.</i></p> <p>NCQA has reached out to health plans and users of RRU data, along with employer focus groups, in order to assess comprehension and utilization of RRU results. In addition, NCQA has published a number of resource documents outlining the possible uses for RRU data as well as suggestions for how the results might be used to engage in payer-purchaser conversations during selection. NCQA has also presented series of webinars each designed for specific audiences to facilitate understanding of the results and how they should be interpreted and used.</p> <p>Due to the high volume of publications and other educational materials available, NCQA created a website dedicated to</p>	<p>3b</p> <p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> NA <input type="checkbox"/></p>

<p>RRU (www.ncqa.org/rru) where all pertinent supporting documents and tools are posted for public access. Currently, following the first year of publicly available RRU data, NCQA is conducting additional qualitative assessments of user experiences documenting innovations in use of data and how the results were received and understood by the general public. Thus far, the stakeholders that were approached have been very positive about the extra effort made by NCQA to assist in the understanding of the RRU measures and their results as they are a set of extremely complex measures. Session-specific assessments were collected by NCQA's education department and the results of these assessments and the direct feedback from the first round of webinars and presentations to all groups have been analyzed in order to ensure that it was appropriate to the intended audience.</p> <p>Currently, NCQA is collecting information from specific users of RRU data to capture their experiences with the first year of publically available RRU data. We plan to release a follow up publication that contains a number of user experiences and "best practices" form the field to further assist NCQA's customers.</p>	
<p>U2.2. Resource use data and result can be decomposed for transparency and understanding.</p> <p><i>Refer to items S11 -S12.3.</i></p>	<p>3c</p> <p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/></p>
<p>U3. If there are similar or related measures (either same measure focus or target population) measures (both the same measure focus and same target population), list the NQF # and title of all related and/or similar measures.</p> <p>U3.1. If this measure has EITHER the same measure focus OR the same target population as NQF-endorsed measure(s): Are the measure specifications completely harmonized?</p> <p>U3.2. If the measure specifications are not completely harmonized identify the differences, rationale, and impact on interpretability and data collection burden. <i>Describe why this measure is superior to competing measures (e.g., a more valid or efficient way to measure quality); OR provide a rationale for the additive value of endorsing an additional measure. (Provide analyses when possible.)</i></p>	<p>3d</p> <p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/> NA <input type="checkbox"/></p>
<p>TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for <i>Usability</i>?</p>	
<p>Steering Committee: Overall, to what extent was the criterion, <i>Usability</i>, met? Rationale:</p>	<p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/></p>
<p>FEASIBILITY</p>	
<p>Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement.</p>	<p>Eval Rating</p>
<p>F1. Data Elements Generated as Byproduct of Care Processes <i>How are the data elements needed to compute measure scores generated? Data used in the measure are:</i></p> <p>Generated by and used by healthcare personnel during the provision of care, e.g., blood pressure, lab value, medical condition Coded by someone other than person obtaining original information (e.g., DRG, ICD-9 codes on claims)</p>	<p>4a</p> <p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/></p>

Abstracted from a record by someone other than person obtaining original information (e.g., chart abstraction for quality measure or registry)	
F2. Electronic Sources <i>Are the data elements needed for the measure as specified available electronically? (Elements that are needed to compute measure scores are in defined, computer-readable fields)</i> ALL data elements are in a combination of electronic sources F2.1. If ALL data elements are not from electronic sources, specify a credible, near-term path to electronic capture, OR provide a rationale for using other than electronic sources.	4b H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/>
F3. Susceptibility to Inaccuracies, Errors, or Unintended Consequences <i>Identify susceptibility to inaccuracies, errors, or unintended consequences of the measurement identified during testing and/or operational use and strategies to minimize or prevent. If audited, provide results.</i> NCQA recognizes that, despite the clear specifications defined for HEDIS RRU, data collection and calculation methods may vary. In addition, errors derived from other sources may affect the results, diminishing the usefulness of HEDIS data for managed care organization (MCO) comparison. In order for HEDIS to reach its full potential, NCQA conducts an independent audit of HEDIS collection and reporting processes, as well as an audit of the data which are manipulated by those processes, in order to verify that HEDIS specifications are met. NCQA has developed a precise, standardized methodology for verifying the integrity of HEDIS collection and calculation processes through a two-part program consisting of an overall information systems capabilities assessment (IS standards), followed by an evaluation of the MCO's ability to comply with HEDIS specifications (HD standards). NCQA-certified auditors using standard audit methodologies will help enable purchasers to make more reliable standardized comparisons between health plans. The HEDIS Compliance Audit addresses the following functions: 1) information practices and control procedures 2) sampling methods and procedures 3) data integrity 4) compliance with HEDIS specifications 5) analytic file production 6) reporting and documentation	4c H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/>
F4. Data Collection Strategy <i>Describe what you have learned/modified as a result of testing regarding barriers to operational use of the measure (e.g., availability of data, missing data, timing and frequency of data collection, sampling, patient confidentiality, time and cost of data collection, cost of proprietary measures).</i> NA – measure currently is in use	4d H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/>
TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for <i>Feasibility</i>?	
Steering Committee: Overall, to what extent was the criterion, <i>Feasibility</i> , met? Rationale:	H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/>
RECOMMENDATION	
Steering Committee: Do you recommend for endorsement? Comments:	Y <input type="checkbox"/> N <input type="checkbox"/>

CONTACT INFORMATION

Co.1 Measure Steward (Intellectual Property Owner)

Co.1 Organization

National Committee for Quality Assurance (NCQA), 1100 13th Street NW, STE 1000, Washington, District Of Columbia, 20005

Co.2 Point of Contact

Ben, Hamlin, MPH, hamlin@ncqa.org, 202-955-1716-

Measure Developer If different from Measure Steward

Co.3 Organization

National Committee for Quality Assurance (NCQA), 1100 13th Street NW, STE 1000, Washington, District Of Columbia, 20005

Co.4 Point of Contact

Ben, Hamlin, MPH, hamlin@ncqa.org, 202-955-1716-

Co.5 Submitter If different from Measure Steward POC

Ben, Hamlin, MPH, hamlin@ncqa.org, 202-955-1716-, National Committee for Quality Assurance (NCQA)

Co.6 Additional organizations that sponsored/participated in measure development

ADDITIONAL INFORMATION

Workgroup/Expert Panel involved in measure development

Ad.1 Provide a list of sponsoring organizations and workgroup/panel members' names and organizations. Describe the members' role in measure development.

The Efficiency Measurement Advisory panel (EMAP) has guided NCQA staff through most of the measure development process. They EMAP provide methodological expertise as well as feedback from their respective organizations experiences in programming the measures. Specific members of the panel have created large research datasets (under contract with NCQA) in which NCQA tests measure concept s and refinements to the measure specifications prior to public release.

Kathleen Curtin, RN, MBA, NP
Kaleida Health System
Michael DeLorenzo
Health Dialog Analytic Solutions
Dan Dunn, PhD
Ingenix
Christopher Phillips
CIGNA Healthcare
Elliott Fisher, MD, MPH
Dartmouth Medical School Center for
Health Policy Research
Irene Fraser, PhD

Agency for Healthcare Research and Quality
 Kyle Grazier, PhD
 University of Michigan
 David Knutson, MS
 University of Minnesota Marilyn MacArthur
 Aetna
 Aucha Prachanronarong, MHS
 Centers for Medicare & Medicaid Services
 Mark Rattray, MD
 CareVariance, LLC
 Meredith Rosenthal, PhD
 Harvard School of Public Health
 Matt Stiefel, MPA
 Institute for Healthcare Improvement
 Timothy Zeddies, PhD, MHSA (Chair)
 HMC Informatics/Reporting
 Ranyan Lu
 United Health Network
 Bob Kelly
 Thomson Reuters

Measure Developer/Steward Updates and Ongoing Maintenance

Ad.2 Year the measure was first released:

2007

Ad.3 Month and Year of most recent revision:

03, 2011

Ad.4 What is your frequency for review/update of this measure?

annually

Ad.5 When is the next scheduled review/update for this measure?

01, 2012

Ad.6 Copyright statement:

NCQA Notice of Use. Broad public use and dissemination of these measures is encouraged and NCQA has agreed with NQF that noncommercial uses do not require the consent of the measure developer. Use by health care physicians in connection with their own practices is not commercial use. Commercial use of a measure requires the prior written consent of NCQA. As used herein, "commercial use" refers to any sale, license or distribution of a measure for commercial gain, or incorporation of a measure into any product or service that is sold, licensed or distributed for commercial gain, even if there is no actual charge for inclusion of the measure.

These performance measures were developed and are owned by NCQA. They are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties or endorsement about the quality of any organization or physician that uses or reports performance measures, and NCQA has no liability to anyone who relies on such measures. NCQA holds a copyright in these measures and can rescind or alter these measures at any time. Users of the measures shall not have the right to alter, enhance or otherwise modify the measures, and shall not disassemble, recompile or reverse engineer the source code or object code relating to the measures. Anyone desiring to use or reproduce the measures without modification for a noncommercial purpose may do so without obtaining approval from NCQA. All commercial uses must be approved by NCQA and are subject to a license at the discretion of NCQA. © 2010 by the National Committee for Quality Assurance

Ad.7 Disclaimers:

Ad. 7 Date of Submission (MM/DD/YY):
03/28/2011

Relative Resource Use for People With Asthma (RAS)**Description**

The relative resource use by members with persistent asthma during the measurement year.

Definitions**Oral medication dispensing event**

One prescription of an amount lasting 30 days or less. To calculate dispensing events for prescriptions longer than 30 days, divide the days supply by 30 and round down to convert. For example, a 100-day prescription is equal to three dispensing events ($100/30 = 3.33$, rounded down to 3). The organization should allocate the dispensing events to the appropriate year based on the date on which the prescription is filled.

Multiple prescriptions dispensed on the same day

Multiple prescriptions for different medications dispensed on the same day should be assessed separately. If multiple prescriptions for the same medication are dispensed on the same day, sum the days supply and divide by 30. Use the Drug ID to determine if the prescriptions are the same or different.

- *Two prescriptions* for different medications dispensed on the same day, each with a 60-day supply, equals four dispensing events (two prescriptions with two dispensing events each).
- *Two prescriptions* for different medications dispensed on the same day, each with a 15-day supply, equals two dispensing events (two prescriptions with one dispensing event each).
- *Two prescriptions* for the same medication dispensed on the same day, each with a 15-day supply, equals one dispensing event (sum the days supply for a total of 30 days).
- *Two prescriptions* for the same medication dispensed on the same day, each with a 60-day supply, equals four dispensing events (sum the days supply for a total of 120 days).

Inhaler/Injection dispensing event

Inhalers and injections count as one dispensing event. For example, an inhaler with a 90-days supply is considered one dispensing event. In addition, multiple inhalers or dispensing events of the same medication (identified by Drug ID in the NDC list) filled on the same date of service should be counted as one dispensing event. For example, a member may obtain two inhalers on the same day (one for home and one for work), but intend to use both during the same 30-day period. The organization should allocate the dispensing events to the appropriate year based on the date on which the prescription is filled.

Eligible Population

Note: The eligible population is based on the ASM measure. It contains additional exclusion criteria and is stratified into reporting categories.

Product lines	Commercial, Medicaid (report each product line separately).
Ages	5–50 years by December 31 of the measurement year.
Continuous enrollment	The measurement year and the year prior to the measurement year.
Allowable gap	No more than one gap in enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage during each year of continuous enrollment year.
Anchor date	December 31 of the measurement year.
Benefits	Medical. Pharmacy during the measurement year.
Event/ diagnosis	Follow the steps below to identify the eligible population for the measure.
Step 1	<p>Identify members as having persistent asthma who met at least one of the following criteria during both the measurement year and the year prior to the measurement year. Criteria need not be the same across years.</p> <ul style="list-style-type: none"> At least one ED visit (Tables ASM-A and ASM-B) with asthma as the principal diagnosis, or At least one acute inpatient discharge (Tables ASM-A and ASM-B) with asthma as the principal diagnosis, or At least four outpatient asthma visits (Tables ASM-A and ASM-B) with asthma as any diagnosis and at least two asthma medication dispensing events (Tables ASM-C), or At least four asthma medication dispensing events (Table ASM-C)
Step 2	<p>A member identified as having persistent asthma because of at least four asthma medication dispensing events, where leukotriene modifiers were the sole asthma medication dispensed in that year, must have at least one diagnosis of asthma, in any setting, in the same year as the leukotriene modifier (i.e., the measurement year or the year prior to the measurement year).</p>

Exclusions (optional)

- Members diagnosed with emphysema, COPD cystic fibrosis or acute respiratory failure (Table ASM-E) any time on or prior to December 31 of the measurement year.

Note: If the optional exclusion is applied for the ASM measure, it must be applied for the RAS measure. If the optional exclusion is not applied for the ASM measure, the optional exclusions for the RAS measure should not be applied.

Exclusions (required)

Members with one or more of the following dominant conditions during the measurement year should be excluded from all RRU measures.

- **Active cancer.** Members who had at least one face-to-face encounter, in any setting, with any diagnosis of cancer in conjunction with any treatment code (Table RRU-A), during the measurement year.
- **ESRD.** Members who had at least one face-to-face encounter, in any setting, with any code to identify ESRD (Table RRU-B), during the measurement year.
- **Organ transplant.** Members who had at least one face-to-face encounter, in any setting, with any code to identify organ transplant (Table RRU-C), during the measurement year.
- **HIV/AIDS.** Members who had at least two face-to-face encounters in an outpatient or nonacute inpatient setting, or at least one face-to-face encounter in an acute inpatient or ED setting, with any diagnosis of HIV (Table RRU-D), with different dates of service during the measurement year. Refer to Table RRU-E for codes to identify visit type.

Table RRU-A: Codes to Identify Active Cancer Treatment

Description	ICD-9-CM Diagnosis
Cancer	140-209, 230-239

WITH

Description	CPT	ICD-9-CM Procedure	UB Revenue
Treatment	38230, 38240-38242, 77261-77799, 79000-79999, 96401-96549	00.10, 00.15, 41.0, 41.91, 92.2, 99.25, 99.28, 99.85	028x, 033x, 0342, 0344, 0973

Table RRU-B: Codes to Identify ESRD

Description	CPT	HCPCS	ICD-9-CM Diagnosis	ICD-9-CM Procedure	UB Revenue	UB Type of Bill	POS
ESRD (including renal dialysis)	36145, 36800-36821, 36831-36833, 90919-90921, 90923-90925, 90935, 90937, 90940, 90945, 90947, 90957-90962, 90965, 90966, 90969, 90970, 90989, 90993, 90997, 90999, 99512	G0257, G0311-G0319, G0321-G0323, G0325-G0327, G0392, G0393, S9339	585.5, 585.6, V42.0, V45.1, V56	38.95, 39.27, 39.42, 39.43, 39.53, 39.93, 39.94, 39.95, 54.98	080x, 082x-085x, 088x	72x	65

Table RRU-C: Codes to Identify Organ Transplant

Description	CPT	HCPCS	ICD-9-CM Procedure	UB Revenue
Organ transplant	32850-32856, 33930-33945, 44132-44137, 44715-44721, 47133-47147, 48160, 48550-48556, 50300-50380	S2152, S2053-S2055, S2060, S2061, S2065	33.5, 33.6, 37.5, 41.94, 46.97, 50.5, 52.8, 55.6	0362, 0367, 0810-0813, 0819

Categorization of Eligible Population

Major clinical condition Asthma.

Standard Cost Calculations

The measure reports total standard costs for all services for which the organization has paid or expects to pay for the eligible population during the treatment period. Total standard costs are assigned by matching codes for services rendered to codes listed in NCQA's SPTs (the tables will be posted on www.ncqa.org by November 15, 2010).

Apply standard price SPTs categorize services as follows.

- Inpatient Facility
- E&M
 - Inpatient Services
 - Outpatient Services
- Imaging Services
- Pharmacy
- Surgery and Procedure
 - Inpatient Services
 - Outpatient Services
- Laboratory Services

Count all services listed in the SPTs rendered to members in the eligible population during the treatment period. Refer to the *Calculating Standard Cost* instructions in the *Guidelines for Cost of Care* for steps on categorizing services and linking service data to NCQA's SPTs.

Calculate total cost Sum the total standard cost for each eligible member. For each service category, if a member's standard cost exceeds the service category cap amount, report the total standard cost specified in the NCQA Cost Cap Amounts table (released with the SPTs).

Sum and report the total standard cost for the eligible population in each service category by member cohort. For RAS the member age cohorts are:

- 5-17
- 18-44
- 45-50

Service Frequency Calculations

Total service frequency Service frequency counts are reported for all services for which the organization has paid or expects to pay for the eligible population during the treatment period. Organizations capture each eligible member's services rendered during the treatment period for the following service categories.

- Total Inpatient Facility: Discharges, Days and ALOS
 - Acute Inpatient: Discharges, Days, ALOS
 - Acute Medicine: Discharges, Days, ALOS
 - Acute Surgery: Discharges, Days, ALOS
 - Nonacute: Discharges, Days, ALOS
- ED Discharges

- Pharmacy Utilization
 - Name brand only (N1)
 - Name brand—Generic exists (N2)
 - Generic only (G1)
 - Generic name—Name brand exists (G2)

Refer to the instructions in the *Guidelines for Cost of Care*.

The Pharmacy Utilization categories are included in Table SPT-Pharm.

Inpatient Facility

This category measures the number of acute and nonacute inpatient facility discharges days and ALOS, regardless of diagnosis. Count each discharge once. Include data from any institution that provides acute or long-term/specialty nonacute care.

If the discharge is counted in the cost calculation, it should also be counted in the inpatient frequency calculation. Refer to *Guidelines for Cost of Care* to identify acute inpatient (including medicine and surgery) and nonacute discharges, days and ALOS. For nonacute discharges, days and ALOS, include care from any institution that provides nonacute care in hospice, nursing homes, rehabilitation, SNFs, transitional care and respite.

ED Discharges

This category measures use of ED services.

Count each visit to an ED during the treatment period that does not result in an inpatient stay, regardless of the intensity of care required during the stay or the length of stay. Count only one ED visit per date of service. Do not count visits to urgent care centers.

Refer to Table AMB-B for codes to identify ED visits. Services for members admitted to the hospital from an ED visit are included in the Inpatient Facility category only.

Pharmacy Utilization

Use Table SPT-Pharm to identify the prescription categories for each drug dispensed in the treatment period.

Sum and report the number of prescriptions within each of the four categories in the Pharmacy—Total Service Frequency by Prescription Category table.

Quality Compass RRU (Commercial) – Asthma

Plan Detail Table:

Submeasure Data

Measure: Relative Resource Use for People with Asthma

Plan: [REDACTED]

Sub Trend ID: [REDACTED]

Print 

			National			Regional		
			Ratio	Lower Confidence Interval	Upper Confidence Interval	Ratio	Lower Confidence Interval	Upper Confidence Interval
Quality Composite Index			1.01	0.90	1.08	1.01	0.90	1.08
Total Medical Index			1.09	0.84	1.16	1.07		
Pharmacy (Rx) Index			1.01	0.93	1.07	1.00		
Total Medical Components	Inpatient Facility Index		1.12			1.24		
	Procedure & Surgery Index	Total	0.92			0.85		
		Inpatient	0.62			0.88		
		Outpatient	0.96			0.84		
	Evaluation & Management Index	Total	1.14			1.03		
		Inpatient	1.40			1.43		
		Outpatient	1.12			1.01		
Inpatient Discharge Index			0.98			1.12		
Emergency Department Discharge Index			0.80			0.81		

Regional Scatterplot for plan RRU graphed with Quality Index

Print  Download 


Atlanta Region HMO Submissions

Measure: Relative Resource Use for People with Asthma

Plan: [REDACTED]

Sub Trend ID: [REDACTED]

- Selected submission
- Selected submission outside of range
- Region submission
- Region submission outside of range



Measuring Health Plan Relative Resource Utilization

May 2005

Joachim Roski, Ph.D., MPH
Dan Dunn, Ph.D.
Sally Turbyville, M.A.

Prepared for the Centers for Medicare & Medicaid Services
under Contract Number 500-00-0054, Modification 000005

NCQA

2000 L. St. NW, Suite 500
Washington D.C. 20036

Table of Contents

List of Final Report Tables	3
Executive Summary	4
I. Background and Research Development	
A. Background	6
B. Development and Field Study	7
C. Research Objectives and Questions	9
II. Methods	
A. Data Source	9
B. Patient Disease Identification Criteria	9
• Clinical Grouping Hierarchies	10
• Co-Morbid Identification	10
• Patient Exclusions	11
C. Cost and Utilization Experience	12
• Disease-Related Costs and Utilization	13
• Total Costs and Utilization: Morbidity Adjustment	14
D. Measures of Relative Resource Utilization	
III. Results	
A. The Relative Resource Utilization Index	16
B. Refining the Metrics and Findings	20
IV. Summary and Conclusions	22
List of Appendix Tables	25
Appendix Tables--Results Discussion	26
List of Efficiency Measurement Advisory Panel	29

List of Final Report Tables

Table 1: Description of Enrolled Populations used for Selecting Study Populations

Table 2: Percent Prevalence of Patients, by Population and Clinical Grouping

Table 3: Percent Prevalence of Patients Identified with One or More Study Co-Morbidities

Table 4: Total Costs PMPM, by Population and Clinical Groupings, Commercial Population

Table 5: Cost PMPM, by Clinical Grouping and Service Category, Commercial Population

Table 6: Total Disease Related Costs PMPM, by Population and Service Category, Using ETG Methodology, Commercial Population

Table 7: Resource Consumption Index, Total Patient Costs, by Population and Services Category, Cardiovascular Clinical Groupings ERGs used for Risk Adjustment

Table 8: Resource Consumption Index, Disease-Related Patient Costs, by Population and Service Category, Cardiovascular Clinical Groupings ETGs used for Assignment of Disease Related Costs

Table 9: Resource Consumption Index, Comparison of Results for Different Measurement Approaches, by Population and Measurement Approach, Across Major Clinical Categories

Table 10: Resource Consumption Index, Comparison of Results for Different Measurement Approaches, by Population and Major Clinical Categories, Including ALL Study Conditions and Diseases

Figure 1a: Standard Error of Relative Resource Utilization, by Condition Member Sample Size-
- Total Services, ERG Adjustment

Figure 1b: Standard Error of Relative Resource Utilization, by Condition Member Sample Size-
- Total Services, Age-Sex Adjustment

Figure 1c: Standard Error of Relative Resource Utilization, by Condition Member Sample Size—Disease-Related Services, ETG Adjustment

Figure 1d: Standard Error of Relative Resource Utilization, by Condition Member Sample Size—Disease-Related Services, DID Adjustment

Executive Summary

Health care costs have continued to escalate at rates that outpace inflation; in 2003 health care expenditures in the United States were nearly \$1.7 trillion, this represents 15.3 percent of the Gross Domestic Product (GDP).¹ In 2004, health care premiums experienced their fourth consecutive year of double-digit growth (11 percent), and they continue to increase much faster than overall inflation (2.3 percent) and wage gains (2.2 percent). Since 2000, health care premiums for family coverage have increased by 59 percent, compared with inflation growth of 9.7 percent and wage growth of 12.3 percent.²

While the upward trend in health care costs continues, employers, consumers and other stakeholders seek improved information on the value of healthcare they purchase. Over the last 15 months, the National Committee for Quality Assurance (NCQA) has engaged in investigations related to the development of economic outcome measures for health plans. The information provided here summarizes these research efforts to measure differences in resource utilization in key clinical areas between health plans. The investigation focused on patients with diabetes, cardiovascular disease, pulmonary and musculoskeletal conditions. Resource utilization was measured along different dimensions, including by condition and by type of service.

NCQA proposed a number of specific objectives to be addressed during the research project:

- Investigate methods for measuring the relative resource consumption for patients with selected conditions.
- Apply alternative methodologies for measuring relative resource consumption – assessing different measurement issues.
- Measure total service and disease-related service costs for patient populations and assessing the merit of these approaches.
- Assess the variation in relative resource consumption findings across different populations, comparing the sensitivity of the results to different measurement approaches.
- Identify denominators (patients) and numerators (cost and utilization measures) for each condition. Assess using both diagnosis and procedure codes to accurately and completely identify populations.
- Apply risk adjustment within clinical conditions for each population.
- Identify resource consumption categories that can be reliably and consistently captured. (For example, evaluation & management visits, procedures, diagnostics etc.)
- Identify resource consumption categories that can be used as a proxy for total resource consumption.
- Investigate the impact of distinguishing between disease-related and non-disease related (or total) resource consumption. Determine if resource consumption scores restricted to disease-related costs only compare to scores based on total services.
- Test the impact of morbidity adjustment using age and gender case-mix adjustment—the Morbidity and Age-Sex Adjusted approach (a study defined methodology using initial clinical categorization of patients with specific morbidity and age-sex classifications within those clinical categories), as well as a more widely available population morbidity adjustment method on performance results, Episode Risk Groups (ERGs – a proprietary population-based health risk assessment technology distributed by Symmetry Health Data Systems, Inc.)

- Test the impact of assigning services to disease-related episode of care approach (a more widely available approach) to assigning disease-related services. Compare results from Episode Treatment Groups (ETGs – a proprietary episode of care grouping methodology distributed by Symmetry Health Data Systems, Inc.) to an alternative using the same logic as used to identify patients for the study, Disease Identification (DID – a study-defined methodology that employs the primary diagnosis codes for a service to identify disease-treated).
- Determine the performance range on resource consumption scores between targeted chronic conditions, health plans and insurance product types.

Study measures included the cost, overall and by type of service, for patients with the selected clinically and financially important conditions. Relative resource utilization was measured for study patients, overall, and for those services directly related to the treatment of the study condition. All study measures were risk-adjusted to support valid comparisons across conditions and health plans.

The study produced a number of key findings related to resource measurement at the health plan level:

- Health plans can be meaningfully measured and compared with respect to the relative resource consumption of their networks for select resource categories.
- Methodologically defensible non-proprietary methods can be identified for severity and case adjustment.
- Standard pricing methods can be employed that removed unit price variation as a factor in resource measurement. A significant obstacle in sharing cost information at the health plan level is the proprietary nature of the fee schedules and contracts that describe their pricing of services.
- Relative resource consumption seems to vary meaningfully between health plans. More specific findings related to these measures provided insights related to the services, conditions and methods used for study.
- The study explored the potential for the use of a subset of services as a proxy for measuring resource use for all services. In this way, services that can be reliably measured could be the focus of initial measurement and also present a reasonable burden on health plans in collecting this information. The study found measures of relative resource utilization were generally similar using “selected” services (inpatient, pharmacy, evaluation and management, and procedures, including Ambulatory Surgery Centers (ASC) costs) versus measurement using all services.
- The relationship between population size and variation in measures of relative resource utilization – i.e., what is a sufficient sample size to produce consistently valid numerators and denominators and how large of a health plan is required to achieve these thresholds -- was explored. Typical standard errors were measured for each condition – demonstrating the relationship between population size and likely precision of measures of relative resource use. A typical standard error for measuring total service relative resource utilization was observed to be approximately 0.025 at samples of 2,000 patients or more. In general, the standard errors were relatively higher for measures of disease-related services versus total services

To further these findings and their utility NCQA plans to continue research in this area and engage in discussions with health care industry consultants, actuaries and other experts to assist in this process. In addition, NCQA is interested in refining the methods developed during this study and finalizing measure specifications for health plan or large health care organization comment and implementation. The feasibility, including health plan burden for collecting and programming measures, needs to be further explored by engaging health plans in a field test study. The field test would also inform an understanding of the metrics comparability, and regional differences which are not sufficiently explored here. NCQA also plans to relate the relative resource utilization measures with quality outcomes, which is an important step to fully understanding health care services efficiencies. This study only looked at selected chronic conditions and it is unknown how the study developed method could be applied to acute events or illnesses. In addition, provider level resource consumption was not explored and it is likely that a more robust risk-adjustment method than the study-developed Age-Sex Morbidity, as well as patient or illness attribution, would need to be applied.

I. Background & Research Development

A. Background

Health care costs continue to escalate at rates that outpace inflation; in 2003 health care expenditures in the United States were nearly \$1.7 trillion, this represents 15.3 percent of the Gross Domestic Product (GDP).³ In 2004, health care premiums experienced their fourth consecutive year of double-digit growth (11 percent), and they continue to increase much faster than overall inflation (2.3 percent) and wage gains (2.2 percent). Since 2000, health care premiums for family coverage have increased by 59 percent, compared with inflation growth of 9.7 percent and wage growth of 12.3 percent.⁴ According to the Center for Medicare and Medicaid Service Office of the Actuary, by 2010 we can expect health care expenditures to represent approximately 17 percent of GDP.⁵

How to contain health care costs is one of the most challenging policy issues facing the United States. Health plans and purchasers are interested in standard measures of relative resource utilization because of their potential to be used as a tool to reduce costs. Health system efficiencies are often defined as attainment compared to the maximum that could be achieved for the observed level of resource use.⁶ Research by Wennberg, Fisher and others shows that the problem of variation in intensity of treatment for chronic illness is primarily a problem of overuse and waste, not underuse and health care rationing (i.e., poor quality). In several studies of Medicare data, Wennberg and Fisher found that Medicare spending can vary by more than twofold in different regions of the United States even after adjusting for differences in health of the population.⁷ In exploring if these differences in Medicare spending led to different outcomes, or health, they found no evidence that the regions of higher spending had any survival advantage.⁸ Differences in resource utilization with no net positive health outcomes represent waste in the health care delivery system.

Methodological solutions are emerging to measure such differences in a reliable and valid fashion. The science of measuring health plan quality has advanced considerably in recent years, and there is good understanding within the industry on how to measure health care quality at various levels (outputs), especially at the health plan and hospital levels. On the other hand, efforts to measure relative resource utilization (input costs) in a standardized method are only just emerging.

NCQA has over the last 15 months engaged in targeted activities to identify opportunities to develop economic outcome measures for health plans. The information provided here summarizes these research efforts to measure differences in resource consumption in key clinical areas between health plans. The development of these metrics is essential to better able relate input costs to output for health care services.

B. Development and Field Study

As part of the investigation, NCQA convened a panel of experts, the Efficiency Measurement Advisory Panel (EMAP), to discuss different methodological issues related to relative resource use measurement and develop an approach to reliably and validly measure relative resource use. Using a large managed care database and with the assistance of Integrated Healthcare Information Services, Inc (IHCIS), NCQA performed research focusing on different methodological issues proposed by the EMAP. This document presents the findings of the field test research study.

The approach to measurement used for the investigation focused on creating and testing a meaningful and “manageable” approach. In particular:

- Select relevant clinical conditions for study – conditions that are both financially and clinically important, but also conditions that can support generalization to a broader group of diseases. These conditions were further selected because relevant quality metrics are currently available for the same conditions allowing for subsequent linking of quality and resource use for the same conditions.
- Employ measures of resource utilization that can be obtained in a reliable and practical way – using methods that can be replicated across health plans and also present a reasonable burden in measurement.
- Explore those components of resource costs that can be measured reliably – if a subset of services can be found that can be measured reliably, that subset can serve as a good proxy for all services.

C. Research Objectives and Questions

NCQA proposed a number of specific objectives to be addressed during the research project:

- Investigate methods for measuring the relative resource consumption for patients with selected conditions.
- Apply alternative methodologies for measuring relative resource consumption – assessing different measurement issues.
- Measure total service and disease-related service costs for patient populations and assessing the merit of these approaches.
- Assess the variation in relative resource consumption findings across different populations, comparing the sensitivity of the results to different measurement approaches.
- Identify denominators (patients) and numerators (cost and utilization measures) for each condition. Assess using both diagnosis and procedure codes to accurately and completely identify populations.
- Apply risk adjustment within clinical conditions for each population.
- Identify resource consumption categories that can be reliably and consistently captured. (For example, evaluation & management visits, procedures, diagnostics etc.)
- Identify resource consumption categories that can be used as a proxy for total resource consumption.
- Investigate the impact of distinguishing between disease-related and non-disease related (or total) resource consumption. Determine if resource consumption scores restricted to disease-related costs only compare to scores based on total services.

- Test the impact of morbidity adjustment using age and gender case-mix adjustment—the Morbidity and Age-Sex Adjusted approach (a study defined methodology using initial clinical categorization of patients with specific morbidity and age-sex classifications within those clinical categories), as well as a more widely available population morbidity adjustment method on performance results, Episode Risk Groups (ERGs – a proprietary population-based health risk assessment technology distributed by Symmetry Health Data Systems, Inc.)
- Test the impact of assigning services to disease-related episode of care approach (a more widely available approach) to assigning disease-related services. Compare results from Episode Treatment Groups (ETGs – a proprietary episode of care grouping methodology distributed by Symmetry Health Data Systems, Inc.) to an alternative using the same logic as used to identify patients for the study, Disease Identification (DID – a study-defined methodology that employs the primary diagnosis codes for a service to identify disease-treated).
- Determine the performance range on resource consumption scores between targeted chronic conditions, health plans and insurance product types.

II. Methods

A. Data Source

The IHCIS Managed Care Benchmark Database served as the source of data for the analysis. The Benchmark Database includes medical and pharmacy claims and enrollment for more than 25 million unique individuals, 30 health plans and other contributors. The database population was comprised of primarily non-elderly, commercially enrolled individuals. All data were standardized and evaluated for completeness and consistency. Costs were based on a standard pricing methodology applied across all contributors and time periods (using Relative Value Units (RVUs) and other methodologies).

For the analysis described here, a subset of the Benchmark Database population was selected. In particular, the study population met the following criteria:

- at least 6 months of enrollment in the year (2003) used to identify patients and measure costs and utilization.
- selected from a number of different populations (health plans) that met sufficient product and geographic variation (given available data).

In the end 1 Medicare Risk, 1 Medicaid and 12 commercial populations were selected for the study meeting the above selection criteria. The total population meeting the above criteria exceeded 7.5 million individuals. The population included a mix of HMO, PPO and POS products and included Blue Cross Blue Shield and regional plans of different sizes from across the U.S. The population was disproportionately from the northeast, with only limited enrollment from the Pacific region.

B. Patient Disease Identification Criteria

Chronic conditions known to have both clinical importance and also have high health plan costs and utilization rates were selected for this research project. In 2004, a study by Thorpe, Florence and Joski found that five health conditions accounted for roughly one-third of the increase in health care costs between 1987 and 2000.⁹ These conditions included heart disease, mental health disorders, pulmonary conditions, cancer and trauma. The major chronic conditions selected for this study initially covered three of these conditions: cardiovascular disease, asthma and chronic obstructive pulmonary disease COPD, and depression and excluded patients with one of these conditions: cancer. In the end, the conditions selected for this study were: cardiovascular disease, diabetes, asthma/COPD, arthritis and low back pain. While depression was initially included as part of the study due to concerns related to the collection of complete and consistent mental health claims information from health plans (due to carve outs and benefit differences), and based on EMAP input, depression was subsequently dropped as a major clinical category for the study. Within these major clinical groupings sub-categories of conditions were also identified.

In the end, patients with one or more of the following clinical groupings were selected for study:

- Cardiovascular
 - AMI
 - Angina
 - CAD
 - CHF
- Diabetes
 - Diabetes Type I
 - Diabetes Type II
- Asthma/COPD
 - Asthma
 - COPD
- Arthritis/Low Back Pain
 - Arthritis
 - Low Back Pain (LBP)

In order to identify patients within these categories, HEDIS[®]-based algorithms were identified. The general approaches used to identify patients for a condition were as follows:

- 12-month period of data available.
- Patients selected for a condition who had at least:
 - one inpatient admission or
 - one ER visit or
 - two or more ambulatory evaluation and management (E&M) services during that period of time with a diagnosis code that met the criteria for a study condition categories (first 3 diagnosis positions searched).
- For condition categories that can be identified by a CPT procedure code (CAD, CABGs and PTCAs), then a patient with one or more services with those procedure codes was used.
- For condition categories that can be identified by a National Drug Code (NDC) (i.e., asthma, diabetes), then members could be identified based on two or more prescriptions on separate days that match one or more of the NDC codes specified.

Clinical Grouping Hierarchies

Members could be identified for more than one of the four major clinical groupings in the study (cardiovascular, asthma/COPD, diabetes, arthritis/LBP). However, within a major clinical group hierarchies were imposed so that a patient was identified only once within that major grouping (see Table A). Thus, within cardiovascular disease, a patient was assigned to one condition using the following hierarchy: CHF, AMI, CAD, or Angina. Within asthma/COPD, a member was assigned to one condition using a hierarchy of COPD and then asthma. Within diabetes, a member was assigned to one condition using a hierarchy of Type I diabetes and then Type II diabetes. Within arthritis/LBP, a member was assigned to one condition using a hierarchy of arthritis and then LBP.

Co-Morbid Identification

The primary clinical groupings, with the exception of arthritis and LBP, were further stratified using the presence of a relevant co-morbid condition. For this analysis, co-morbid conditions included: cardiovascular disease, diabetes, depression, hypertension, COPD/asthma, and chronic renal failure (CRF) (for diabetes only). Hypertension and CRF were not initially included as co-

HEDIS[®] is a registered trademark of the National Committee for Quality Assurance.

morbid conditions in but were added during the research study based on clinical expert input following review of proposed methods.

Based on the four major clinical categories, the ten sub-clinical categories, and the co-morbidities, the following 18 patient populations were identified. As stated previously, patients could be identified for more than one of the four major clinical groupings. However, within a major clinical group (i.e., cardiovascular, asthma/COPD, diabetes, and arthritis/LBP) a member was assigned to only one sub-clinical condition using the hierarchy described above. All study analyses were performed at the 18 detailed clinical categories and then aggregated to higher levels using appropriate methods.¹

Table A: Clinical Hierarchies and Co-Morbid Groups

Major Clinical Category	Clinical Sub-Category	Co-Morbidity Group
Cardiovascular	CHF	CHF
Cardiovascular	CHF	CHF, with Co-morbidity
Cardiovascular	AMI	AMI
Cardiovascular	AMI	AMI, with Co-Morbidity
Cardiovascular	CAD	CAD
Cardiovascular	CAD	CAD, with Co-Morbidity
Cardiovascular	Angina	Angina
Cardiovascular	Angina	Angina, with Co-Morbidity
Diabetes	Diabetes, Type I	Diabetes, Type I
Diabetes	Diabetes, Type I	Diabetes, Type I, with Co-Morbidity
Diabetes	Diabetes, Type II	Diabetes, Type II
Diabetes	Diabetes, Type II	Diabetes, Type II, with Co-Morbidity
Asthma/COPD	COPD	COPD
Asthma/COPD	COPD	COPD, with Co-Morbidity
Asthma/COPD	Asthma	Asthma
Asthma/COPD	Asthma	Asthma, with Co-Morbidity
Arthritis/LBP	Arthritis	Arthritis
Arthritis/LBP	LBP	LBP

Patient Exclusions

Members with evidence of other dominant medical conditions, such as active cancer, organ transplants, end stage renal disease (ESRD) or HIV/AIDS, were excluded from the analysis. Patient age criteria were also used to exclude individuals, specifically: patients less than 5 years of age were excluded from asthma/COPD; patients less than 18 years of age were excluded from diabetes, LBP, and arthritis; and patients less than 35 years of age were excluded from all cardiovascular conditions.

¹ Note that the clinical categorization provides the first step in risk adjustment for the study and is built into all analyses – whether or not any further methodological approaches/adjustments are applied. All other methods, including ERGs and ETGs build from this structure.

C. Cost and Utilization Experience

Cost and utilization experience were measured for the same 12 months used to identify patients. All inpatient facility, outpatient facility, professional, ancillary and pharmacy claims for the disease-identified members were selected. Measures of cost and utilization were produced for all services and some selected service categories that may serve as a proxy for all services. The selected service categories included inpatient facility, pharmacy, evaluation and management (including consults), and procedures (including outpatient facility and ambulatory surgical center services.) These categories were identified by NCQA and the EMAP as potential services that can be reliably and consistently captured based on initial analyses. The following service categories were used to measure costs and utilization:

- Ambulatory surgery – services provided by outpatient facilities for procedures.
- Consultations – patient consultations in the office and other settings.
- Diagnostic – diagnostic services, other than lab and radiology, provided by professional and facility providers.
- Evaluation and management (E&M) – evaluation and management services other than consultations and emergency room visits (primarily office and inpatient physician visits)
- Emergency room (ER) – emergency room services provided by professional and facility providers.
- Inpatient facility – inpatient services provided by facilities.
- Laboratory – lab services provided by professional and facility providers.
- Physical medicine – physical therapy and other physical medicine services provided by professional and facility providers.
- Procedures – surgical procedures provided by professional providers
- Pharmacy – prescription drug services.
- Radiology – radiology services provided by professional and facility providers.
- Other – all other services not identified above.

The cost measure used in the analysis was based on a standard costing methodology and priced at calendar year (CY) 2003 levels. Early on in the process it was determined that collecting true unit price would not be possible due to the proprietary nature of prices and discounts negotiated between health plans and providers. In this study, pricing levels reflect total allowed payments, inclusive of health plan liability and patient cost-sharing. Costs were reported by a cost per patient per month (PMPM) measure. Since a standard costing methodology was employed for the study data, the costs reported can be considered “weighted utilization,” i.e., they were computed using service counts and RVUs per service and a dollar factor to convert RVUs to dollars. These RVUs represent units of standard priced dollars, in relative terms.

Disease-Related Costs and Utilization

Two different approaches were used to identify disease-related costs. The first approach employed a widely-used tool, ETGs, which uses an episode of care approach to assign medical and pharmacy services to conditions and diseases. More specifically, ETGs use a basic illness classification methodology that combines related services into a medically relevant unit describing a complete episode of care. Episodes are created based on a series of rules and the diagnoses and procedures found on medical claims, including drug treatments listed on

pharmacy claims. Examples of ETGs are: insulin-dependent diabetes, with co-morbidity; coronary disease, with AMI, with coronary artery bypass graft; and asthma, without co-morbidity, age less than 18. For this field study the ETG grouper software was applied to 12-months of medical and pharmacy claims used for each patient. The result was an output file that includes the ETG assigned to each service, along with other information, which were then mapped to each of the major clinical groupings.

Where patients were identified for a clinical grouping within a larger major clinical category (e.g., cardiovascular or asthma/COPD), all of the disease-related costs within that category were assigned as disease-related for that clinical grouping for that patient. For example, for a member assigned ultimately to a CHF clinical category, any disease-related costs for all ETGs assigned to CAD, angina, and AMI were also included. The same approach was used for asthma/COPD, where a patient identified ultimately as a COPD patient received the disease-related costs for both asthma and COPD. Since ETGs assign each service uniquely to a single episode of care, services could not be disease-related to multiple major clinical categories. For example, an inpatient stay could not be assigned as disease-related to both CHF and type I diabetes.

The second approach to assigning disease-related costs employed the same diagnosis and procedure-based methodology as was used to identify patients for the study. This approach was called the Disease Identification (DID) approach. A medical service was determined to be disease-related if any of the diagnosis (using the first 3 diagnostic positions) or procedure codes on the service corresponded to one or more of the diagnosis or procedure codes used to identify the clinical categories. Disease-related pharmacy services were identified based on the NDC code on the pharmacy claim and were mapped to the highest-level therapeutic categorization developed for each major clinical category. For example, Cardiovascular System Agents, Blood Agents, Agents that Affect Blood Lipids/Sugar/Amino Acids, and Drugs Given To Alter Blood Coagulation were included as disease-related to cardiovascular conditions. Since a single service could have multiple diagnosis codes (some of which could be assigned to a different clinical category), using the DID approach allows a service to be used as disease-related for multiple conditions. For example, an inpatient stay with diagnoses listed for both CHF and diabetes type I would be assigned as disease-related for both conditions.

Further in the research study, hypertension episode of care services were included as co-morbid clinical category in disease-related costs for the cardiovascular clinical category.

Total Costs and Utilization: Morbidity Adjustment

The disease-related methodologies were used to assign services and costs to each clinical category. An important objective of the study was also to measure total service costs for patients in each clinical category, including those related to the disease and other services. This measurement required a population-based risk assessment approach that could capture the overall patient morbidity, including conditions related to the clinical category being studied as well as all conditions observed for the patient.

Morbidity categories include groups of patients with similar levels of health risk. Two different approaches were used to assign patients to morbidity categories for the analysis. The first method employed a widely used diagnosis-based tool, Episode Risk Groups (ERGs). ERGs are an episode-based approach to health risk assessment and compute an overall level of risk for an

individual based on their observed mix of episodes of care. A patient's relative risk score is a number such as 0.50, 1.00, or 1.50. A risk score of 0.50 indicates a health risk approximately half of that of the average member in an index population, a score of 1.00 means the patient's relative risk is equal to the average member, and 1.50 indicates a fifty percent greater risk. The index population for ERGs is a large, non-elderly managed care population. Retrospective (concurrent) values of health risk were used for the analysis. Eight ERG morbidity categories were created for use in the study:

- | | |
|--------------------------------------|--|
| 1. risk score less than 1.00 | 5. risk score 8.00 to less than 12.00 |
| 2. risk score 1.00 to less than 2.00 | 6. risk score 12.00 to less than 15.00 |
| 3. risk score 2.00 to less than 4.00 | 7. risk score 15.00 to less than 20.00 |
| 4. risk score 4.00 to less than 8.00 | 8. risk score 20.00 or higher |

Using their risk score a patient was assigned to the appropriate ERG morbidity category. The ranges used for these categories were based on the observed distribution of risk for study patients and the desire to create a limited number of categories to support sufficient sample size within each grouping and also to limit reporting burden.

The second approach to morbidity adjustment for measuring the relative resource utilization for total service employed an age-sex model. Based on an analysis of the distribution of study patients and their costs, the following age-sex categories were employed, where "All" indicates both genders for the same age range:

- | | |
|------------------------|--------------------|
| • All, 00-17 years | • All, 55-64 years |
| • Females, 18-44 years | • All, 65-74 years |
| • Males, 18-44 years | • All, 75+ years |
| • All, 45-54 years | |

In summary, ERGs and the age-sex model were used as the basis for creating morbidity categories to support total service measurement. Further, given the stratification of patients into the 18 clinical categories previously described, the final population-based risk assessment methodology was:

- ERG-based Morbidity Adjustment – using ERGs within clinical categories, including with and without co-morbidity.
- "Age-Sex" and Clinical Category-based Morbidity Adjustment – using age-sex groupings, within clinical categories, including with and without co-morbidity. (The study controlled for a clinical condition, such as CHF, with co-morbidity, and then applied age-sex morbidity adjustment within that condition.)

D. Measures of Relative Resource Utilization

Relative resource utilization was measured along a number of dimensions, including clinical categories, service categories, and populations. Relative resource utilization is defined as the observed costs or utilization for a service category (or total services) divided by the "peers" amount. Peers experience is the expected resource consumption if the peers had a similar mix of patients to that observed for the population. In other words, for this study, the peers amount is the risk adjusted value for that service category, after accounting for the patient's clinical

category (including co-morbidity) and morbidity category (based on ERGs or age-sex). For this study, *peers* was based on the total population of patients used for the study. Alternatively, peers could be based on an external population or benchmark, using different assumptions.

Services were also assigned to disease-related, or not disease-related categories using the ETG and the DID methodology. Patients were assigned to an ERG and an Age-Sex morbidity category.

For example, for disease-related cost ETG approach, a patient's costs determined to be CHF-related were summarized by service category and overall, which is the observed CHF-related experience for that patient. Peer values for CHF-related costs for that patient were determined by averaging CHF-related costs, by service category, for all patients assigned to the CHF with co-morbidity clinical category. The resource consumption index for that patient for disease-related CHF is their observed costs divided by peer amounts. The observed and peers disease-related costs using the DID approach were computed separately, using a similar methodology.

For total-service cost ERG approach, the patient's overall costs, i.e., CHF-related and other, were summarized by service category and overall, which is the observed costs for total services for that patient. Peer values for total service costs for that patient were determined by averaging the total service costs, by service category, for all patients assigned to the CHF with co-morbidity clinical category. The resource consumption index for that patient for total service costs for CHF is their observed costs divided by peer amounts. The observed and peers total service costs using the Age-Sex morbidity approach were computed separately, using a similar methodology.

The observed and peers amounts created in this way can then be aggregated across patients to produce findings at different levels (e.g., population and sub-clinical category or population and major clinical category). Further, these amounts and the resource index can be computed using four different approaches:

- Total services, ERG Morbidity Approach
- Total services, Age-Sex Morbidity Approach
- Disease-related services, ETG Approach
- Disease-related services, DID Approach

III. Results

A. The Relative Resource Utilization Index

The research focused on patients identified with one or more of the following major clinical groupings:

- Cardiovascular disease
- Diabetes
- Asthma/COPD
- Arthritis/LBP

Methods were developed to identify denominators (patients) and numerators (cost and utilization measures) for each condition. Risk adjustment within clinical conditions for each population was performed using different approaches. Cost and utilization was measured by type of service and for both total services and disease-related services.

Results and general conclusions in this part of the research are presented in Tables 1 – 10.

Table 1: Description of Enrolled Populations used for Selecting Study Populations (General description of population size, the percentage of members less than 35 and over 64, the percent female, and pharmacy benefit status.

Question/Issue Addressed -- What are the general characteristics of the study populations?

High-Level Interpretation

- The populations describe enrolled populations of different size, including some larger groups of enrollees.
- As expected, the Medicare and Medicaid populations include primarily elderly and younger individuals, respectively.
- The commercial populations (populations A-S), were mostly similar in terms of age and gender mix.
- There was some variation in the percentage of each population with a pharmacy benefit (63 to 100 percent) suggesting pharmacy data was available for that component of the population for the study.

Table 2: Percent Prevalence of Patients, by Population and Clinical Grouping (Describes the prevalence of each clinical category (before co-morbidity split).) The table includes the percentage of the enrolled population identified with a condition. As noted before, members can be identified for multiple major clinical categories, but with some major categories, hierarchies were applied to assign the patient to a single category within that group (e.g., cardiovascular).

Question/Issue Addressed -- What is the prevalence of each condition? How does it vary across populations? What will be the typical sample of patients for a health plan of a certain size for a particular condition?

High-Level Interpretation

- For the commercial population, the prevalence of patients by clinical condition was similar, in general, across the individual populations.
- The magnitudes of prevalence were consistent, in general with expectations, given the study identification methods and a typical elderly, Medicaid, and commercial population.
- For the commercial population, the most prevalent conditions were asthma, depression and LBP; the least prevalent were AMI, angina, and CHF.
- For the Medicare population, the most prevalent conditions were arthritis, CAD and diabetes (combined); the least prevalent were asthma and angina.
- For the Medicaid population, the most prevalent condition was asthma; the least prevalent were the cardiovascular conditions.

Table 3: Percent Prevalence of Patients Identified with One or More Study Co-Morbidities (Describes the prevalence of co-morbidities within each clinical category. The table includes the percentage of the patients for a clinical category that were also identified as having a qualified co-morbidity (cardiovascular, diabetes, asthma/COPD, and depression.))

Question/Issue Addressed -- What is the prevalence of co-morbidities for each condition? How does it vary across populations? What will be the typical sample of patients for a health plan of a certain size for a particular condition, by co-morbidity?

High-Level Interpretation

- For the Medicare population, co-morbidity prevalence was somewhat higher than that for the other populations – reflecting the relatively high likelihood of multiple chronic and other conditions for an elderly patient with one or more of the study conditions.
- For the Medicaid population, co-morbidity prevalence varies and was highest for the cardiovascular conditions.
- For the commercial populations, although some modest differences were observed, co-morbidity prevalence, by condition was similar across populations. In general, diabetes and cardiovascular conditions have the higher co-morbidity prevalence, while depression and asthma were lowest.
- No co-morbid conditions were identified for arthritis and LBP.

NOTE: All the remaining tables are for the commercial populations only.

Table 4: Total Costs PMPM, by Population and Clinical Groupings, Commercial Population (Describes the total costs for all services, by sub-clinical grouping and population. The table includes costs PMPM for patients in each grouping.)

Question/Issue Addressed -- What is the typical total expenditures for patients with different conditions? Do patients with the same condition and co-morbidity have different costs? How do the estimates vary across populations?

High-Level Interpretation

- Patient costs were highest for AMI and CHF and lowest, on average, for asthma patients.
- As expected, costs for members with a condition and a qualified co-morbidity were higher than for patients with the same condition without co-morbidity.

- In general (with a few exceptions), the average costs for a clinical grouping were similar across plans.

Table 5: Cost PMPM, by Clinical Grouping and Service Category, Commercial Population

(Describes costs for all services, by detailed clinical grouping and service category. The table includes service category costs PMPM for patients in each grouping. The bottom portion of the tables presents service category costs as a percentage of total costs for each clinical category.)

Question/Issue Addressed -- What is the typical total expenditures for patients with different conditions, by service category? What is the most important service category financially? How do the estimates vary across clinical categories?

High-Level Interpretation

- As expected, variation in patient costs across clinical categories was observed. Further, differences in the relative importance of categories by clinical grouping were also evident.
- Inpatient and pharmacy services comprise the largest individual service category percentages. Inpatient services were most important for cardiovascular conditions.
- The “Other” category (denoting services that may be more difficult to quantify and measure) comprises 10-15 percent of total service costs – a consistent percentage across clinical groupings.

Table 6: Total Disease Related Costs PMPM, by Population and Service Category, Using ETG Methodology, Commercial Population (Focuses on disease-related costs. Estimates were provided by clinical grouping and service category for the ETG methodology of disease-related costs. These analyses were also conducted using the study-developed DID methodology.)

Question/Issue Addressed -- What is the magnitude of disease-related costs for each clinical grouping? How do these amounts vary by service category?

High-Level Interpretation

- Disease-related costs represent a significant portion of total service costs for some conditions – in particular the cardiovascular conditions (approx 50-80 percent). These percentages vary by service category.
- Disease-related costs represent a lesser portion of total service costs for some conditions, e.g., asthma, COPD, arthritis and LBP.
- For many conditions, the magnitude of the disease-related costs was comparable whether using the ETG or DID approach – the exceptions were asthma, COPD and diabetes, with co-morbidity, where the DID amounts were higher (for total services and other service categories). In general, findings were comparable between the two approaches.

Table 7: Resource Consumption Index, Total Patient Costs, by Population and Services Category, Cardiovascular Clinical Groupings ERGs used for Risk Adjustment (Describes the resource utilization index findings for cardiovascular conditions and presents the total service results (disease plus non-disease related costs) using ERG morbidity adjustment.)

Table 8: Resource Consumption Index, Disease-Related Patient Costs, by Population and Service Category, Cardiovascular Clinical Groupings ETGs used for Assignment of Disease Related Costs (Presents disease-related results using the ETG disease-related approach.)

The results for the cardiovascular conditions represent the aggregate findings across AMI, CHF, angina and CAD at the population level.

Question/Issue Addressed-- Tables 7 and 8 and their charts focus on the variation in relative resource utilization across service categories and populations for a clinical grouping. The importance of each service category to total costs for cardiovascular conditions is shown at the bottom of each table (as a percentage of total costs, excluding other). The questions/issues addressed by these tables relate to the correspondence of findings across measurement methods and clinical categories and the variation in resource utilization across the studied plans.

Table 9: Resource Consumption Index, Comparison of Results for Different Measurement Approaches, by Population and Measurement Approach, Across Major Clinical Categories (Compares the relative resource consumption index findings across different methods, by major clinical category and population. The index is the ratio of actual to peers experience, adjusted for risk.)

Table 10: Resource Consumption Index, Comparison of Results for Different Measurement Approaches, by Population and Major Clinical Categories, Including ALL Study Conditions and Diseases (This table compares the relative resource consumption index findings across different methods, by major clinical category and population. The index is the ratio of actual to peers experience, adjusted for risk.)

Question/Issue Addressed-- Tables 9 and 10 describe the resource utilization index findings for all major clinical categories and for all study conditions combined. Both tables include the results for total costs both for total services or total disease-related services. Table 9 compares the findings for a given measurement approach across clinical categories. Table 10 compares the findings for a given clinical category, across the four measurement approaches. The charts at the bottom of the tables present the key findings graphically.

The following four measurement approaches were compared for each major clinical category:

- Total services, ERG Morbidity Approach
- Total services, Age-Sex Morbidity Approach
- Disease-related services, ETG Approach
- Disease-related services, DID Approach

High Level Interpretation of Tables 7 through 10

- Findings on Relative Resource Utilization – Variation by Type of Service (**Table 7**):
 - For a given health plan and clinical category, measures of relative resource utilization were generally similar across different types of service, with only some modest variations. The consistency was greatest for those services comprising a larger portion of overall costs measured (e.g., inpatient and pharmacy).
 - In addition to showing the variation in findings across type of service categories, Table 7 also shows the correspondence of findings when using all types of services or the subset of services (rightmost columns of the table). For a given health plan and clinical category, measures of relative resource utilization were generally similar using the “selected” group of services (inpatient, pharmacy, E&M and procedures) versus all types of service. In general, where differences were observed, relative resource utilization for diagnostic services (radiology, laboratory, and other diagnostic testing) were the primary factor.

- Findings on Relative Resource Utilization – Variation Across Clinical Category (**Table 9**)
 - For a given population, measures of relative resource utilization were generally similar across the major clinical categories, i.e., similar findings were observed for the same population for cardiovascular disease, diabetes, depression, asthma/COPD, and arthritis/LBP. This was particularly true for total service costs. For disease-related costs somewhat greater variation was observed across conditions for the same population.
- Findings on Relative Resource Utilization – Variation Across the Four Methods (**Table 10**)
 - For a given population and clinical category, measures of resource utilization were generally similar across the four different approaches to measurement described above, with only some modest variations.

B. Refining the Metrics and Findings

Following review of the research findings discussed above NCQA and the EMAP identified additional analyses necessary to further this study findings. Some of these analyses addressed refinements to the study methodologies, while others focused on different approaches to summarize key findings and results. The primary component during the later part of the work was to update the analyses using changes to the underlying methodologies and explore related issues summarizing the findings.

In addition to refining these methods, the following was also addressed:

- Identify potential service categories that were straightforward to measure and were reasonable proxies for total resource measurement. These categories included:
 - Inpatient utilization
 - Pharmacy Services
 - Evaluation and Management
 - Procedures, including Outpatient Facility and ASC costs.
- Summarize the relationship between population size and variation in measures of relative resource utilization – i.e., determine sufficient sample size to produce consistently valid numerators and denominators and how large of a health plan is required to achieve these thresholds. Provide information to determine expected confidence intervals for key study measures.

Figure 1a: Standard Error of Relative Resource Utilization, by Condition Member Sample Size-- Total Services, ERG Adjustment (This figure describes the effect of sample size within a major clinical category and the relative resource utilization measurement when using the ERG adjustment method.)

Figure 1b: Standard Error of Relative Resource Utilization, by Condition Member Sample Size-- Total Services, Age-Sex Adjustment (This figure describes the affect of sample size within a major clinical category and the relative resource utilization measurement when using the study developed Age-Sex adjustment method.)

Figure 1c: Standard Error of Relative Resource Utilization, by Condition Member Sample Size—Disease-Related Services, ETG Adjustment (This figure describes the affect of sample

size within a major clinical category and the relative resource utilization measurement when using the ETG adjustment method.)

Figure 1d: Standard Error of Relative Resource Utilization, by Condition Member Sample Size—Disease-Related Services, DID Adjustment (This figure describes the affect of sample size within a major clinical category and the relative resource utilization measurement when using the study developed DID method.)

Summary Questions/Issues Addressed -- What is the relationship between population size and variation in measures of relative resource utilization – i.e., what is a sufficient sample size to produce consistently valid numerators and denominators and how large of a health plan is required to achieve these thresholds? What is the expected confidence interval around a measure for a health plan of typical size and disease characteristics? Does the relationship between sample size and variation differ by disease or methodology used?

Figures 1a-1d Summary Interpretation

- A typical standard error for measuring total service relative resource utilization was observed to be approximately 0.025 at samples of 2,000 patients or more. For example, for a condition with a typical prevalence of 1 percent of enrolled members, a health plan of 250,000 members would yield a patient sample of 2,500. Based on the above standard error, the expected 95 percent confidence interval around the estimated resource utilization index would be approximately +/- 0.05, where 0.05 equals twice 0.025 (a 95 percent confidence interval is approximately 2 standard errors).
- In general, the standard errors were relatively higher for measures of disease-related services versus total services.

IV. Summary and Conclusions

The investigations described in this report can provide insights into the conceptual and methodological issues in measuring relative utilization at a health plan level. Using a large research database and the methods described above, the study addressed a number of questions related to assessing resource utilization at the health plan and population levels. Study measures included the cost, overall and by type of service, for patients with selected clinically and financially important conditions. Relative resource utilization was measured for study patients, overall, and for those services directly related to the treatment of the study condition. All study measures were risk-adjusted to support valid comparisons across conditions and health plans.

The study produced a number of key findings related to resource measurement:

- Health plans can be meaningfully measured and compared with respect to the relative resource consumption of their networks for select resource categories.
- Methodologically defensible non-proprietary methods can be identified for severity and case adjustment. These methods can serve as the basis for the development of practical algorithms to support measurement of resource utilization at the health plan level – involving a reasonable burden on health plans in measurement and also avoiding the need for requiring their use of a proprietary tool.
- A significant obstacle in sharing cost information at the health plan level is the proprietary nature of the fee schedules and contracts that describe their pricing of services. This study employed standard pricing methods that removed unit price variation as a factor in resource measurement.
- Relative resource consumption seems to vary meaningfully between health plans. More specific findings related to these measures provided insights related to the services, conditions and methods used for study:
 - Services – for a given health plan and clinical category, measures of relative resource utilization were generally similar across different types of service, with only some modest variations. The consistency was greatest for those services comprising a larger portion of overall costs measured (e.g., inpatient and pharmacy).
 - Study Conditions – for a given health plan, measures of relative resource utilization were generally similar across the study conditions – i.e., similar findings were observed for the same population for cardiovascular disease, diabetes, depression, asthma/COPD, arthritis and LBP.
 - Methods – four different approaches were used by the study to measure relative resource use – varying by the risk adjustment methodology employed and the focus on total service versus disease-related costs. For a given population and clinical category, measures of resource utilization were generally similar across the four different approaches to measurement described above, with only some modest variations.
- The study explored the potential for the use of a subset of services as a proxy for measuring resource use for all services (see Table 7). In this way, services that can be reliably measured could be the focus of initial measurement and also present a reasonable burden on health plans in collecting this information. The study found measures of relative resource utilization were generally similar using “selected” services

(inpatient, pharmacy, evaluation and management, and procedures, including ASC costs) versus measurement using all services.

- The relationship between population size and variation in measures of relative resource utilization – i.e., what is a sufficient sample size to produce consistently valid numerators and denominators and how large of a health plan is required to achieve these thresholds – was explored. Typical standard errors were measured for each condition – demonstrating the relationship between population size and likely precision of measures of relative resource use. A typical standard error for measuring total service relative resource utilization was observed to be approximately 0.025 at samples of 2,000 patients or more. In general, the standard errors were relatively higher for measures of disease-related services versus total services

Methodological solutions are emerging to measure such differences in a reliable and valid fashion. However, we are still challenged by how to characterize the value of these metrics and their meaning to purchasers. The importance of these metrics with respect to “bottom-line” considerations in the short- or mid-term is not immediately clear. To that end, we plan to engage in discussions with health care industry consultants, actuaries and other experts to assist in this process. In addition, NCQA is interested in refining the methods developed during this study and finalizing measure specifications for health plan or large health care organization comment and implementation. The feasibility, including health plan burden for collecting and programming measures, needs to be further explored by engaging health plans in a field test study. The field test would also inform an understanding of the metrics comparability, and regional differences. In addition, NCQA would like to explore other conditions, including acute episodes of illness. Lastly, a comparison of the relative resource utilization measures with quality outcomes is an important step to fully understanding health care services efficiencies. This study only looked at selected chronic conditions and it is unknown how the study developed method could be applied to acute events or illnesses. In addition, provider level resource consumption was not explored and it is likely that a more robust risk-adjustment method than the study-developed Age-Sex Morbidity, as well as patient or illness attribution, would need to be applied.

References

- ¹ Henry J. Kaiser Foundation and Health Research and Educational Trust, “Trends and Indicators in the Changing Health Care Marketplace” <http://www.kff.org/insurance/7031/ti2004-1-1.cfm> (Web accessed April 2005).
- ² Henry J. Kaiser Foundation and Health Research and Educational Trust, “Summary of Findings, Employer Health Benefits 2004 Annual Survey” <http://www.kff.org/insurance/7148/summary/index.cfm> (Web accessed May 2005).
- ³ Henry J. Kaiser Foundation and Health Research and Educational Trust, “Trends and Indicators in the Changing Health Care Marketplace” <http://www.kff.org/insurance/7031/ti2004-1-1.cfm> (Web accessed April 2005).
- ⁴ Henry J. Kaiser Foundation and Health Research and Educational Trust, “Summary of Findings, Employer Health Benefits 2004 Annual Survey” <http://www.kff.org/insurance/7148/summary/index.cfm> (Web accessed May 2005).
- ⁵ Center for Medicare and Medicaid Services, “An Overview of the U.S. Healthcare System: Two Decades of Change, 1980-2000,” *Office of the Actuary*. March 12 2002.
<http://www.cms.hhs.gov/charts/healthcaresystem/chapter1.pdf>
- ⁶ Tandon, Ajay, Lauer, Jeremy A., Evans, David B., Murray, Christopher J.L. “Health System Efficiency: Concepts” *Health System Performance Assessment*, chapter 50.
[http://whqlibdoc.who.int/publications/2003/9241562455_\(part4\)_chp50-60.pdf](http://whqlibdoc.who.int/publications/2003/9241562455_(part4)_chp50-60.pdf)
- ⁷ Wennberg, John E., Fisher, Elliot S., Skinner, Jonathan, S. “Geography and The Debate Over Medicare Reform,” *Health Affairs* Web Exclusive, February 2002.
- ⁸ E.S. Fisher et al., “Associations among Hospital Capacity, Utilization, and Mortality of U.S. Medicare Beneficiaries, Controlling for Sociodemographic Factors,” *Health Services Research*, 34 no. 6 (2000): 1351-1362.
- ⁹ Thorpe et. al., *Health Affairs*. August 25, 2004.

List of Appendix Tables

Table A-1 and A-1a: Percent of Patients Identified with a Clinical Grouping also Identified for Another Clinical Grouping (Overlap between Clinical Groupings)

Table A-2: The Impact of Pharmacy Data on Identification--the Number of Patients Identified for a Clinical Grouping Using Only Medical Claims Data as a Percentage of the Number Identified Using both Medical and Pharmacy Claims

Table A-3a: Total Disease Related Costs PMPM, by Population and Service Category, using Episode Treatment Groups (ETGs) Methodology, Commercial Population

Table A-3b: Total Disease Related Costs PMPM, by Population and Service Category, using Disease Identification (DID) Methodology, Commercial Population

Table A-3c: Disease Related Costs as a Percentage of Total Costs, by Clinical Grouping and Service Category, using Episode Treatment Groups (ETGs) Methodology, Commercial Population

Table A-3d: Disease Related Costs as a Percentage of Total Costs, by Clinical Grouping and Service Category, using Disease Identification (DID) Methodology, Commercial Population

Table A-3e: Comparison of Disease-Related Costs using Two Alternative Methodologies-ETGs and the DID Approach. Disease-related Costs assigned by DID as a Percentage of Disease-related Costs Assigned by ETGs, by Clinical Grouping and Service Category

Table A-4: Assignment of Patients to Morbidity Categories using ERGs-Patients Prevalence by ERG Morbidity Category and Clinical Category, Commercial Population

Table A-4a: Total Costs PMPM for Patients Assigned to Morbidity Categories Assigned using ERGs, Commercial Population

Table A-5: Assignment of Patients to Morbidity Categories using Age and Sex Groupings – Patient Prevalence by Age-Sex Category and Clinical Category, Commercial Population

Table A-5a: Total Costs PMPM for Patients Assigned to Morbidity Categories Assigned using Age-Sex, Commercial Population

Tables A-6: Correspondence of Relative Resource Utilization Indices Across Types of Service - Rank-Order Correlations

Table A-7: Correspondence of Relative Resource Utilization Indices Across Methods -- Rank-Order Correlations

Appendix Tables--Results Discussion

Appendix Tables A-1, A-1a, and A-2 provide further descriptive information on the study populations, including:

- Appendix Table A-1. Describes the overlap between the major clinical groupings for the combined commercial population. The table includes the percentage of the patients for a major clinical grouping that were also identified for one or more other clinical groupings included in the study.
- Appendix Table A-1a. Describes the overlap between the major clinical groupings for the combined commercial population in greater detail – showing the multiple overlaps between conditions. The table includes the percentage of the patients for a major clinical grouping that were identified for each combination of the other clinical groupings.

Question/Issue Addressed by Tables A-1 and A-1a -- How often will patients be included in multiple conditions/multiple measures?

- Appendix Table A-2. Describes the impact of excluding pharmacy data from the patient identification process – where pharmacy data is part of the patient identification algorithm. The table includes the number of patients identified for a clinical grouping using medical claims data only, as a percentage of the number identified using both medical and pharmacy claims. Since asthma and diabetes are the only categories which employ pharmacy data in identification, estimates are only included for these conditions.

Appendix Tables A-3a through A-3e. Focus on disease-related costs and their relationship to total costs. Estimates are provided by clinical grouping and service category. In particular,

- Table A-3a includes disease-related costs based on the ETG approach
- Table A-3b includes disease-related costs based on the DID approach
- Table A-3c includes disease-related costs based on the ETG approach as a percentage of total service costs
- Table A-3d includes disease-related costs based on the ETG approach as a percentage of total service costs
- Table A-3e includes disease-related costs based on the DID approach as a percentage of disease-related costs based on the ETG approach (the relative size of the disease-related amounts using each approach)

Question/Issue Addressed by Tables A-3a through A-3e -- How large are disease-related costs as a percentage of total costs for each clinical grouping? How do these amounts vary by service category? What is the difference in the magnitude of disease-related costs using the ETG vs. DID approach?

High-Level Interpretation

- Whether using the ETG or DID approach, disease-related costs represent a significant portion of total service costs for some conditions – in particular the cardiovascular conditions (approx 50-80%). These percentages vary by service category.

-
- Whether using the ETG or DID approach, disease-related costs represent a lesser portion of total service costs for some conditions – e.g., asthma, COPD, arthritis and LBP.
 - For many conditions, the magnitude of the disease-related costs is comparable whether using the ETG or DID approach – the exceptions are Asthma, COPD and Diabetes, with co-morbidity, where the DID amounts are higher (for total services and other service categories).

Appendix Tables A-4 and A-4a. Describes the distribution of patients by ERG morbidity category and their average costs (Table A-4a).

Question/Issue Addressed -- *What is the distribution of patients across ERG morbidity categories? Will there be sufficient number of patients in each category to support analysis and the calculation of peer amounts? Do the ranges of risk effectively capture the “tails” of the risk distribution – particularly at the higher end? Do average costs increase with the level of risk?*

High-Level Interpretation

- Table A-4 shows a reasonable distribution of patients across ERG morbidity categories. As expected, some clinical conditions require more differentiation at the higher or lower ends of the risk range (e.g., AMI at the higher end, Asthma at the lower end).
- Table A-4a shows increasing total costs with increasing risk --- suggesting the ERG groupings are capturing differences in overall risk for each of the patient populations.

Appendix Tables A-5 and A-5a. Describes the distribution of patients by Age-Sex morbidity category and their average costs (Table A-5a).

Question/Issue Addressed -- *What is the distribution of patients across age-sex categories? Will there be sufficient number of patients in each category to support analysis and the calculation of peer amounts? Do the ranges effectively capture the “tails” of the age distribution – particularly at the higher and lower ends? Do average costs vary as expected with age and gender?*

High-Level Interpretation

- Table A-5 shows a reasonable distribution of patients across the age-sex morbidity categories. As expected, some clinical conditions experience a different distribution of patients by age. (The missing amounts for some conditions reflect the age-based exclusions used in the patient identification approach.
- Table A-5a shows somewhat increasing total costs with increasing age --- although not as marked as shown in Table A-4a for ERGs – suggesting the age-sex groupings will not provide the same level of precision at the individual level in measuring risk within a clinical category. This is to be expected given the use of greater clinical information by ERGs, but the impact may average out at the population (plan) level – unless the mix of ERG risk differs significantly within an age-sex category across populations.

Appendix Tables A-6 and A-7 include Spearman Rank Order Correlations that address the following questions:

- What is the correlation in the relative population rankings of resource utilization across different types of service? – addresses the issue of potential proxies for using all services in measuring resource utilization.
- What is the correlation in the relative population rankings of resource utilization across the four different methodologies used (Total services, ERG Morbidity Approach; Total services, Age-Sex Morbidity Approach; Disease-related services, ETG Approach; Disease-related services, DID Approach) -- addresses the issue of the impact of methodological approach on the relative findings.

Efficiency Measurement Advisory Panel

Laurie Case
Assistant Director, Provider Profiling
CIGNA Healthcare

Kathleen Curtin
VP, Quality Management
Administration
Excellus Health Plan

Daniel Dunn, PhD
Vice President, Research and Development
IHCIS

Elliott Fisher, MD, MPH
Professor of Medicine
Dartmouth Medical School
Strasenburgh Hall, Room 319
Dartmouth Medical School

Irene Fraser, PhD
Director, Center for Delivery, Organization and
Markets
Agency for Healthcare Research and Quality

Kyle Grazier, PhD
Associate Professor
University of Michigan

Trent Haywood, MD, JD
Deputy Director, Quality Measurement & Health
Assessment Group
Centers for Medicare and Medicaid Services

Randall Herman, FSA, MAAA
CEO and Chairman
Patient Choice Healthcare, Inc.

David J. Knutson, PhD
Director, Health Systems Studies
Park Nicollet

Mark Rattray, MD
Chief Medical Officer
Regence BlueShield

Robert Scalettar, MD, MPH
Corporate Medical Director
Anthem BCBS

Cary Sennett, MD, PhD
Vice President, Applied Healthcare Research
Ingenix (member through October 2004)
William Glasheen, PhD
Ingenix

Ron Stettler
Vice President, Medical Informatics
PacifiCare Health Systems

Matt Stiefel, MPA
Associate Executive Director
Care Management Institute,
Kaiser Permanente

Janet Thomson, R.Ph.
Business Information Manager
Aetna Integrated Informatics

Joe P. Woods
Vice President, Marketing & Business Integration
Humana

Timothy C. Zeddies, Ph.D.
Senior Director, Research and Evaluation
Independence Blue Cross

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Final Results Table

Table 1: Description of Enrolled Populations used for Selecting Study Patients

Population	Size Group (Members)	% of Members Age < 35	% of Members Age > 64	% Female	% Pharmacy Benefit
Medicare Risk	0-250K	N/A	92%	59%	100%
Medicaid	251K-500K	90%	0%	56%	100%
Population A	501K+	51%	1%	51%	100%
Population B	501K+	45%		51%	63%
Population C	251K-500K	53%	3%	52%	85%
Population D	251K-500K	51%	1%	51%	86%
Population F	501K+	48%	2%	51%	90%
Population H	251K-500K	53%	1%	50%	89%
Population J	251K-500K	60%	1%	51%	91%
Population M	501K+	49%	3%	51%	86%
Population O	501K+	51%	2%	53%	91%
Population Q	0-250K	49%	1%	53%	72%
Population R	501K+	51%	1%	51%	100%
Population S	251K-500K	51%	2%	51%	100%

Note: A Medicare Risk, Medicaid and 12 Managed Care Populations were selected for the study. This table describes the approximate membership, demographics and pharmacy benefit status.

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Final Results Table

Table 2: Percent Prevalence of Patients, by Population and Clinical Grouping

	Populations						
Clinical Grouping	Medicare Risk	Medicaid	A	B	C	D	F
AMI Year 2	0.6%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%
Angina	0.6%	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%
Arthritis	6.8%	0.4%	0.9%	1.4%	1.0%	0.9%	1.3%
Asthma	2.6%	4.7%	3.4%	2.9%	2.4%	2.8%	3.7%
CAD	8.5%	0.1%	0.6%	1.1%	0.8%	0.5%	0.8%
CHF	4.8%	0.1%	0.1%	0.5%	0.2%	0.1%	0.2%
COPD	5.9%	0.3%	0.4%	0.8%	0.5%	0.4%	0.6%
Diabetes Type I	2.8%	0.5%	0.7%	0.7%	0.7%	0.6%	0.8%
Diabetes Type II	12.9%	0.8%	2.0%	2.4%	2.3%	1.9%	2.5%
Low Back Pain	3.4%	1.8%	2.2%	2.3%	2.3%	2.5%	2.5%

Clinical Grouping	Populations							All Commercial Plans (A-S)
	H	J	M	O	Q	R	S	
AMI Year 2	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
Angina	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%
Arthritis	0.9%	0.5%	1.1%	0.8%	1.2%	0.7%	1.0%	1.0%
Asthma	2.6%	3.1%	2.5%	3.1%	2.7%	3.1%	1.5%	2.9%
CAD	0.5%	0.5%	0.7%	0.9%	0.4%	0.5%	0.9%	0.7%
CHF	0.1%	0.1%	0.3%	0.2%	0.1%	0.1%	0.2%	0.2%
COPD	0.3%	0.3%	0.5%	0.5%	0.3%	0.4%	0.4%	0.5%
Diabetes Type I	0.6%	0.5%	0.8%	0.6%	0.7%	0.7%	0.6%	0.7%
Diabetes Type II	1.8%	1.8%	2.7%	2.1%	2.6%	1.8%	2.3%	2.2%
Low Back Pain	2.2%	1.3%	2.4%	1.5%	2.7%	1.9%	2.2%	2.1%

- Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.
- Pharmacy data used as part of the patient identification for Asthma and Diabetes

-Members can be identified for more than one major clinical grouping (Cardiovascular, Asthma/COPD, Diabetes, and Arthritis/LBP). Within Cardiovascular, a patient is assigned to one condition using the following hierarchy, CHF, AMI, CAD, and Angina. Within Asthma/COPD, a member is assigned to one condition using a hierarchy of COPD and then Asthma. Within Diabetes, a member is assigned to one condition using a hierarchy of Type I and then Type II. Within Arthritis/LBP, a member is assigned to one condition using a hierarchy of Arthritis and then LBP.

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions

Final Results Table

Table 3: Percent Prevalence of Patients Identified with One or More Study Co-Morbidities

	% Patients with one or more Study CoMorbidity						
Clinical Grouping	Medicare Risk	Medicaid	Population A	Population B	Population C	Population D	Population F
AMI Year 2	42%	47%	31%	31%	33%	31%	30%
Angina	34%	62%	37%	30%	28%	36%	30%
Arthritis	0%	0%	0%	0%	0%	0%	0%
Asthma	66%	13%	23%	25%	23%	24%	25%
CAD	33%	66%	34%	31%	35%	35%	34%
CHF	51%	70%	59%	50%	53%	56%	58%
COPD	75%	59%	57%	68%	63%	55%	58%
Diabetes Type I	82%	58%	55%	60%	56%	53%	63%
Diabetes Type II	78%	60%	66%	73%	63%	65%	70%
Low Back Pain	0%	0%	0%	0%	0%	0%	0%

	% Patients with one or more Study CoMorbidity						
Clinical Grouping	Population H	Population J	Population M	Population O	Population Q	Population R	Population S
AMI Year 2	28%	27%	33%	27%	35%	31%	25%
Angina	14%	21%	32%	21%	32%	29%	27%
Arthritis	0%	0%	0%	0%	0%	0%	0%
Asthma	23%	13%	24%	21%	24%	22%	25%
CAD	33%	30%	36%	31%	33%	33%	29%
CHF	52%	52%	54%	50%	55%	57%	47%
COPD	61%	42%	64%	53%	53%	53%	64%
Diabetes Type I	56%	38%	59%	55%	57%	49%	63%
Diabetes Type II	64%	43%	64%	63%	57%	59%	66%
Low Back Pain	0%	0%	0%	0%	0%	0%	0%

more study comorbidities: Asthma/COPD, Cardiovascular, including Hypertension, Diabetes, Depression, and Renal Failure (for Diabetes).

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.

-Pharmacy data used as part of the patient identification for Asthma and Diabetes

-Members can be identified for more than one major clinical grouping (Cardiovascular, Asthma/COPD, Diabetes, and Arthritis/LBP). Hierarchies applied for some conditions (see note for Table 2).

**NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Final Results Table**

Table 4: Total Costs PMPM, by Population and Clinical Groupings, Commercial Population

	Total Costs PMPM, by Population											
	A	B	C	D	F	H	J	M	O	Q	R	S
AMI	\$2,709	\$2,907	\$3,119	\$3,068	\$3,257	\$3,132	\$2,807	\$2,615	\$2,394	\$2,607	\$2,480	\$2,535
AMI w/Comorbid	\$3,531	\$3,406	\$3,332	\$3,381	\$3,829	\$4,180	\$4,826	\$3,398	\$3,347	\$3,384	\$3,540	\$3,304
Angina	\$739	\$815	\$795	\$690	\$782	\$915	\$762	\$828	\$516	\$690	\$687	\$709
Angina w/Comorbid	\$1,193	\$1,162	\$1,170	\$1,259	\$1,384	\$1,483	\$1,098	\$1,163	\$904	\$1,237	\$786	\$1,054
Arthritis	\$945	\$1,033	\$1,004	\$1,051	\$1,117	\$1,067	\$947	\$904	\$936	\$772	\$891	\$852
Asthma	\$305	\$366	\$380	\$340	\$367	\$337	\$300	\$317	\$326	\$300	\$283	\$315
Asthma w/Comorbid	\$734	\$873	\$886	\$794	\$896	\$869	\$881	\$811	\$793	\$717	\$695	\$767
CAD	\$991	\$1,005	\$1,159	\$1,326	\$1,214	\$1,422	\$1,112	\$1,128	\$951	\$980	\$950	\$1,118
CAD w/Comorbid	\$1,497	\$1,546	\$1,755	\$2,019	\$1,673	\$1,726	\$1,791	\$1,604	\$1,460	\$1,284	\$1,414	\$1,641
CHF	\$2,573	\$2,002	\$3,574	\$2,148	\$2,932	\$2,497	\$2,585	\$2,098	\$2,128	\$2,188	\$2,043	\$2,134
CHF w/Comorbid	\$3,343	\$2,965	\$2,807	\$3,101	\$4,147	\$3,563	\$4,157	\$3,287	\$3,367	\$3,141	\$3,030	\$2,687
COPD	\$721	\$775	\$975	\$798	\$729	\$911	\$704	\$781	\$580	\$636	\$674	\$909
COPD w/Comorbid	\$1,643	\$1,775	\$1,754	\$1,813	\$1,780	\$1,715	\$1,860	\$1,788	\$1,515	\$1,561	\$1,570	\$1,808
Diabetes I	\$583	\$675	\$586	\$678	\$690	\$622	\$687	\$552	\$641	\$609	\$589	\$540
Diabetes I w/Comorbid	\$1,328	\$1,538	\$1,480	\$1,389	\$1,521	\$1,400	\$1,708	\$1,383	\$1,415	\$1,095	\$1,344	\$1,219
Diabetes II	\$394	\$463	\$413	\$435	\$460	\$422	\$419	\$353	\$397	\$351	\$344	\$311
Diabetes II w/Comorbid	\$708	\$880	\$823	\$800	\$861	\$750	\$891	\$731	\$742	\$606	\$656	\$703
LBP	\$579	\$678	\$704	\$655	\$741	\$713	\$593	\$663	\$648	\$518	\$512	\$653

-This table shows the total costs PMPM for Year 2 for patients identified for each clinical grouping. Total costs equals the costs for all services, including medical and pharmacy services. For pharmacy services costs, only members with a pharmacy benefit were included.

-Costs based on IHCIS Standard Pricing Methodology (consistent methodology and pricing levels applied to all populations and services).

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.

-Pharmacy data used as part of the patient identification for Asthma, and Diabetes

-Members can be identified for more than one major clinical grouping (Cardiovascular, Asthma/COPD, Diabetes, and Arthritis/LBP). Hierarchies applied for some conditions (see note for Table 2).

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions

Final Results Table

Table 5: Cost PMPM, by Clinical Grouping and Service Category, Commercial Population

All Commercial Populations		PMPM Costs, by Service Category													
Clinical Grouping	Total Patients	Amb. Surg.	Consult	Diagnostic	E & M	E & M (MH)	ER	Inpat.	Lab	Other	Phys Medicine	Procs	RX	Rad.	Total
AMI	4,051	\$25	\$22	\$112	\$93	\$5	\$54	\$1,712	\$37	\$235	\$37	\$169	\$160	\$74	\$2,735
AMI w/Comorbid	1,750	\$37	\$34	\$119	\$133	\$8	\$65	\$2,180	\$41	\$305	\$37	\$203	\$275	\$85	\$3,523
Angina	2,146	\$34	\$12	\$69	\$52	\$6	\$21	\$145	\$26	\$79	\$10	\$39	\$131	\$65	\$689
Angina w/Comorbid	818	\$34	\$18	\$74	\$71	\$12	\$30	\$284	\$31	\$123	\$10	\$61	\$276	\$87	\$1,112
Arthritis	67,805	\$44	\$14	\$26	\$61	\$8	\$13	\$286	\$28	\$131	\$31	\$85	\$174	\$67	\$970
Asthma	157,768	\$13	\$6	\$11	\$33	\$8	\$12	\$37	\$11	\$48	\$7	\$17	\$102	\$22	\$327
Asthma w/Comorbid	46,204	\$30	\$12	\$33	\$56	\$18	\$19	\$153	\$27	\$99	\$13	\$42	\$253	\$52	\$807
CAD	34,212	\$35	\$13	\$75	\$54	\$4	\$17	\$403	\$29	\$105	\$14	\$72	\$174	\$72	\$1,066
CAD w/Comorbid	16,571	\$44	\$20	\$90	\$79	\$7	\$25	\$591	\$39	\$165	\$18	\$98	\$315	\$88	\$1,580
CHF	6,540	\$34	\$27	\$102	\$117	\$5	\$36	\$1,288	\$40	\$230	\$13	\$101	\$200	\$69	\$2,261
CHF w/Comorbid	7,283	\$44	\$44	\$109	\$180	\$9	\$56	\$1,748	\$54	\$398	\$18	\$128	\$367	\$92	\$3,247
COPD	13,772	\$23	\$12	\$27	\$55	\$7	\$19	\$203	\$21	\$110	\$8	\$38	\$148	\$53	\$725
COPD w/Comorbid	19,679	\$36	\$24	\$63	\$105	\$10	\$35	\$738	\$34	\$204	\$13	\$78	\$281	\$80	\$1,702
Diabetes I	20,129	\$19	\$9	\$11	\$38	\$6	\$12	\$99	\$23	\$115	\$8	\$28	\$218	\$31	\$618
Diabetes I w/Comorbid	26,082	\$38	\$19	\$43	\$80	\$8	\$24	\$462	\$39	\$192	\$14	\$74	\$356	\$60	\$1,409
Diabetes II	54,976	\$17	\$7	\$12	\$31	\$4	\$7	\$43	\$20	\$52	\$8	\$23	\$142	\$28	\$393
Diabetes II w/Comorbid	99,466	\$27	\$11	\$32	\$51	\$5	\$12	\$189	\$28	\$89	\$11	\$45	\$219	\$45	\$765
LBP	146,352	\$34	\$11	\$18	\$49	\$10	\$21	\$119	\$22	\$85	\$34	\$52	\$118	\$73	\$646

-This table shows the costs PMPM for Year 2 for patients identified for each clinical grouping, by service category. Total costs equals the costs for all services, including medical and pharmacy services. For pharmacy services costs, only members with a pharmacy benefit were included.

-Costs based on IHCIS Standard Pricing Methodology (consistent methodology and pricing levels applied to all populations and services).

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.

-Pharmacy data used as part of the patient identification for Asthma, and Diabetes

-Members can be identified for more than one major clinical grouping (Cardiovascular, Asthma/COPD, Diabetes, and Arthritis/LBP). Hierarchies applied for some conditions (see note for Table 2).

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions

Final Results for Presentation, 12/03/04

Table 7 (cont): Cost PMPM, by Clinical Grouping and Service Category, Commercial Population (Percentage)

All Commercial Populations		Service Category Costs as a Percentage of Total Service Costs													
Clinical Grouping	Total Patients	Amb. Surg.	Consult	Diagnostic	E & M	E & M (MH)	ER	Inpat.	Lab	Other	Phys Medicine	Procs	RX	Rad.	Total
AMI	4,051	1%	1%	4%	3%	0%	2%	63%	1%	9%	1%	6%	6%	3%	100%
AMI w/Comorbid	1,750	1%	1%	3%	4%	0%	2%	62%	1%	9%	1%	6%	8%	2%	100%
Angina	2,146	5%	2%	10%	7%	1%	3%	21%	4%	11%	1%	6%	19%	9%	100%
Angina w/Comorbid	818	3%	2%	7%	6%	1%	3%	26%	3%	11%	1%	5%	25%	8%	100%
Arthritis	67,805	5%	1%	3%	6%	1%	1%	30%	3%	13%	3%	9%	18%	7%	100%
Asthma	157,768	4%	2%	3%	10%	2%	4%	11%	3%	15%	2%	5%	31%	7%	100%
Asthma w/Comorbid	46,204	4%	1%	4%	7%	2%	2%	19%	3%	12%	2%	5%	31%	6%	100%
CAD	34,212	3%	1%	7%	5%	0%	2%	38%	3%	10%	1%	7%	16%	7%	100%
CAD w/Comorbid	16,571	3%	1%	6%	5%	0%	2%	37%	2%	10%	1%	6%	20%	6%	100%
CHF	6,540	2%	1%	5%	5%	0%	2%	57%	2%	10%	1%	4%	9%	3%	100%
CHF w/Comorbid	7,283	1%	1%	3%	6%	0%	2%	54%	2%	12%	1%	4%	11%	3%	100%
COPD	13,772	3%	2%	4%	8%	1%	3%	28%	3%	15%	1%	5%	20%	7%	100%
COPD w/Comorbid	19,679	2%	1%	4%	6%	1%	2%	43%	2%	12%	1%	5%	16%	5%	100%
Diabetes I	20,129	3%	1%	2%	6%	1%	2%	16%	4%	19%	1%	5%	35%	5%	100%
Diabetes I w/Comorbid	26,082	3%	1%	3%	6%	1%	2%	33%	3%	14%	1%	5%	25%	4%	100%
Diabetes II	54,976	4%	2%	3%	8%	1%	2%	11%	5%	13%	2%	6%	36%	7%	100%
Diabetes II w/Comorbid	99,466	4%	1%	4%	7%	1%	2%	25%	4%	12%	1%	6%	29%	6%	100%
LBP	146,352	5%	2%	3%	8%	2%	3%	18%	3%	13%	5%	8%	18%	11%	100%

-This table shows the costs PMPM for Year 2 for patients identified for each clinical grouping, by service category. Total costs equals the costs for all services, including medical and pharmacy services. For pharmacy services costs, only members with a pharmacy benefit were included.

-Costs based on IHCIS Standard Pricing Methodology (consistent methodology and pricing levels applied to all populations and services).

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.

-Pharmacy data used as part of the patient identification for Asthma, and Diabetes

-Members can be identified for more than one major clinical grouping (Cardiovascular, Asthma/COPD, Diabetes, and Arthritis/LBP). Hierarchies applied for some conditions (see note for Table 2).

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Final Results Table

Table 6: Total Disease Related Costs PMPM, by Population and Service Category, using Episode Treatment Groups (ETGs) Methodology, Commercial Population

All Commercial Populations		PMPM Costs, by Service Category													
Clinical Grouping	Total Patients	Amb. Surg.	Consult	Diagnostic	E & M	E & M (MH)	ER	Inpat.	Lab	Other	Phys Medicine	Procs	RX	Rad.	Total
AMI	4,051	\$10	\$14	\$98	\$68	\$1	\$45	\$1,573	\$23	\$178	\$30	\$140	\$74	\$45	\$2,299
AMI w/Comorbid	1,750	\$13	\$21	\$103	\$96	\$0	\$52	\$1,889	\$25	\$207	\$28	\$159	\$153	\$50	\$2,797
Angina	2,146	\$11	\$5	\$50	\$26	\$0	\$12	\$80	\$10	\$26	\$3	\$8	\$49	\$31	\$310
Angina w/Comorbid	818	\$9	\$8	\$54	\$41	\$0	\$14	\$155	\$15	\$50	\$4	\$20	\$147	\$43	\$561
Arthritis	67,805	\$11	\$4	\$3	\$20	\$0	\$2	\$162	\$6	\$43	\$21	\$42	\$43	\$22	\$381
Asthma	157,768	\$0	\$1	\$4	\$8	\$0	\$4	\$5	\$1	\$4	\$0	\$0	\$40	\$2	\$69
Asthma w/Comorbid	46,204	\$0	\$1	\$5	\$8	\$0	\$4	\$12	\$1	\$6	\$0	\$0	\$50	\$3	\$92
CAD	34,212	\$12	\$5	\$60	\$31	\$0	\$10	\$310	\$13	\$50	\$7	\$37	\$73	\$40	\$647
CAD w/Comorbid	16,571	\$15	\$10	\$71	\$51	\$0	\$15	\$417	\$21	\$81	\$9	\$50	\$174	\$47	\$961
CHF	6,540	\$12	\$12	\$75	\$63	\$0	\$20	\$788	\$19	\$102	\$7	\$51	\$84	\$29	\$1,262
CHF w/Comorbid	7,283	\$15	\$23	\$82	\$114	\$0	\$36	\$1,168	\$28	\$190	\$10	\$64	\$203	\$41	\$1,973
COPD	13,772	\$1	\$2	\$9	\$16	\$0	\$6	\$53	\$2	\$20	\$0	\$1	\$45	\$7	\$163
COPD w/Comorbid	19,679	\$1	\$3	\$9	\$19	\$0	\$7	\$101	\$2	\$22	\$0	\$1	\$50	\$6	\$221
Diabetes I	20,129	\$2	\$3	\$2	\$19	\$0	\$5	\$24	\$10	\$48	\$2	\$7	\$143	\$3	\$268
Diabetes I w/Comorbid	26,082	\$4	\$5	\$5	\$32	\$0	\$8	\$66	\$14	\$45	\$2	\$14	\$178	\$6	\$380
Diabetes II	54,976	\$1	\$1	\$2	\$12	\$0	\$1	\$5	\$7	\$6	\$1	\$2	\$67	\$2	\$108
Diabetes II w/Comorbid	99,466	\$1	\$2	\$3	\$16	\$0	\$2	\$14	\$9	\$10	\$1	\$4	\$89	\$3	\$156
LBP	146,352	\$13	\$4	\$3	\$18	\$0	\$7	\$43	\$3	\$29	\$28	\$25	\$32	\$35	\$239

-This table shows the disease-related costs PMPM for Year 2 for patients identified for each clinical grouping, by service category. Disease-related costs were identified for this table using Symmetry's Episode Treatment Groups (ETGs). To do this, Year 2 medical and pharmacy claims for each member were grouped using ETGs. Specific ETGs determined to be disease-related were mapped to each clinical category. The patient's disease-related ETG experience for each clinical category was then summarized by service category.

-Costs based on IHCIS Standard Pricing Methodology (consistent methodology and pricing levels applied to all populations and services).

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.

-Pharmacy data used as part of the patient identification for Asthma, and Diabetes

-Members can be identified for more than one major clinical grouping (Cardiovascular, Asthma/COPD, Diabetes, and Arthritis/LBP). Hierarchies applied for some conditions (see note for Table 2).



Episode Treatment Groups are proprietary to Symmetry Health Data Systems.

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Final Results Table

Table 7: Resource Consumption Index, Total Patient Costs, by Population and Service Category, Cardiovascular Clinical Groupings
ERGs used for Risk Adjustment

Population	Risk Adjusted Relative Resource Consumption Index, by Service Category -- Total Services													
	AmbSrg	Consult	Diagn	E & M	ER	Inpat	Lab	Other	PhysMed	Procs	RX	Radiol	Total*	Total
A	0.80	0.96	1.01	0.95	0.82	0.98	1.10	1.04	0.92	0.93	1.07	1.05	0.98	1.00
B	0.74	0.88	0.82	0.99	0.83	0.86	0.81	0.90	0.93	0.82	1.12	0.93	0.88	0.88
C	0.72	0.87	1.07	0.98	0.66	1.01	0.74	0.92	1.11	1.17	1.09	0.94	1.01	1.00
D	0.77	0.81	1.91	0.97	1.82	1.07	1.71	1.61	2.12	1.17	0.98	1.55	1.06	1.23
F	0.84	0.82	1.28	0.89	1.24	1.02	1.60	1.29	1.79	0.94	1.09	1.28	1.01	1.10
H	1.14	0.84	1.70	0.90	1.75	1.30	1.58	1.48	1.53	1.15	0.87	1.56	1.17	1.27
J	0.79	1.24	1.68	1.19	1.47	1.27	0.68	0.92	1.06	1.13	1.03	1.19	1.19	1.18
M	0.84	1.07	0.94	0.95	1.53	1.12	0.56	1.05	1.16	0.99	0.90	0.96	1.06	1.04
O	1.54	1.33	0.81	1.14	0.75	0.93	0.33	0.61	0.66	1.01	1.04	0.80	1.00	0.92
Q	0.54	0.59	1.26	0.91	1.32	0.92	1.07	1.24	0.86	1.04	0.79	1.02	0.90	0.97
R	1.48	1.02	0.73	0.94	0.79	1.00	0.92	0.72	0.29	0.99	1.02	0.85	1.01	0.95
S	0.97	0.80	0.82	1.05	0.45	1.05	2.84	1.05	0.54	1.29	0.77	1.00	0.99	1.02
% of Total	3%	1%	6%	6%	2%	52%	2%	n/a	1%	6%	16%	5%	85%	100%



-This table shows the resource consumption index for a clinical category, by Population. The index is the ratio of actual to peers experience, adjusted for risk. Peers experience is the expected resource consumption if the peers had a similar mix of patients to that observed for the population. For this table, ERG Morbidity and clinical categories w/ co-morbidities are used for the risk adjustment.



Index for total services excludes "Diagnostics", "E & M (MH)", "Other", "Laboratory", "Phys Medicine", "Radiology". Patients exceeding \$100,000 in total costs excluded from analysis.

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year. -Pharmacy data used as part of the patient identification for Asthma and Diabetes

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Final Results Table

Table 8: Resource Consumption Index, Disease-Related Patient Costs, by Population and Service Category,
Cardiovascular Clinical Groupings
ETGs used for Assignment of Disease-Related Costs

Population	Risk Adjusted Relative Resource Consumption Index, by Service Category -- Disease-Related Services												
	AmbSrg	Consult	Diagn	E & M	ER	Inpat	Lab	Other	PhysMed	Procs	RX	Radiol	Total*
A	0.39	0.96	1.02	0.94	0.78	0.98	1.06	1.08	1.30	0.95	1.06	1.04	1.03
B	0.38	0.94	0.84	1.06	0.77	0.87	0.78	1.00	1.15	0.78	1.11	0.89	0.94
C	0.39	1.00	1.08	1.01	0.64	1.05	0.65	1.00	1.23	1.19	1.15	0.93	1.10
D	0.37	0.82	1.99	0.94	1.97	1.09	1.78	1.85	2.43	1.27	1.00	1.50	1.17
F	0.43	0.89	1.31	0.86	1.31	1.08	1.47	1.35	1.71	0.98	1.05	1.31	1.12
H	0.67	0.82	1.75	0.85	1.87	1.29	1.60	1.43	1.52	1.27	0.83	1.49	1.28
J	0.38	1.03	1.68	1.08	1.39	1.21	0.57	0.83	0.89	1.15	1.23	1.07	1.25
M	0.31	1.03	0.94	0.94	1.57	1.06	0.51	1.12	1.10	0.91	0.86	0.97	1.07
O	2.46	1.25	0.77	1.14	0.69	0.92	0.20	0.47	0.40	0.93	1.05	0.82	1.03
Q	0.63	0.58	1.27	0.89	1.41	0.92	1.05	1.56	1.06	1.13	0.76	0.85	0.96
R	2.25	1.01	0.70	0.93	0.78	0.97	0.81	0.70	0.17	1.07	1.01	0.79	1.04
S	1.38	0.83	0.78	1.01	0.44	1.05	3.68	1.19	0.43	1.44	0.79	1.09	1.09
% of Total	1%	1%	7%	5%	2%	54%	2%	n/a	1%	5%	11%	4%	79%



-This table shows the disease-related resource consumption index for a clinical category, by Population. The index is the ratio of actual to peers experience, adjusted for risk. Peers experience is the expected resource consumption if the peers had a similar mix of patients to that observed for the population. For this table, ETGs, clinical categories w/ co-morbidities are used for the risk adjustment. "Index for total" services excludes "Diagnostics", "E & M (MH)", "Other", "Laboratory", "Phys Medicine", "Radiology". Patients exceeding \$100,000 in total costs excluded from analysis.

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year. -Pharmacy data used as part of the patient identification for Asthma, Diabetes, and Depression.

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Final Results Table

Table 9: Resource Consumption Index, Comparison of Results for Different Measurement Approaches, by Population and Measurement Approach, Across Major Clinical Categories

Population	Risk Adjusted Relative Resource Consumption Index, by Measurement Method and Major Clinical Category -- Total Costs*									
	Total Services, ERG					Total Services, Asex				
	Cardiovasc	Asthma/ COPD	Diabetes	Arthritis/ LBP	All Study Conditions	Cardiovasc	Asthma/ COPD	Diabetes	Arthritis/ LBP	All Study Conditions
A	0.98	0.96	1.00	0.99	0.98	0.97	0.93	0.97	0.97	0.96
B	0.88	0.98	1.00	0.97	0.95	0.97	1.02	1.06	0.97	1.00
C	1.01	1.04	1.04	1.06	1.04	1.04	1.08	1.04	1.07	1.06
D	1.06	0.98	1.01	0.97	1.00	1.01	0.93	0.98	0.93	0.96
F	1.01	0.97	0.99	0.98	0.99	1.01	0.99	1.01	1.02	1.01
H	1.17	1.03	1.01	1.10	1.07	1.09	0.99	0.94	1.04	1.01
J	1.19	1.11	1.15	1.07	1.13	1.11	1.09	1.15	0.98	1.09
M	1.06	1.06	1.00	1.02	1.03	1.04	1.07	0.99	1.02	1.03
O	1.00	1.02	1.05	1.08	1.04	0.98	1.02	1.07	1.10	1.04
Q	0.90	0.87	0.85	0.81	0.85	0.89	0.86	0.82	0.77	0.82
R	1.01	0.98	1.00	0.98	0.99	0.99	0.95	0.98	0.97	0.97
S	0.99	0.99	0.90	0.92	0.94	0.98	1.02	0.89	0.93	0.94
StdDev	0.092	0.059	0.073	0.081	0.070	0.060	0.070	0.086	0.084	0.068

Population	Risk Adjusted Relative Resource Consumption Index, by Measurement Method and Major Clinical Category -- Total Costs*									
	Disease-Related Services, ETGs					Disease-Related Services, DID				
	Cardiovasc	Asthma/ COPD	Diabetes	Arthritis/ LBP	All Study Conditions	Cardiovasc	Asthma/ COPD	Diabetes	Arthritis/ LBP	All Study Conditions
A	1.03	1.02	1.02	1.15	0.98	0.99	0.96	0.96	0.96	0.97
B	0.94	1.10	1.17	1.15	0.96	0.93	1.13	1.18	1.03	1.03
C	1.10	1.11	1.03	1.28	1.06	1.04	1.14	1.04	1.11	1.08
D	1.17	0.98	1.08	1.19	1.00	1.24	1.02	1.17	1.13	1.00
F	1.12	1.00	1.08	1.24	1.04	1.12	0.96	1.08	1.12	1.00
H	1.28	1.03	0.91	1.48	1.10	1.27	1.14	1.04	1.32	1.12
J	1.25	1.08	1.22	1.19	1.12	1.16	1.04	1.20	0.96	1.12
M	1.07	1.10	0.95	1.15	0.99	0.98	1.00	0.91	0.97	0.96
O	1.03	1.04	1.07	1.14	1.01	0.90	0.94	0.96	0.89	1.01
Q	0.96	0.95	0.96	0.91	0.85	1.00	0.99	0.93	0.79	0.86
R	1.04	0.98	0.99	1.10	0.98	0.93	0.92	0.90	0.86	0.96
S	1.09	0.96	0.79	1.13	0.95	1.06	1.05	0.86	0.98	0.97
StdDev	0.103	0.057	0.115	0.132	0.073	0.123	0.078	0.119	0.142	0.074

*This table compares the relative resource consumption index findings across different methods, by Major Clinical Category and Population. The index is the ratio of actual to peers experience,

adjusted for risk. Peers experience is the expected resource consumption if the peers had a similar mix of patients to that observed for the population.

For this table, different methodologies are used for services included (disease-related and all services) and population risk adjustment (ERGs and Age-Sex).


Index for total services excludes "Diagnostics", "E & M (MH)", "Other", "Laboratory", "Phys Medicine", "Radiology". Patients exceeding \$100,000 in total costs excluded from analysis.

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year. -Pharmacy data used as part of the patient identification for Asthma and Diabetes.

Standard deviation of index measures across populations is shown at the bottom of each column. This can be considered a measure of the variation in the index across populations.



NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Final Results for Presentation, 12/09/04

Table 9: Resource Consumption Index, Comparison of Results for Different Measurement Approaches, by Population and Measurement Approach, Across Major Clinical Categories



NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Final Results for Presentation, 12/09/04

Table 9: Resource Consumption Index, Comparison of Results for Different Measurement Approaches, by Population and Measurement Approach, Across Major Clinical Categories



NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Final Results Table

Table 10: Resource Consumption Index, Comparison of Results for Different Measurement Approaches, by Population and Major Clinical Category, including All Study Conditions and Diseases

Population	Risk Adjusted Relative Resource Consumption Index, by Measurement Method and Major Clinical Category -- Total Costs*											
	Cardiovascular				Asthma/COPD				Diabetes			
	Total Services, ERG	Total Services, Asex	Related Services, ETGs	Disease-Related Services, DID	Total Services, ERG	Total Services, Asex	Related Services, ETGs	Disease-Related Services, DID	Total Services, ERG	Total Services, Asex	Related Services, ETGs	Disease-Related Services, DID
A	0.98	0.97	1.03	0.99	0.96	0.93	1.02	0.96	1.00	0.97	1.02	0.96
B	0.88	0.97	0.94	0.93	0.98	1.02	1.10	1.13	1.00	1.06	1.17	1.18
C	1.01	1.04	1.10	1.04	1.04	1.08	1.11	1.14	1.04	1.04	1.03	1.04
D	1.06	1.01	1.17	1.24	0.98	0.93	0.98	1.02	1.01	0.98	1.08	1.17
F	1.01	1.01	1.12	1.12	0.97	0.99	1.00	0.96	0.99	1.01	1.08	1.08
H	1.17	1.09	1.28	1.27	1.03	0.99	1.03	1.14	1.01	0.94	0.91	1.04
J	1.19	1.11	1.25	1.16	1.11	1.09	1.08	1.04	1.15	1.15	1.22	1.20
M	1.06	1.04	1.07	0.98	1.06	1.07	1.10	1.00	1.00	0.99	0.95	0.91
O	1.00	0.98	1.03	0.90	1.02	1.02	1.04	0.94	1.05	1.07	1.07	0.96
Q	0.90	0.89	0.96	1.00	0.87	0.86	0.95	0.99	0.85	0.82	0.96	0.93
R	1.01	0.99	1.04	0.93	0.98	0.95	0.98	0.92	1.00	0.98	0.99	0.90
S	0.99	0.98	1.09	1.06	0.99	1.02	0.96	1.05	0.90	0.89	0.79	0.86
StdDev	0.092	0.060	0.103	0.123	0.059	0.070	0.057	0.078	0.073	0.086	0.115	0.119

Population	Risk Adjusted Relative Resource Consumption Index, by Measurement Method and Major Clinical Category -- Total Costs*									
	Arthritis/LBP				Population	All Study Conditions				
	Total Services, ERG	Total Services, Asex	Related Services, ETGs	Disease-Related Services, DID		Total Services, ERG	Total Services, Asex	Related Services, ETGs	Disease-Related Services, DID	
A	0.99	0.97	1.15	0.96	A	0.98	0.96	0.98	0.97	
B	0.97	0.97	1.15	1.03	B	0.95	1.00	0.96	1.03	
C	1.06	1.07	1.28	1.11	C	1.04	1.06	1.06	1.08	
D	0.97	0.93	1.19	1.13	D	1.00	0.96	1.00	1.00	
F	0.98	1.02	1.24	1.12	F	0.99	1.01	1.04	1.00	
H	1.10	1.04	1.48	1.32	H	1.07	1.01	1.10	1.12	
J	1.07	0.98	1.19	0.96	J	1.13	1.09	1.12	1.12	
M	1.02	1.02	1.15	0.97	M	1.03	1.03	0.99	0.96	
O	1.08	1.10	1.14	0.89	O	1.04	1.04	1.01	1.01	
Q	0.81	0.77	0.91	0.79	Q	0.85	0.82	0.85	0.86	
R	0.98	0.97	1.10	0.86	R	0.99	0.97	0.98	0.96	
S	0.92	0.93	1.13	0.98	S	0.94	0.94	0.95	0.97	
StdDev	0.081	0.084	0.132	0.142	StdDev	0.070	0.068	0.073	0.074	

-This table compares the relative resource consumption index findings across different methods, by Major Clinical Category and Population. The index is the ratio of actual to peers experience, adjusted for risk. Peers experience is the expected resource consumption if the peers had a similar mix of patients to that observed for the population.

For this table, different methodologies are used for services included (disease-related and all services) and population risk adjustment (ERGs and Age-Sex).


Index for total services excludes "Diagnostics", "E & M (MH)", "Other", "Laboratory", "Phys Medicine", "Radiology". Patients exceeding \$100,000 in total costs excluded from analysis.

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year. -Pharmacy data used as part of the patient identification for Asthma and Diabetes

Standard deviation of index measures across populations is shown at the bottom of each column. This can be considered a measure of the variation in the index across populations.


NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Final Results for Presentation, 12/09/04

Table 10: Resource Consumption Index, Comparison of Results for Different Measurement Approaches, by Population and Major Clinical Category, including All Study Conditions and Diseases




NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Final Results for Presentation, 12/09/04

Table 10: Resource Consumption Index, Comparison of Results for Different Measurement Approaches, by Population and Major Clinical Category, including All Study Conditions and Diseases



NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Final Results Table

Table 11a: Sample Size and Standard Error, by Clinical Category
Total Costs*, Total Services, ERGs used for Risk Adjustment




Index for total services excludes "Diagnostics", "E & M (MH)", "Other", "Laboratory", "Phys Medicine", "Radiology".

Prepared for NCQA by IHCIS, December, 2004. Proprietary and confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Final Results Table

Table 11b: Sample Size and Standard Error, by Clinical Category
Total Costs*, Total Services, AgeSex used for Morbidity Adjustment




Index for total services excludes "Diagnostics", "E & M (MH)", "Other", "Laboratory", "Phys Medicine", "Radiology".

Prepared for NCQA by IHCIS, December, 2004. Proprietary and confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Final Results Table


Table 11c: Sample Size and Standard Error, by Clinical Category
Total Costs*, Disease-Related Services, ETGs



Index for total services excludes "Diagnostics", "E & M (MH)", "Other", "Laboratory", "Phys Medicine", "Radiology".
Prepared for NCQA by IHCIS, December, 2004. Proprietary and confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Final Results Table

Table 11d: Sample Size and Standard Error, by Clinical Category
Total Costs*, Disease-Related Services, DID



Index for total services excludes "Diagnostics", "E & M (MH)", "Other", "Laboratory", "Phys Medicine", "Radiology".

Prepared for NCQA by IHCIS, December, 2004. Proprietary and confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions

Appendix Table

Table A-1: Percent of Patients Identified with a Clinical Grouping also Identified for Another Clinical Grouping (Overlap between Clinical Groupings)

Major Clinical Grouping	Total Patients	Cardiovasc	Asthma/ COPD	Arthritis/ LBP	Diabetes
Cardiovascular	73,371	100%	12%	11%	26%
Asthma/COPD	237,423	4%	100%	6%	5%
Arthritis/LBP	214,157	4%	7%	100%	7%
Diabetes	200,653	9%	6%	8%	100%

-This table shows the percentage of total members identified for a clinical grouping that were also identified for another clinical

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.

-Pharmacy data used as part of the patient identification for Asthma, and Diabetes

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions

Appendix Table

Table A-1a: Percent of Patients Identified with a Clinical Grouping also Identified for Another Clinical Grouping (Includes Multiple Overlap between Clinical Groupings)

Major Clinical Grouping	Number of Patients
Cardiovascular	73,371
Asthma/COPD	237,423
Arthritis/LBP	214,157
Diabetes	200,653

Major Clinical Grouping					% of Members in Major Clinical Category			
Cardiovascular	Asthma/COPD	Arthritis/LBP	Diabetes	# of Patients	Cardiovascular	Asthma/COPD	Arthritis/LBP	Diabetes
No	No	No	Yes	159,301				79%
No	No	Yes	No	180,314			84%	
No	No	Yes	Yes	12,270			6%	6%
No	Yes	No	No	206,143		87%		
No	Yes	No	Yes	8,863		4%		4%
No	Yes	Yes	No	12,518		5%	6%	
No	Yes	Yes	Yes	1,258		1%	1%	1%
Yes	No	No	No	43,412	59%			
Yes	No	No	Yes	14,789	20%			7%
Yes	No	Yes	No	4,814	7%		2%	
Yes	No	Yes	Yes	1,715	2%		1%	1%
Yes	Yes	No	No	5,268	7%	2%		
Yes	Yes	No	Yes	2,105	3%	1%		1%
Yes	Yes	Yes	No	916	1%	0%	0%	
Yes	Yes	Yes	Yes	352	0%	0%	0%	0%

-This table shows the percentage of total members identified for a clinical grouping that were also identified for another clinical Grouping.

For example, 79% of members identified with Diabetes were not identified for another study condition.

As a second example, 7% of the patients identified with Diabetes were also identified with Cardiovascular -- but not Asthma/COPD nor Arthritis/LBP.

-Members identified with a condition in Year 2 with 6 or more member months enrolled during

-Pharmacy data used as part of the patient identification for Asthma, and Diabetes

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Appendix Table

Table A-2: The Impact of Pharmacy Data on Identification--the Number of Patients Identified for a Clinical Grouping Using Only Medical Claims Data as a Percentage of the Number Identified Using both Medical and Pharmacy Claims.

	Patients Identified using Medical Claims as a Percentage of Patients Identified using Medical and Pharmacy Claims						
Clinical Grouping	Medicare Risk	Medicaid	A	B	C	D	F
AMI Year 2							
Angina							
Arthritis							
Asthma	56%	63%	56%	66%	59%	61%	64%
CAD							
CHF							
COPD							
Diabetes Type I	59%	42%	47%	65%	45%	48%	54%
Diabetes Type II	92%	101%	85%	92%	84%	92%	89%
Low Back Pain							

	Patients Identified using Medical Claims as a Percentage of Patients Identified using Medical and Pharmacy Claims						
Clinical Grouping	H	J	M	O	Q	R	S
AMI Year 2							
Angina							
Arthritis							
Asthma	56%	54%	63%	64%	63%	54%	48%
CAD							
CHF							
COPD							
Diabetes Type I	45%	42%	51%	50%	50%	45.9%	42.6%
Diabetes Type II	91%	72%	84%	83%	91%	82.9%	76.1%
Low Back Pain							

-This table shows the number of patients identified for a clinical grouping using medical claims as a percentage of the number of patients identified using medical and pharmacy claims.

Blank denotes Disease where Pharmacy is not part of the Identification Criteria

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.

-Pharmacy data used as part of the patient identification for Asthma, and Diabetes

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Appendix Table

Table A-3a: Total Disease Related Costs PMPM, by Population and Service Category, using Episode Treatment Groups (ETGs) Methodology, Commercial Population

All Commercial Populations		PMPM Costs, by Service Category													
Clinical Grouping	Total Patients	Amb. Surg.	Consult	Diagnostic	E & M	E & M (MH)	ER	Inpat.	Lab	Other	Phys Medicine	Procs	RX	Rad.	Total
AMI	4,051	\$10	\$14	\$98	\$68	\$1	\$45	\$1,573	\$23	\$178	\$30	\$140	\$74	\$45	\$2,299
AMI w/Comorbid	1,750	\$13	\$21	\$103	\$96	\$0	\$52	\$1,889	\$25	\$207	\$28	\$159	\$153	\$50	\$2,797
Angina	2,146	\$11	\$5	\$50	\$26	\$0	\$12	\$80	\$10	\$26	\$3	\$8	\$49	\$31	\$310
Angina w/Comorbid	818	\$9	\$8	\$54	\$41	\$0	\$14	\$155	\$15	\$50	\$4	\$20	\$147	\$43	\$561
Arthritis	67,805	\$11	\$4	\$3	\$20	\$0	\$2	\$162	\$6	\$43	\$21	\$42	\$43	\$22	\$381
Asthma	157,768	\$0	\$1	\$4	\$8	\$0	\$4	\$5	\$1	\$4	\$0	\$0	\$40	\$2	\$69
Asthma w/Comorbid	46,204	\$0	\$1	\$5	\$8	\$0	\$4	\$12	\$1	\$6	\$0	\$0	\$50	\$3	\$92
CAD	34,212	\$12	\$5	\$60	\$31	\$0	\$10	\$310	\$13	\$50	\$7	\$37	\$73	\$40	\$647
CAD w/Comorbid	16,571	\$15	\$10	\$71	\$51	\$0	\$15	\$417	\$21	\$81	\$9	\$50	\$174	\$47	\$961
CHF	6,540	\$12	\$12	\$75	\$63	\$0	\$20	\$788	\$19	\$102	\$7	\$51	\$84	\$29	\$1,262
CHF w/Comorbid	7,283	\$15	\$23	\$82	\$114	\$0	\$36	\$1,168	\$28	\$190	\$10	\$64	\$203	\$41	\$1,973
COPD	13,772	\$1	\$2	\$9	\$16	\$0	\$6	\$53	\$2	\$20	\$0	\$1	\$45	\$7	\$163
COPD w/Comorbid	19,679	\$1	\$3	\$9	\$19	\$0	\$7	\$101	\$2	\$22	\$0	\$1	\$50	\$6	\$221
Diabetes I	20,129	\$2	\$3	\$2	\$19	\$0	\$5	\$24	\$10	\$48	\$2	\$7	\$143	\$3	\$268
Diabetes I w/Comorbid	26,082	\$4	\$5	\$5	\$32	\$0	\$8	\$66	\$14	\$45	\$2	\$14	\$178	\$6	\$380
Diabetes II	54,976	\$1	\$1	\$2	\$12	\$0	\$1	\$5	\$7	\$6	\$1	\$2	\$67	\$2	\$108
Diabetes II w/Comorbid	99,466	\$1	\$2	\$3	\$16	\$0	\$2	\$14	\$9	\$10	\$1	\$4	\$89	\$3	\$156
LBP	146,352	\$13	\$4	\$3	\$18	\$0	\$7	\$43	\$3	\$29	\$28	\$25	\$32	\$35	\$239

-This table shows the disease-related costs PMPM for Year 2 for patients identified for each clinical grouping, by service category. Disease-related costs were identified for this table using Symmetry's Episode Treatment Groups (ETGs). To do this, Year 2 medical and pharmacy claims for each member were grouped using ETGs. Specific ETGs determined to be disease-related were mapped to each clinical category. The patient's disease-related ETG experience for each clinical category was then summarized by service category.

-Costs based on IHCIS Standard Pricing Methodology (consistent methodology and pricing levels applied to all populations and services).

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.

-Pharmacy data used as part of the patient identification for Asthma, and Diabetes

-Members can be identified for more than one major clinical grouping (Cardiovascular, Asthma/COPD, Diabetes, and Arthritis/LBP). Hierarchies applied for some conditions (see note for Table 2).

Episode Treatment Groups are proprietary to Symmetry Health Data Systems.

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Appendix Table

Table A-3b: Total Disease Related Costs PMPM, by Population and Service Category, using Disease Identification(DID) Methodology, Commercial Population

All Commercial Populations		PMPM Costs, by Service Category													
Clinical Grouping	Total Patients	Amb. Surg.	Consult	Diagnostic	E & M	E & M (MH)	ER	Inpat.	Lab	Other	Phys Medicine	Procs	RX	Rad.	Total
AMI	4,051	\$11	\$11	\$76	\$59	\$1	\$39	\$1,590	\$19	\$136	\$21	\$138	\$103	\$33	\$2,234
AMI w/Comorbid	1,750	\$17	\$18	\$79	\$88	\$0	\$47	\$1,997	\$23	\$169	\$21	\$155	\$170	\$37	\$2,823
Angina	2,146	\$12	\$3	\$34	\$23	\$0	\$9	\$96	\$8	\$21	\$2	\$7	\$68	\$21	\$305
Angina w/Comorbid	818	\$16	\$6	\$42	\$39	\$0	\$15	\$204	\$15	\$48	\$2	\$13	\$157	\$27	\$585
Arthritis	67,805	\$12	\$4	\$2	\$22	\$0	\$3	\$177	\$6	\$40	\$12	\$38	\$53	\$14	\$383
Asthma	157,768	\$2	\$1	\$4	\$10	\$0	\$5	\$17	\$1	\$7	\$0	\$0	\$49	\$1	\$97
Asthma w/Comorbid	46,204	\$3	\$1	\$5	\$12	\$0	\$5	\$39	\$2	\$10	\$0	\$0	\$63	\$2	\$142
CAD	34,212	\$15	\$4	\$45	\$27	\$0	\$8	\$315	\$13	\$41	\$5	\$36	\$108	\$29	\$645
CAD w/Comorbid	16,571	\$21	\$8	\$55	\$48	\$0	\$13	\$474	\$21	\$74	\$7	\$49	\$192	\$35	\$997
CHF	6,540	\$11	\$8	\$44	\$55	\$0	\$18	\$945	\$16	\$75	\$4	\$38	\$96	\$20	\$1,331
CHF w/Comorbid	7,283	\$20	\$18	\$53	\$108	\$0	\$35	\$1,345	\$27	\$172	\$8	\$52	\$193	\$29	\$2,062
COPD	13,772	\$3	\$2	\$9	\$22	\$0	\$9	\$134	\$3	\$28	\$0	\$1	\$48	\$6	\$266
COPD w/Comorbid	19,679	\$4	\$4	\$10	\$32	\$0	\$13	\$392	\$5	\$45	\$1	\$1	\$54	\$6	\$567
Diabetes I	20,129	\$6	\$3	\$2	\$19	\$0	\$6	\$53	\$11	\$50	\$1	\$4	\$87	\$3	\$247
Diabetes I w/Comorbid	26,082	\$13	\$6	\$8	\$38	\$0	\$10	\$202	\$18	\$62	\$2	\$9	\$113	\$7	\$487
Diabetes II	54,976	\$3	\$1	\$2	\$13	\$0	\$2	\$17	\$8	\$9	\$1	\$1	\$49	\$2	\$108
Diabetes II w/Comorbid	99,466	\$6	\$2	\$5	\$21	\$0	\$3	\$66	\$12	\$18	\$1	\$3	\$58	\$3	\$199
LBP	146,352	\$11	\$3	\$2	\$18	\$0	\$8	\$49	\$3	\$24	\$22	\$20	\$35	\$28	\$223

-This table shows the disease-related costs PMPM for Year 2 for patients identified for each clinical grouping, by service category. Disease-related costs were identified for this table using a methodology called the "disease identification" (DID) approach. The DID approach assigns each service to "disease-related" if that service also meets the diagnostic and procedural codes used to identify the patient for that condition. For pharmacy services, additional logic not used for disease identification is also employed. For cardiovascular conditions, services with a hypertension diagnosis were also included as disease related. The patient's disease-related DID experience for each clinical category was then summarized by service category.

-Costs based on IHCIS Standard Pricing Methodology (consistent methodology and pricing levels applied to all populations and services).

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.

-Pharmacy data used as part of the patient identification for Asthma, and Diabetes

-Members can be identified for more than one major clinical grouping (Cardiovascular, Asthma/COPD, Diabetes, and Arthritis/LBP). Hierarchies applied for some conditions (see note for Table 2).

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Appendix Table

Table A-3c: Disease Related Costs as a Percentage of Total Costs, by Clinical Grouping and Service Category, using ETG Methodology, Commercial Population

All Commercial Populations		Percentage Disease Related Costs of Total Costs, by Service Category													
Clinical Grouping	Total Patients	Amb. Surg.	Consult	Diagnostic	E & M	E & M (MH)	ER	Inpatient	Lab	Other	Phys Medicine	Procs	RX	Rad	Total
AMI	4,051	40%	62%	88%	73%	15%	82%	92%	62%	76%	80%	83%	46%	60%	84%
AMI w/Comorbid	1,750	34%	63%	86%	72%	5%	80%	87%	61%	68%	77%	78%	56%	58%	79%
Angina	2,146	32%	38%	72%	50%	1%	55%	55%	38%	33%	30%	21%	37%	48%	45%
Angina w/Comorbid	818	27%	43%	73%	58%	1%	47%	55%	48%	41%	41%	33%	53%	50%	50%
Arthritis	67,805	26%	31%	12%	33%	0%	18%	57%	20%	33%	66%	49%	25%	33%	39%
Asthma	157,768	1%	17%	40%	24%	0%	32%	15%	6%	9%	2%	0%	39%	7%	21%
Asthma w/Comorbid	46,204	1%	10%	17%	15%	0%	19%	8%	4%	6%	1%	0%	20%	6%	11%
CAD	34,212	34%	42%	80%	57%	2%	57%	77%	46%	47%	49%	51%	42%	55%	61%
CAD w/Comorbid	16,571	34%	50%	79%	64%	2%	59%	71%	54%	49%	51%	51%	55%	53%	61%
CHF	6,540	34%	43%	74%	54%	7%	54%	61%	48%	44%	52%	51%	42%	43%	56%
CHF w/Comorbid	7,283	34%	52%	75%	63%	3%	64%	67%	51%	48%	59%	50%	55%	45%	61%
COPD	13,772	3%	19%	33%	30%	1%	34%	26%	12%	18%	2%	3%	30%	13%	22%
COPD w/Comorbid	19,679	1%	12%	15%	18%	0%	21%	14%	7%	11%	2%	1%	18%	8%	13%
Diabetes I	20,129	10%	38%	19%	49%	1%	42%	25%	44%	41%	19%	25%	65%	10%	43%
Diabetes I w/Comorbid	26,082	11%	28%	13%	40%	1%	31%	14%	37%	24%	15%	19%	50%	9%	27%
Diabetes II	54,976	3%	22%	16%	39%	1%	21%	11%	32%	13%	15%	9%	47%	8%	27%
Diabetes II w/Comorbid	99,466	4%	19%	10%	32%	0%	18%	7%	32%	12%	12%	8%	41%	7%	20%
LBP	146,352	39%	38%	18%	38%	1%	33%	36%	13%	34%	80%	48%	27%	47%	37%

This table shows the disease-related costs PMPM as a percentage of total costs (disease-related and other) for Year 2 for patients identified for each clinical grouping, by service category. Disease-related costs were identified for this table using Symmetry's Episode Treatment Groups (ETGs). See also note for Table 7a.

-Costs based on IHCIS Standard Pricing Methodology (consistent methodology and pricing levels applied to all populations and services).

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.

-Pharmacy data used as part of the patient identification for Asthma, and Diabetes

-Members can be identified for more than one major clinical grouping (Cardiovascular, Asthma/COPD, Diabetes, and Arthritis/LBP). Hierarchies applied for some conditions (see note for Table 2).

Episode Treatment Groups are proprietary to Symmetry Health Data Systems.

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Appendix Table

Table A-3d: Disease Related Costs as a Percentage of Total Costs, by Clinical Grouping and Service Category, using Disease Identification (DID) Methodology, Commercial

All Commercial Populations		Percentage Disease Related Costs of Total Costs, by Service Category													
Clinical Grouping	Total Patients	Amb. Surg.	Consult	Diagnostic	E & M	E & M (MH)	ER	Inpatient	Lab	Other	Phys Medicine	Procs	RX	Rad	Total
AMI	4,051	42%	48%	68%	63%	12%	71%	93%	53%	58%	55%	82%	64%	45%	82%
AMI w/Comorbid	1,750	47%	53%	66%	66%	5%	73%	92%	57%	55%	58%	76%	62%	44%	80%
Angina	2,146	36%	25%	50%	44%	4%	44%	66%	32%	27%	18%	18%	52%	32%	44%
Angina w/Comorbid	818	48%	33%	57%	54%	1%	50%	72%	48%	39%	21%	21%	57%	31%	53%
Arthritis	67,805	27%	25%	9%	36%	1%	23%	62%	22%	31%	39%	44%	30%	21%	40%
Asthma	157,768	15%	18%	35%	30%	0%	39%	45%	10%	15%	0%	1%	48%	6%	30%
Asthma w/Comorbid	46,204	10%	11%	15%	21%	0%	25%	25%	8%	10%	0%	1%	25%	4%	18%
CAD	34,212	42%	30%	60%	51%	2%	45%	78%	43%	39%	33%	50%	62%	40%	60%
CAD w/Comorbid	16,571	48%	40%	61%	60%	2%	53%	80%	54%	45%	37%	50%	61%	39%	63%
CHF	6,540	34%	31%	44%	47%	7%	50%	73%	39%	33%	34%	37%	48%	29%	59%
CHF w/Comorbid	7,283	45%	42%	49%	60%	2%	62%	77%	49%	43%	47%	40%	53%	32%	63%
COPD	13,772	13%	20%	32%	40%	1%	45%	66%	17%	25%	4%	3%	33%	11%	37%
COPD w/Comorbid	19,679	11%	15%	17%	30%	1%	36%	53%	13%	22%	4%	2%	19%	8%	33%
Diabetes I	20,129	33%	34%	19%	51%	1%	48%	54%	49%	44%	15%	13%	40%	10%	40%
Diabetes I w/Comorbid	26,082	33%	29%	18%	47%	2%	43%	44%	47%	32%	17%	12%	32%	11%	35%
Diabetes II	54,976	19%	20%	16%	41%	1%	28%	40%	37%	18%	11%	6%	34%	6%	27%
Diabetes II w/Comorbid	99,466	21%	20%	15%	42%	1%	29%	35%	43%	20%	10%	6%	26%	8%	26%
LBP	146,352	31%	28%	13%	37%	1%	39%	41%	14%	28%	64%	39%	30%	38%	34%

-This table shows the disease-related costs PMPM as a percentage of total costs (disease-related and other) for Year 2 for patients identified for each clinical grouping, by service category.

Disease-related costs were identified for this table using the Disease Identification (DID) methodology. See also note for Table 7b.

-Costs based on IHCIS Standard Pricing Methodology (consistent methodology and pricing levels applied to all populations and services).

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.

-Pharmacy data used as part of the patient identification for Asthma, and Diabetes

-Members can be identified for more than one major clinical grouping (Cardiovascular, Asthma/COPD, Diabetes, and Arthritis/LBP). Hierarchies applied for some conditions (see note for Table 2).

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Appendix Table

Table A-3e: Comparison of Disease-Related Costs using Two Alternative Methodologies-ETGs and the DID Approach. The Ratio of Disease-related Costs assigned by DID to Disease-related Costs Assigned by ETGs, by Clinical Grouping and Service Category, Commercial Population

All Commercial Populations		The Ratio of DID Disease-Related Costs to ETG Disease-Related Costs, by Service Category													
Clinical Grouping	Total Patients	Amb. Surg.	Consult	Diagnostic	E & M	E & M (MH)	ER	Inpatient	Lab	Other	Phys Medicine	Procs	RX	Rad	Total
AMI	4,051	1.04	0.78	0.77	0.86	0.82	0.87	1.01	0.86	0.76	0.69	0.98	1.38	0.75	0.97
AMI w/Comorbid	1,750	1.38	0.84	0.77	0.92	0.97	0.91	1.06	0.93	0.81	0.75	0.98	1.11	0.76	1.01
Angina	2,146	1.14	0.68	0.69	0.88	5.49	0.80	1.19	0.86	0.81	0.58	0.85	1.40	0.67	0.98
Angina w/Comorbid	818	1.79	0.77	0.79	0.94	1.07	1.05	1.31	1.00	0.96	0.51	0.65	1.07	0.63	1.04
Arthritis	67,805	1.04	0.82	0.75	1.11	1.89	1.23	1.09	1.10	0.93	0.59	0.90	1.22	0.63	1.01
Asthma	157,768	16.77	1.08	0.88	1.24	1.82	1.24	3.06	1.60	1.63	0.26	2.43	1.24	0.87	1.40
Asthma w/Comorbid	46,204	14.15	1.06	0.93	1.41	3.36	1.30	3.24	1.87	1.64	0.50	2.43	1.24	0.75	1.55
CAD	34,212	1.23	0.71	0.75	0.88	1.05	0.79	1.02	0.93	0.82	0.67	0.98	1.49	0.74	1.00
CAD w/Comorbid	16,571	1.43	0.80	0.77	0.94	1.49	0.89	1.14	1.00	0.91	0.73	0.98	1.10	0.74	1.04
CHF	6,540	0.99	0.72	0.59	0.86	0.94	0.93	1.20	0.81	0.74	0.64	0.73	1.14	0.67	1.05
CHF w/Comorbid	7,283	1.32	0.81	0.65	0.95	0.81	0.98	1.15	0.96	0.91	0.80	0.81	0.95	0.72	1.04
COPD	13,772	4.26	1.07	0.96	1.35	1.64	1.35	2.55	1.43	1.40	1.84	0.98	1.08	0.79	1.63
COPD w/Comorbid	19,679	7.31	1.34	1.13	1.68	2.56	1.70	3.90	1.99	2.08	2.38	1.57	1.09	0.96	2.57
Diabetes I	20,129	3.23	0.90	0.99	1.03	2.03	1.15	2.17	1.12	1.06	0.79	0.53	0.61	0.98	0.92
Diabetes I w/Comorbid	26,082	3.11	1.02	1.45	1.18	1.95	1.36	3.07	1.27	1.37	1.11	0.61	0.64	1.19	1.28
Diabetes II	54,976	6.26	0.91	1.03	1.07	1.58	1.37	3.52	1.15	1.41	0.78	0.67	0.72	0.75	1.00
Diabetes II w/Comorbid	99,466	5.39	1.05	1.50	1.31	2.57	1.58	4.70	1.34	1.69	0.86	0.78	0.65	1.10	1.28
LBP	146,352	0.79	0.74	0.70	0.99	1.45	1.18	1.15	1.11	0.82	0.80	0.80	1.09	0.80	0.93

-This table compares the magnitude of disease-related costs using two alternative approaches Episode Treatment Groups (ETGs) and the Disease Identification (DID) method to assign these costs. The table shows DID assigned disease-related costs as a percentage of ETG assigned disease-related costs. Costs are for Year 2 for patients identified for each clinical grouping, by service category. See also notes for Tables 7a and 7b.

-Costs based on IHCIS Standard Pricing Methodology (consistent methodology and pricing levels applied to all populations and services).

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.

-Pharmacy data used as part of the patient identification for Asthma, and Diabetes

-Members can be identified for more than one major clinical grouping (Cardiovascular, Asthma/COPD, Diabetes, and Arthritis/LBP). Hierarchies applied for some conditions (see note for Table 2).

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential
 Episode Treatment Groups are proprietary to Symmetry Health Data Systems.

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Appendix Table

Table A-4: Assignment of Patients to Morbidity Categories using ERGs-Patients Prevalence by ERG Morbidity Category and Clinical Category, Commercial Population

All Commercial Populations		Percent of Patients, by ERG Morbidity Category							
Clinical Grouping	Total Patients	01	02	03	04	05	06	07	08
AMI	4,051	.	.	6.5%	4.1%	55.6%	21.3%	7.9%	4.5%
AMI w/Comorbid	1,750	.	.	3.0%	4.7%	33.0%	31.7%	15.8%	11.8%
Angina	2,146	7.1%	5.8%	46.6%	31.0%	6.2%	3.3%	.	.
Angina w/Comorbid	818	1.1%	5.9%	28.4%	42.8%	12.8%	9.0%	.	.
Arthritis	67,805	12.9%	25.0%	30.6%	22.4%	5.6%	3.6%	.	.
Asthma	157,768	53.0%	24.1%	15.6%	6.3%	0.8%	0.3%	.	.
Asthma w/Comorbid	46,204	13.3%	27.4%	30.9%	20.9%	4.6%	2.8%	.	.
CAD	34,212	.	.	52.3%	34.8%	7.9%	2.5%	1.5%	0.9%
CAD w/Comorbid	16,571	.	.	24.9%	46.8%	15.5%	5.6%	4.2%	2.9%
CHF	6,540	.	.	21.4%	35.7%	17.8%	8.6%	7.8%	8.7%
CHF w/Comorbid	7,283	.	.	7.4%	27.4%	21.2%	11.6%	13.7%	18.6%
COPD	13,772	.	42.2%	27.3%	21.0%	5.5%	1.8%	2.2%	.
COPD w/Comorbid	19,679	.	15.5%	22.9%	30.3%	13.6%	6.1%	11.7%	.
Diabetes I	20,129	.	42.0%	35.9%	18.0%	2.9%	0.6%	0.6%	.
Diabetes I w/Comorbid	26,082	.	7.3%	31.6%	35.1%	12.2%	5.1%	8.7%	.
Diabetes II	54,976	.	66.2%	21.7%	9.7%	1.7%	0.4%	0.3%	.
Diabetes II w/Comorbid	99,466	.	40.1%	29.3%	20.5%	5.6%	2.1%	2.4%	.
LBP	146,352	30.2%	28.4%	24.1%	13.2%	2.5%	1.6%	.	.

-This table presents the distribution of patients in each clinical category assigned to an ERG Morbidity Category. The ERG Morbidity Categories are used as one approach to risk-adjust total costs for the study. ERGs are an episode-based population health risk assessment tool licensed by Symmetry Health Data Systems. For this analysis, the following ranges of retrospective risk were used to create morbidity categories (category and range of risk shown – a risk score of 1.00 can be considered the average risk of a typical non-elderly commercial population):

01 – risk score less than 1.00	05 – risk score 8.00 to less than 12.00
02 – risk score 1.00 to less than 2.00	06 – risk score 12.00 to less than 15.00
03 – risk score 2.00 to less than 4.00	07 – risk score 15.00 to less than 20.00
04 – risk score 4.00 to less than 8.00	08 – risk score 20.00 or higher

For some clinical categories, morbidity categories at the extremes were collapsed due to low prevalence. Six morbidity groupings were used for each clinical category

-Costs based on IHCIS Standard Pricing Methodology (consistent methodology and pricing levels applied to all populations and services).

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.

-Pharmacy data used as part of the patient identification for Asthma, and Diabetes

-Members can be identified for more than one major clinical grouping (Cardiovascular, Asthma/COPD, Diabetes, and Arthritis/LBP). Hierarchies applied for some conditions (see note for Table 2).

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential
Episode Treatment Groups are proprietary to Symmetry Health Data Systems.

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Appendix Table

Table A-4a: Total Costs PMPM for Patients Assigned to Morbidity Categories Assigned using ERGs, Commercial Population.

All Commercial Populations		Average Costs PMPM, by ERG Morbidity Category							
Clinical Grouping	Total Patients	01	02	03	04	05	06	07	08
AMI	4,051	.	.	\$1,834	\$2,680	\$2,379	\$2,993	\$3,756	\$5,584
AMI w/Comorbid	1,750	.	.	\$2,529	\$2,621	\$2,806	\$3,204	\$4,008	\$6,394
Angina	2,146	\$309	\$552	\$482	\$913	\$1,182	\$1,667	.	.
Angina w/Comorbid	818	\$433	\$611	\$732	\$1,115	\$1,544	\$2,052	.	.
Arthritis	67,805	\$328	\$543	\$863	\$1,302	\$1,953	\$3,470	.	.
Asthma	157,768	\$151	\$325	\$547	\$937	\$1,663	\$3,370	.	.
Asthma w/Comorbid	46,204	\$226	\$404	\$721	\$1,206	\$1,894	\$3,556	.	.
CAD	34,212	.	.	\$725	\$1,176	\$1,622	\$2,164	\$2,928	\$5,197
CAD w/Comorbid	16,571	.	.	\$865	\$1,376	\$2,004	\$2,434	\$2,999	\$4,872
CHF	6,540	.	.	\$1,087	\$1,484	\$2,252	\$2,967	\$3,854	\$6,313
CHF w/Comorbid	7,283	.	.	\$1,420	\$1,750	\$2,367	\$3,017	\$4,120	\$6,699
COPD	13,772	.	\$295	\$636	\$1,075	\$1,541	\$2,154	\$3,517	.
COPD w/Comorbid	19,679	.	\$406	\$805	\$1,384	\$2,193	\$2,785	\$4,882	.
Diabetes I	20,129	.	\$284	\$547	\$1,061	\$1,584	\$2,268	\$3,883	.
Diabetes I w/Comorbid	26,082	.	\$361	\$577	\$1,141	\$1,922	\$2,484	\$4,976	.
Diabetes II	54,976	.	\$223	\$521	\$864	\$1,366	\$1,834	\$3,624	.
Diabetes II w/Comorbid	99,466	.	\$297	\$619	\$1,081	\$1,664	\$2,282	\$4,152	.
LBP	146,352	\$210	\$438	\$740	\$1,243	\$2,002	\$3,752	.	.

- This table presents the average total costs PMPM for patients in each clinical category assigned to an ERG Morbidity Category. The ERG Morbidity Categories are used as one approach to risk-adjust total costs for the study. See table 8 for notes on how ERGs were used.
- Costs based on IHCIS Standard Pricing Methodology (consistent methodology and pricing levels applied to all populations and services).
- Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.
- Pharmacy data used as part of the patient identification for Asthma, and Diabetes
- Members can be identified for more than one major clinical grouping (Cardiovascular, Asthma/COPD, Diabetes, and Arthritis/LBP). Hierarchies applied for some conditions (see note for Table 2).

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential
Episode Treatment Groups are proprietary to Symmetry Health Data Systems.

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Appendix Table

Table A-5: Assignment of Patients to Morbidity Categories using Age and Sex Groupings – Patient Prevalence by Age-Sex Category and Clinical Category, Commercial Population.

All Commercial Populations		Percent of Patients, by Age-Sex Morbidity Category						
Clinical Grouping	Total Patients	All, 00-17	Females, 18-44	Males, 18-44	All, 45-54	All, 55-64	All, 65-74	All, 75+
AMI	4,051	0.0%	2.4%	9.2%	32.9%	40.8%	9.2%	5.5%
AMI w/Comorbid	1,750	0.0%	2.1%	5.4%	30.5%	43.1%	12.7%	6.2%
Angina	2,146	0.0%	5.8%	7.5%	27.1%	37.8%	13.5%	8.2%
Angina w/Comorbid	818	0.0%	3.5%	3.9%	23.5%	43.5%	16.5%	9.0%
Arthritis	67,805	0.0%	8.5%	6.6%	28.3%	39.8%	10.9%	6.0%
Asthma	157,768	37.1%	24.0%	15.2%	14.5%	7.7%	1.2%	0.2%
Asthma w/Comorbid	46,204	3.2%	19.1%	9.9%	30.4%	29.7%	6.2%	1.6%
CAD	34,212	0.0%	1.4%	4.3%	22.9%	45.3%	17.0%	9.0%
CAD w/Comorbid	16,571	0.0%	1.2%	2.5%	21.3%	47.3%	19.0%	8.7%
CHF	6,540	0.0%	3.1%	4.6%	18.1%	30.0%	16.3%	27.9%
CHF w/Comorbid	7,283	0.0%	1.3%	2.0%	14.4%	38.3%	22.1%	22.0%
COPD	13,772	7.2%	13.9%	9.9%	23.4%	31.7%	9.4%	4.5%
COPD w/Comorbid	19,679	0.2%	4.1%	2.9%	19.2%	42.6%	18.2%	12.9%
Diabetes I	20,129	0.0%	27.6%	26.7%	24.2%	17.5%	3.3%	0.7%
Diabetes I w/Comorbid	26,082	0.0%	8.7%	8.5%	28.2%	40.2%	10.8%	3.7%
Diabetes II	54,976	0.0%	16.2%	12.5%	31.7%	31.4%	6.6%	1.5%
Diabetes II w/Comorbid	99,466	0.0%	5.7%	6.1%	28.5%	42.9%	12.3%	4.4%
LBP	146,352	0.0%	27.8%	23.0%	27.0%	17.7%	3.2%	1.3%

-This table presents the distribution of patients in each clinical category assigned to an Age-Sex Category. The Age-Sex Morbidity Categories are used as one approach to risk-adjust total costs for the study.

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.

-Pharmacy data used as part of the patient identification for Asthma, and Diabetes

-Members can be identified for more than one major clinical grouping (Cardiovascular, Asthma/COPD, Diabetes, and Arthritis/LBP). Hierarchies applied for some conditions (see note for Table 2).

"All", indicates both males and females for that age range.

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Appendix Table

Table A-5a: Total Costs PMPM for Patients Assigned to Morbidity Categories Assigned using Age-Sex, Commercial Population.

All Commercial Populations		Age-Sex Morbidity Category						
Clinical Grouping	Total Patients	All, 00-17	Females, 18-44	Males, 18-44	All, 45-54	All, 55-64	All, 65-74	All, 75+
AMI	4,051	-	\$2,007	\$2,330	\$2,629	\$2,880	\$3,037	\$2,793
AMI w/Comorbid	1,750	-	\$3,699	\$3,020	\$3,418	\$3,651	\$3,639	\$3,253
Angina	2,146	-	\$797	\$610	\$693	\$679	\$662	\$785
Angina w/Comorbid	818	-	\$1,449	\$959	\$1,236	\$1,057	\$986	\$1,224
Arthritis	67,805	-	\$807	\$692	\$890	\$1,031	\$1,116	\$1,211
Asthma	157,768	\$210	\$413	\$273	\$439	\$491	\$511	\$628
Asthma w/Comorbid	46,204	\$808	\$804	\$583	\$781	\$867	\$924	\$1,193
CAD	34,212	-	\$1,238	\$921	\$1,076	\$1,064	\$1,110	\$1,023
CAD w/Comorbid	16,571	-	\$1,925	\$1,763	\$1,614	\$1,598	\$1,507	\$1,464
CHF	6,540	-	\$2,124	\$2,038	\$2,250	\$2,739	\$2,149	\$1,887
CHF w/Comorbid	7,283	-	\$3,003	\$2,437	\$3,244	\$3,612	\$3,171	\$2,767
COPD	13,772	\$429	\$650	\$559	\$736	\$788	\$850	\$1,076
COPD w/Comorbid	19,679	\$2,638	\$1,403	\$1,416	\$1,559	\$1,697	\$1,821	\$1,904
Diabetes I	20,129	-	\$694	\$430	\$602	\$652	\$674	\$812
Diabetes I w/Comorbid	26,082	-	\$1,200	\$987	\$1,284	\$1,534	\$1,632	\$1,795
Diabetes II	54,976	-	\$451	\$285	\$360	\$404	\$449	\$546
Diabetes II w/Comorbid	99,466	-	\$668	\$525	\$662	\$792	\$940	\$1,157
LBP	146,352	-	\$582	\$431	\$679	\$861	\$1,019	\$1,258

-This table presents the average total costs PMPM for patients in each clinical category assigned to an Age-Sex Morbidity Category. The Age-Sex Morbidity Categories are used as one approach to risk-adjust total costs for the study.

-Costs based on IHCIS Standard Pricing Methodology (consistent methodology and pricing levels applied to all populations and services).

-Members identified with a condition in Year 2 with 6 or more member months enrolled during that year.

-Pharmacy data used as part of the patient identification for Asthma, and Diabetes

-Members can be identified for more than one major clinical grouping (Cardiovascular, Asthma/COPD, Diabetes, and Arthritis/LBP).

Hierarchies applied for some conditions (see note for Table 2).

-A00_17 indicates all genders, and so on.

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Appendix Table

Table A-6a: Correspondence of Relative Resource Utilization Indices Across Types of Service -- Rank-Order Correlations.
Total Patient Costs, ERGs used for Risk Adjustment

Type of Service	Rank Order Correlations for Total Services, ERG Model Risk Adjustment									
	All Diseases		Arthritis/LBP		Asthma/COPD		Cardiovascular		Diabetes	
	Total* (selected)	Total	Total* (selected)	Total	Total* (selected)	Total	Total* (selected)	Total	Total* (selected)	Total
Amb. Surg.	0.71	0.59	0.54	0.84	0.27	0.62	0.29	0.13	0.64	0.65
Consult	0.50	(0.11)	0.56	(0.10)	0.41	(0.16)	0.27	(0.25)	0.55	(0.08)
Diagnostic	0.59	0.73	0.42	0.71	0.50	0.78	0.51	0.73	0.52	0.71
E & M	0.06	(0.21)	0.20	(0.11)	0.24	0.01	(0.11)	(0.20)	0.31	(0.16)
ER	0.55	0.50	0.62	0.48	0.45	0.46	0.57	0.52	0.32	0.39
Inpatient	0.70	0.43	0.89	0.26	0.82	0.38	0.90	0.87	0.56	0.30
Lab	(0.48)	0.34	(0.52)	0.31	(0.50)	0.34	(0.08)	0.55	(0.53)	0.27
Other	0.07	0.62	0.05	0.57	(0.36)	0.34	0.32	0.73	0.26	0.75
Phys Medicine	0.48	0.68	0.19	0.57	0.27	0.51	0.56	0.61	0.36	0.52
Procs	0.38	0.29	0.45	0.38	0.22	(0.07)	0.29	0.43	0.43	(0.01)
RX	0.09	(0.04)	0.04	(0.10)	(0.20)	(0.03)	(0.20)	(0.31)	0.35	0.27
Rad	0.14	0.71	0.06	0.69	(0.14)	0.64	0.49	0.88	0.08	0.64
Total* (selected)	1.00	0.62	1.00	0.51	1.00	0.48	1.00	0.73	1.00	0.55
Total	0.62	1.00	0.51	1.00	0.48	1.00	0.73	1.00	0.55	1.00

- Spearman Rank Order Correlation of Relative Resource Utilization Index for a Type of Service versus Index for Total Services (all services) or Index for Total* (Selected) services -- across commercial populations.

-Selected services include AmbSurg, Consults, E&M, ER, Inpatient, Procs and RX.

- For example, the rank order correlation for the Inpatient Relative Resource Utilization Index with the Index for all services, for All Diseases, is shown in the row labelled "Inpatient" and the section "All Diseases", "Total" column.

- Correlations statistically significant at the 0.05 level are shaded (in yellow in color, and gray in black and white)

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Appendix Table

Table A-6b: Correspondence of Relative Resource Utilization Indices Across Types of Service -- Rank-Order Correlations.
Total Patient Costs, Age/Sex used for Risk Adjustment

Type of Service	Rank Order Correlations for Total Services, AgeSex Model Risk Adjustment									
	All Diseases		Arthritis/LBP		Asthma/COPD		Cardiovascular		Diabetes	
	Total* (selected)	Total	Total* (selected)	Total	Total* (selected)	Total	Total* (selected)	Total	Total* (selected)	Total
Amb. Surg.	0.51	0.42	0.65	0.76	0.18	0.49	0.02	(0.14)	0.34	0.52
Consult	0.62	(0.29)	0.53	(0.10)	0.59	(0.18)	0.22	(0.43)	0.79	0.03
Diagnostic	0.41	0.62	0.34	0.69	0.46	0.78	0.41	0.76	0.34	0.74
E & M	0.39	(0.11)	0.29	0.21	0.61	0.21	(0.06)	(0.35)	0.71	0.31
ER	0.48	0.36	0.48	0.38	0.21	0.26	0.45	0.50	0.36	0.48
Inpatient	0.72	0.32	0.78	0.24	0.80	0.29	0.88	0.76	0.68	0.07
Lab	(0.60)	0.43	(0.50)	0.27	(0.33)	0.38	(0.24)	0.50	(0.50)	0.17
Other	(0.08)	0.65	(0.06)	0.51	(0.30)	0.50	0.05	0.63	0.08	0.66
Phys Medicine	0.45	0.73	0.31	0.61	0.31	0.64	0.51	0.71	0.43	0.60
Procs	0.27	0.28	0.59	0.45	0.41	0.22	0.38	0.47	0.41	0.10
RX	0.38	0.05	0.36	0.18	0.33	0.23	(0.08)	(0.22)	0.79	0.56
Rad	0.04	0.73	(0.09)	0.59	(0.10)	0.62	0.24	0.71	0.11	0.70
Total* (selected)	1.00	0.33	1.00	0.57	1.00	0.55	1.00	0.69	1.00	0.48
Total	0.33	1.00	0.57	1.00	0.55	1.00	0.69	1.00	0.48	1.00

- Spearman Rank Order Correlation of Relative Resource Utilization Index for a Type of Service versus Index for Total Services (all services) or Index for Total* (Selected) services -- across commercial populations.

-Selected services include AmbSurg, Consults, E&M, ER, Inpatient, Procs and RX.

- For example, the rank order correlation for the Inpatient Relative Resource Utilization Index with the Index for all services, for All Diseases, is shown in the row labelled "Inpatient" and the section "All Diseases", "Total" column.

- Correlations statistically significant at the 0.05 level are shaded (in yellow in color, and gray in black and white)

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Appendix Table

Table A-6c: Correspondence of Relative Resource Utilization Indices Across Types of Service -- Rank-Order Correlations.
Total Patient Disease-Related Costs, using ETG methodology

Type of Service	Rank Order Correlations for Disease-Related Services, ETG Model Risk Adjustment									
	All Diseases		Arthritis/LBP		Asthma/COPD		Cardiovascular		Diabetes	
	Total* (selected)	Total	Total* (selected)	Total	Total* (selected)	Total	Total* (selected)	Total	Total* (selected)	Total
Amb. Surg.	0.52	0.40	0.82	0.71	0.31	0.29	(0.15)	(0.24)	0.43	0.18
Consult	0.35	(0.24)	0.00	(0.29)	0.49	0.13	(0.08)	(0.37)	0.39	(0.13)
Diagnostic	0.68	0.69	0.31	0.33	0.27	0.29	0.66	0.80	0.57	0.68
E & M	0.09	(0.38)	0.22	0.08	0.48	0.17	(0.17)	(0.31)	0.64	(0.01)
ER	0.46	0.31	0.29	0.01	0.29	0.14	0.39	0.48	0.46	0.50
Inpatient	0.77	0.81	0.47	0.20	0.38	0.24	0.95	0.93	0.33	(0.24)
Lab	(0.25)	0.45	0.12	0.45	(0.32)	(0.10)	0.29	0.56	0.10	0.41
Other	0.01	0.54	0.58	0.68	(0.02)	(0.11)	0.30	0.57	0.36	0.69
Phys Medicine	0.55	0.57	0.52	0.64	(0.15)	(0.67)	0.38	0.57	0.21	0.31
Procs	0.45	0.55	0.39	0.52	0.59	0.80	0.66	0.74	0.50	(0.10)
RX	0.42	0.20	0.31	0.42	0.62	0.31	0.01	(0.13)	0.92	0.75
Rad	0.30	0.78	0.59	0.77	(0.06)	0.03	0.74	0.90	0.49	0.41
Total* (selected)	1.00	0.72	1.00	0.87	1.00	0.58	1.00	0.91	1.00	0.60
Total	0.72	1.00	0.87	1.00	0.58	1.00	0.91	1.00	0.60	1.00

- Spearman Rank Order Correlation of Relative Resource Utilization Index for a Type of Service versus Index for Total Services (all services) or Index for Total* (Selected) services -- across commercial populations.
- Selected services include AmbSurg, Consults, E&M, ER, Inpatient, Procs and RX.
- For example, the rank order correlation for the Inpatient Relative Resource Utilization Index with the Index for all services, for All Diseases, is shown in the row labelled "Inpatient" and the section "All Diseases", "Total" column.
- Correlations statistically significant at the 0.05 level are shaded (in yellow in color, and gray in black and white)

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Appendix Table

Table A-6d: Correspondence of Relative Resource Utilization Indices Across Types of Service -- Rank-Order Correlations.
Total Patient Disease-Related Costs, using DID methodology

Type of Service	Rank Order Correlations for Disease-Related Services, DID Model Risk Adjustment									
	All Diseases		Arthritis/LBP		Asthma/COPD		Cardiovascular		Diabetes	
	Total* (selected)	Total	Total* (selected)	Total	Total* (selected)	Total	Total* (selected)	Total	Total* (selected)	Total
Amb. Surg.	0.62	0.55	0.53	0.69	(0.01)	0.15	0.27	0.13	0.60	0.76
Consult	(0.26)	(0.62)	0.29	(0.20)	(0.12)	(0.52)	(0.42)	(0.67)	0.17	(0.41)
Diagnostic	0.41	0.67	0.41	0.27	(0.10)	0.19	0.54	0.78	0.35	0.73
E & M	(0.19)	(0.61)	0.03	(0.08)	0.08	(0.48)	(0.63)	(0.74)	0.15	(0.24)
ER	0.27	0.41	0.37	0.07	(0.08)	(0.01)	0.27	0.50	0.29	0.59
Inpatient	0.80	0.47	0.82	0.19	0.73	0.64	0.97	0.84	0.61	0.25
Lab	(0.12)	0.44	(0.38)	0.49	0.06	0.40	0.36	0.59	(0.38)	0.27
Other	0.18	0.53	0.31	0.82	0.23	0.33	0.15	0.57	0.29	0.78
Phys Medicine	0.38	0.75	0.13	0.60	(0.06)	(0.13)	0.23	0.50	(0.06)	0.53
Procs	0.14	0.55	0.27	0.62	0.23	(0.10)	0.67	0.77	(0.27)	(0.08)
RX	0.50	0.21	0.31	0.43	0.38	0.36	(0.03)	(0.25)	0.87	0.83
Rad	0.07	0.55	0.17	0.80	0.02	0.34	0.33	0.69	0.06	0.58
Total* (selected)	1.00	0.66	1.00	0.48	1.00	0.70	1.00	0.86	1.00	0.65
Total	0.66	1.00	0.48	1.00	0.70	1.00	0.86	1.00	0.65	1.00

- Spearman Rank Order Correlation of Relative Resource Utilization Index for a Type of Service versus Index for Total Services (all services) or Index for Total* (Selected) services -- across commercial populations.

-Selected services include AmbSurg, Consults, E&M, ER, Inpatient, Procs and RX.

- For example, the rank order correlation for the Inpatient Relative Resource Utilization Index with the Index for all services, for All Diseases, is shown in the row labelled "Inpatient" and the section "All Diseases", "Total" column.

- Correlations statistically significant at the 0.05 level are shaded (in yellow in color, and gray in black and white)

Prepared for NCQA by IHCIS, December 2004. Proprietary and Confidential

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Appendix Table

Table A-7: Correspondence of Relative Resource Utilization Indices Across Methods -- Rank-Order Correlations.
Comparison of Method for Total and Total* Services, Different Risk Adjustment Methods

All Diseases								
ERG Total* (Selected)	ERG Total	Asex Total* (Selected)	Asex Total	ETG Total* (Selected)	ETG Total	DID Total* (Selected)	DID Total	
ERG Total* (Selected)	1.00	0.62	0.87	0.50	0.91	0.52	0.69	0.48
ERG Total		1.00	0.35	0.95	0.78	0.97	0.61	0.94
Asex Total* (Selected)			1.00	0.33	0.83	0.29	0.64	0.27
Asex Total				1.00	0.73	0.97	0.59	0.93
ETG Total* (Selected)					1.00	0.72	0.76	0.66
ETG Total						1.00	0.52	0.94
DID Total* (Selected)							1.00	0.66
DID Total								1.00

Arthritis/LBP								
ERG Total* (Selected)	ERG Total	Asex Total* (Selected)	Asex Total	ETG Total* (Selected)	ETG Total	DID Total* (Selected)	DID Total	
ERG Total* (Selected)	1.00	0.51	0.88	0.59	0.62	0.34	0.78	0.19
ERG Total		1.00	0.36	0.93	0.86	0.85	0.49	0.78
Asex Total* (Selected)			1.00	0.57	0.52	0.32	0.79	0.18
Asex Total				1.00	0.87	0.86	0.69	0.80
ETG Total* (Selected)					1.00	0.87	0.71	0.78
ETG Total						1.00	0.47	0.93
DID Total* (Selected)							1.00	0.48
DID Total								1.00

Asthma/COPD								
ERG Total* (Selected)	ERG Total	Asex Total* (Selected)	Asex Total	ETG Total* (Selected)	ETG Total	DID Total* (Selected)	DID Total	
ERG Total* (Selected)	1.00	0.48	0.83	0.50	0.57	0.52	0.57	0.52
ERG Total		1.00	0.26	0.80	0.07	0.57	0.09	0.67
Asex Total* (Selected)			1.00	0.55	0.66	0.54	0.60	0.45
Asex Total				1.00	0.36	0.64	0.38	0.74
ETG Total* (Selected)					1.00	0.58	0.57	0.38
ETG Total						1.00	0.22	0.50
DID Total* (Selected)							1.00	0.70
DID Total								1.00

NCQA EMAP Field Test - Relative Resource Utilization for Selected Clinical Conditions
Appendix Table

Table A-7: Correspondence of Relative Resource Utilization Indices Across Methods -- Rank-Order Correlations.
Comparison of Method for Total and Total* Services, Different Risk Adjustment Methods

Method

ERG Total* (Selected)	ERG Total	Asex Total* (Selected)	Asex Total	ETG Total* (Selected)	ETG Total	DID Total* (Selected)	DID Total
ERG Total* (Selected)	1.00	0.73	0.94	0.73	0.87	0.69	0.73
ERG Total		1.00	0.61	0.94	0.88	0.97	0.84
Asex Total* (Selected)			1.00	0.69	0.85	0.62	0.73
Asex Total				1.00	0.92	0.97	0.87
ETG Total* (Selected)					1.00	0.91	0.94
ETG Total						1.00	0.87
DID Total* (Selected)							1.00
DID Total							

Cardiovascular

ERG Total* (Selected)	ERG Total	Asex Total* (Selected)	Asex Total	ETG Total* (Selected)	ETG Total	DID Total* (Selected)	DID Total
ERG Total* (Selected)	1.00	0.73	0.94	0.73	0.87	0.69	0.73
ERG Total		1.00	0.61	0.94	0.88	0.97	0.84
Asex Total* (Selected)			1.00	0.69	0.85	0.62	0.73
Asex Total				1.00	0.92	0.97	0.87
ETG Total* (Selected)					1.00	0.91	0.94
ETG Total						1.00	0.87
DID Total* (Selected)							1.00
DID Total							

Method

ERG Total* (Selected)	ERG Total	Asex Total* (Selected)	Asex Total	ETG Total* (Selected)	ETG Total	DID Total* (Selected)	DID Total
ERG Total* (Selected)	1.00	0.55	0.65	0.57	0.38	0.48	0.54
ERG Total		1.00	0.16	0.89	0.24	0.87	0.23
Asex Total* (Selected)			1.00	0.48	0.80	0.38	0.93
Asex Total				1.00	0.62	0.91	0.56
ETG Total* (Selected)					1.00	0.60	0.91
ETG Total						1.00	0.49
DID Total* (Selected)							1.00
DID Total							

Diabetes

ERG Total* (Selected)	ERG Total	Asex Total* (Selected)	Asex Total	ETG Total* (Selected)	ETG Total	DID Total* (Selected)	DID Total
ERG Total* (Selected)	1.00	0.55	0.65	0.57	0.38	0.48	0.54
ERG Total		1.00	0.16	0.89	0.24	0.87	0.23
Asex Total* (Selected)			1.00	0.48	0.80	0.38	0.93
Asex Total				1.00	0.62	0.91	0.56
ETG Total* (Selected)					1.00	0.60	0.91
ETG Total						1.00	0.49
DID Total* (Selected)							1.00
DID Total							

- Spearman Rank Order Correlation of Relative Resource Utilization Index for a Method for Total Services (all services) or Index for Total* (Selected) services versus Index for another Method -- across commercial populations.

'-Selected services include AmbSurg, Consults, E&M, ER, Inpatient, Procs and RX.

- For example, the rank order correlation for the ERG Risk Adjustment Method, Total* (Selected) Services Index with the Index for the same services using the Asex Method, for All Diseases, is shown in the "All Diseases" Table, row labelled "ERG Total* (Selected)" and the "Asex Total* (Selected)" column.

- Correlations statistically significant at the 0.05 level are shaded (in yellow in color, and gray in black and white)

Information from Measure Evaluation

Measure Number and Name: Relative Resource Use for People with Asthma (#1560)

Description:

Measure Developer: NCQA

Summary Assessment

The measure presented is Relative Resource Use for People with Asthma. This measure is based on standard prices and includes all costs for treating people with asthma whether they are related to the condition or not.

Reliability and validity of the measure have been established.

The measure is restricted to patients 5-50 years old and has been tested in Medicaid and commercial populations → it can be endorsed for use in commercial and Medicaid populations.

The measure is submitted for implementation in:

Clinician : Group/Practice

Health Plan

Integrated Delivery System

Population : National

Population : Regional

Reliability (2a)

2a1. Is the measure well defined and precisely specified?

- a) Measure clinical logic described? Yes ☒ No ☐
- b) Measure construction logic described? Yes ☒ No ☐
- c) Risk-adjustment methodology described? Yes ☒ No ☐
- d) Is the data derivation process described in sufficient detail for users to implement the measure?
 - i. Target population and data sources identified
 - ii. Measure specific target conditions and events identified
 - iii. Data elements and outcome variable(s) clearly defined
 - iv. Measurement windows, exclusions, risk adjustment methodology clearly defined and explained
- a) The clinical logic is defined including the methods to identify the conditions and the time frames for identification and measurement.
- b) The construction logic is also described. The conditions are identified during the measurement year and the year prior to the measurement year. To be in the population a patient needs to have at least one ED visit with asthma as the principal diagnosis, or at least one acute inpatient discharge with asthma as the principal diagnosis, or at least four outpatient asthma visits with asthma as any diagnosis and at least two asthma medication dispensing events, or at least four asthma medication dispensing events. Patients with active cancers, ESRD, organ transplant or HIV/AIDS during the measurement year are

excluded. Optionally, patients with emphysema, COPD, cystic fibrosis or acute respiratory failure diagnosed at any time before the end of the measurement year are also excluded.

- c) Yes. The risk adjustment methodology is based on CMS' Hierarchical Condition Categories (HCC).
- d) Yes, users should be able to implement the method based on the information provided.
 - i. The target population is identified as patients with asthma, 5-50 years old as of the end of the measurement period. The data sources are identified as complete administrative data during the two year period of interest including demographic, clinical diagnoses and encounters and medical benefit information.
 - ii. The target condition is defined in terms of diagnoses or events. Condition-specific codes are provided. All events listed in the standard price tables are included. Criteria are given for when to excluded services, such as denied claims or invalid or missing information.
 - iii. The data elements are identified and a way of calculating standard costs for the different services is described.
 - iv. The measurement window consists of 2 years of observations: one for identification and one for measurement. Requirements for data completeness are given. Exclusions are defined in terms of age, coverage and other conditions. The risk adjustment methodology is also identified and explained.

2a2 Reliability Testing

Data Reliability

- a) Was data reproducibility assessed?

There was no evidence of assessment of data reproducibility. However, the measure was tested in a large managed care database provided by Integrated Healthcare Information Services, Inc. (IHCIS). For commercial claims databases, it is presumed that the database vendors performed reliability assessments as part of their QA process.

Measure Score Reliability

- a) Measure score reliability tested (signal-to-noise ratio analysis by means of ANOVA, Intra-class Correlation Coefficient or other means)

For this measure, it is important to ensure the reliability of the Relative Resource Use (RRU) units from which the standard costs are derived. The measure developers conduct annually an analysis of the RRUs submitted by Medicare, Medicaid and commercial plans. They verified that sufficient number of plans report across all the RRU measures and by the type of plan. They report that the O/E results remained stable over time. While this approach is probably sufficient to demonstrate reliability, it would have been preferable that the developers report that variability over time in RRUs at the individual plan level and specifically for the

condition of interest.

Validity (2b)

2b1 Is there evidence presented that the measure specifications allow to demonstrate variations in resource use across providers and/ or population groups? Does the measure and risk-adjustment methodology address this variability allowing for fair comparisons?

2b2 Validity Testing

Data Elements

- a) Has the data been compared to other authoritative data sources? (Other databases, literature, etc.)

No. The researchers performed a thorough evaluation of the methodology as compared to an episode-based approach but no comparison to other databases was found.

- b) Data integrity checked? (e.g. Percent of missing values, missing diagnosis codes, inconsistent dates, range checks, etc.)

No evidence of checking for data integrity as there is no mention of any checks performed during measure development.

- c) Is the data representative of the target population?

No. The database included commercial, Medicare and Medicaid populations but did not include enough regional variation.

Measure Score

- a) Has the measure score validity been shown? (By correlating to another valid indicator, or showing that it produces different results when applied to subgroups known to have differences in resource use or by expert opinion or other methods)

Yes. The distribution of costs across different lines of services and different plans was analyzed using different methods: Episode Treatment Groups and a methodology that included only disease-related costs in order to investigate if services that could be measured more reliably could account for the majority of costs. In the asthma and asthma with comorbidities categories, the majority of the costs were attributable to prescription medications. Inpatient costs were an important component in the asthma with comorbidities group; total costs were also higher for these patients. The analysis also compared the standard errors of the total relative resource use and found it comparable to those of episode-based approaches such as ETGs for all sample sizes. The rank correlation of ETGs and RRUs was also high.

2b3 Are exclusions supported by clinical evidence?

- a) Has a sensitivity analysis been performed of the measure with and without the exclusions in terms of distribution of the outcome and number of patients affected?

This analysis was not performed

- b) Are the reasons for exclusions properly addressed?

The reasons for exclusions are not addressed.

- c) Are any of the exclusions based on patient preferences?

No

2b4 Is the measure risk-adjusted? If not, is there a rationale that supports no risk-adjustment/risk stratification?

- a) Is the risk-adjustment methodology described completely and accurately?

Yes. The methodology is based on CMS's Hierarchical Condition Categories. The steps to identify the members risk score and risk reporting category are detailed in S10.1

- b) If a statistical model was used, is it appropriate for the problem at hand?

N/A

- c) Candidate and final variable selection adequately described

N/A

- d) Summary indicators of model fit, calibration and discrimination if appropriate provided

N/A

- e) Risk factors identified make clinical/practical sense

N/A

- f) Missing data/imputation methodology explained.

None used.

- g) The model validates when applied to a new dataset (i.e., no overfitting)

N/A

- h) How are influential observations handled?

The standard costs are truncated at set amounts (different for different lines of service)

2b5 Risk factors identified are associated with statistically significant and clinically meaningful differences

a) Are issues of statistical vs. practical significance addressed?

N/A

2b6 Demonstration that the method produces comparable results in different data sources

a) Does the method produce expected results when applied to different databases accounting for the differences in databases (e.g., an option to use administrative **or** medical record data)?

The method performance in different data sources was not analyzed.

2c Are identified disparities in care being used as risk factors?

Factors that identify groups with differences/inequalities in care (race, socioeconomic status, gender, etc.) should not be part of the risk-adjustment methodology

Age and gender appear to be part of the risk adjustment methodology.

Other comments:

Reviewer: Carlos Alzola